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C1q is an abundant plasma protein and is the first component of the complement 
classical pathway. It binds to antibody-opsonized microbial pathogens or certain 
pathogenic self antigens and initiates the activation of the complement classical 
pathway. It is also known to have diverse functions beyond providing immunity 
against pathogens, and is implicated in the pathogenesis of diseases such as 
transmissible spongiform encephalopathy, Alzheimer’s disease and familial 
dementia. Conversely, hereditary C1q deficiency in human almost always leads to 
the autoimmune condition known as systemic lupus erythematosus (SLE), and 
lupus-like conditions also developed in C1q-/- mice. In addition, SLE itself causes 
consumption of C1q in patients who can produce C1q normally, and these patients 
also developed anti-C1q antibodies that can deplete bioavailable C1q. 
 
C1q is produced by dendritic cells (DCs) and macrophages, the two main types of 
antigen presentation cells, and DCs are particularly important in the maintenance of 
tolerance as well as induction of immunity. In view of the strong association of C1q 
and DCs with autoimmune SLE conditions, we investigated the regulation of C1q 
production in DCs. We have developed assays to quantitate cellular C1q mRNA, 
protein expression and also developed an ELISA assay for measuring secreted C1q 
in the DC culture. By ELISA, we screened a large number of stimuli for their ability 
to modulate C1q production in DCs. Marked downregulation of C1q production was 
observed by two stimuli, i.e. zymosan and interferon alpha (IFN-α). On the other 
hand, IFN-γ was found to be a potent inducer of C1q production. 
 
 vi
In terms of the signaling mechanisms involved, we found that zymosan signals 
through the Dectin-1 receptor to mediate the downregulation of C1q production. It 
resulted in a thorough reduction in C1q mRNA, cellular protein and secreted protein. 
In contrast, IFN-α upregulated C1q mRNA and cellular protein levels, but it 
reduced the secretion of C1q by DCs after prolonged treatments. In this case, we 
found that C1q was mainly trapped in the endoplasmic reticulum with little being 
detected in the Golgi apparatus which explains the retarded secretion.  
 
C1q production by DCs raises the possibility of autocrine DC regulation by C1q. 
We then proceeded to study how C1q may influence DC development and found 
that C1q primed the development of DCs with tolerogenic properties. These C1q-
conditioned DCs, which are expected in vivo, are better at clearing apoptotic cells, 
produce less inflammatory cytokines, and are less able to activate Th1 and Th17 
cells. Higher ERK activity seems to contribute to these tolerance-related features of 
DCs differentiated with C1q. These properties suggest that the C1qDCs may raise 
the threshold of immune reactions or enhance tolerance, thus negating the 
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Chapter 1   Introduction 
 
 
1.1 The immune system and its receptors 
1.1.1 Innate and adaptive immunity 
The immune system confers the ability for an organism to defend against 
exogenous microbial infection and also to respond to endogenously derived dangers 
such as malignancy and tissue damage. The vertebrate immune system is divided 
into two intimately linked arms, the innate and the adaptive immunity. The innate 
immune system reacts rapidly to dangers, possibly within hours or minutes, and in a 
general manner rather than specific to a particular pathogen or aberrant cell. It 
represents the first line of defense against microbial infections, including viruses, 
bacteria, fungi and parasites (Medzhitov and Janeway, 2000). In contrast, the 
adaptive immunity takes time to develop, about 4 – 7 days. It provides 
immunological memory, or lasting protection against re-encounters with a 
particular pathogen. Possibly, re-encounters with the specific antigen could result in 
an even stronger immune response against it.  
 
The adaptive immune response comprises of T-cell mediated cellular immunity and 
B-cell mediated humoral or antibody immunity. T-cell and B-cell receptors are 
required for specific antigen recognition. An extremely diverse repertoire of B-cell 
and T-cell receptors are generated somatically during lymphocyte development 
because of the random nature of VDJ gene segment recombination during the 
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process of receptor gene rearrangement. Consequently, there is a high probability of 
the existence of an individual receptor on a single cell specific to a particular 
antigen. A lymphocyte with its receptor presented with its specific antigen by APCs 
would subsequently be activated and proliferates. The clonal selection and 
expansion of the destined cell is the key behind immunological response and 
immune memory in adaptive immunity. 
 
The distinctive difference between the innate and adaptive immune systems lies in 
the receptors used for danger recognition. Innate immunity is mediated by 
germline-encoded receptors that have evolved to recognize a few highly conserved 
structures present in different groups of microorganisms, referred to as pathogen 
associated molecular patterns (PAMPs) (Medzhitov and Janeway, 2000). The 
receptors that recognize PAMPs are known as pattern recognition receptors (PRRs). 
 
1.1.2 Pattern recognition receptors 
Immune cells, particularly the antigen-presenting cells (APCs) such as macrophages 
and dendritic cells (DCs), express different PRRs that can be cell membrane-
associated, in intracellular compartments or secreted into the blood stream and 
tissues, and all receptors facilitate the recognition of PAMPs. More recently, PRRs 
were discovered to also recognize endogenous molecules released from damaged 
cells, termed damage-associated molecular patterns (DAMPs). Some PRRs capture 
pathogens and subsequently mediate their phagocytosis and endocytosis, and these 
are the phagocytic/endocytic receptors. Among the membrane-associated receptors 
of this category are the mannose receptor (MR), scavenger receptors (SRs) and 
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complement receptors (CRs) (Aderem and Underhill, 1999). There are also secreted 
PRRs or pattern recognition molecules (PRM) that could bind their targets and act 
as opsonins. These include the pentraxins (PTX) such as C-reactive protein (CRP), 
serum amyloid protein (SAP) and PTX3 (Gewurz et al., 1995; Bottazzi et al., 2006); 
collectins such as lung surfactant proteins A (SP-A) and D (SP-D) and mannose-
binding lectin (MBL) (Kishore et al., 2006; Takahashi et al., 2006; Gupta and 
Surolia, 2007); complement components such as C1q (Lu et al., 2008) and C3 
(Sahu and Lambris, 2001); LPS-binding protein (LBP); and CD14 (Fenton and 
Golenbock, 1998; Schutt, 1999). 
 
Sensing PRRs include the transmembrane Toll-like receptors (TLRs) and C-type 
lectin receptors (CLRs). Cytosolic sensing PRRs include the RIG-I-like receptors 
(RLRs) and NOD-like receptors (NLRs). Engagement of these receptors leads to 
signaling cascades resulting in transcriptional expression of inflammatory mediators 
that coordinate the elimination of pathogens and infected cells. However, aberrant 
activation of this system could lead to immunodeficiency, septic shock, or induction 
of autoimmunity (Takeuchi and Akira, 2010). Table 1.1 provides a summary of the 
ligands recognized by these sensing PRRs. 
 
Currently, 10 TLRs are identified in humans and 12 in mice (Akira et al., 
2006). TLRs have extracellular N-terminal leucine-rich repeats, a transmembrane 
region followed by a cytoplasmic Toll/IL-1R homology (TIR) domain. Stimulation 
of TLRs result in the recruitment of TIR domain-containing adaptors, such as 
MyD88 and TRIF, with downstream signaling cascades activating NF-κB, MAP 
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kinases and IRFs, leading to inflammation, as characterized by the production of 
cytokines, chemokines and type I interferon (Akira et al., 2006).  
 
The CLRs have one or more domains that are homologous to carbohydrate 
recognition domains and can exist both as soluble and transmembrane proteins 
(Geijtenbeek and Gringhuis, 2009). Some CLRs can induce signalling pathways 
that directly activate NF-κB, whereas other CLRs affect signaling by TLRs. DC 
expressed CLRs that have garnered interest lately include the DEC205, DC-SIGN, 
Dectin-1 and Dectin-2. Importantly, Dectin-1 and Dectin-2 are immunoreceptor 
tyrosine-based activation motif (ITAM)-coupled and are important for detection of 
β-glucans from fungi.DCs activated by Dectin-1 or Dectin-2 are shown to activate 
T cells and confer protective immunity against C. albicans (Robinson et al., 2009) 
  
RLRs are composed of two N-terminal caspase recruitment domains (CARDs), a 
central DEAD box helicase/ATPase domain, and a C-terminal regulatory domain 
(Yoneyama and Fujita, 2008). They are cytoplasmic sensors that recognize the 
genomic RNA of dsRNA viruses and dsRNA generated as the replication 
intermediate of ssRNA viruses. The CARDs of RLRs are activate the signaling 
cascades by interacting with the N-terminal CARD-containing adaptor IFN-β-
promoter stimulator 1 (IPS-1) and the downstream signaling events activate type I 
interferon genes. NLRs are cytoplasmic pathogen sensors with a central nucleotide-
binding domain and C-terminal leucine-rich repeats. The N-terminal harbor protein-
binding motifs, such as CARDs, apyrin domain, and a baculovirus inhibitor 
of apoptosis protein repeat (BIR) domain (Takeuchi and Akira, 2010). TLRs and 
NODs can synergize and activate inflammatory cytokine production.  
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Table 1.1.  PRRs and Their Ligands. Adapted from Takeuchi and Akira (2010). 
 
PRRs Localization Ligand Origin of the Ligand 
TLR 
TLR1 Plasma membrane Triacyl lipoprotein Bacteria 
TLR2 Plasma membrane Lipoprotein 
Bacteria, viruses, 
parasites, self 
TLR3 Endolysosome dsRNA Virus 
TLR4 Plasma membrane LPS Bacteria, viruses, self 
TLR5 Plasma membrane Flagellin Bacteria 
TLR6 Plasma membrane Diacyl lipoprotein Bacteria, viruses 
TLR7 (human 
TLR8) Endolysosome ssRNA Virus, bacteria, self 
TLR9 Endolysosome CpG-DNA Virus, bacteria, protozoa, self 
TLR10 Endolysosome Unknown Unknown 
TLR11 Plasma membrane Profilin-like molecule Protozoa 
RLR 
RIG-I Cytoplasm Short dsRNA, 5′triphosphate dsRNA RNA viruses, DNA virus
MDA5 Cytoplasm Long dsRNA RNA viruses (Picornaviridae) 
LGP2 Cytoplasm Unknown RNA viruses 
NLR 
NOD1 Cytoplasm iE-DAP Bacteria 
NOD2 Cytoplasm MDP Bacteria 
CLR 
Dectin-1 Plasma membrane β-Glucan Fungi 
Dectin-2 Plasma membrane β-Glucan Fungi 






1.2 Dendritic cells 
1.2.1 Roles of DC in immunity and tolerance 
DCs play a vital role in the immune system. As the major APC, DCs provide a 
bridge between innate and adaptive immunity (Banchereau and Steinman, 1998). In 
their immature state, DCs act as sentinels, and through its effective antigen 
sampling via macropinocytosis and endocytosis, they sense their macroenvironment 
for danger signals (PAMPs) from pathogens and endogenous sources (DAMPs). On 
sensing a danger signal, DCs undergo maturation, mount an immune response 
leading to inflammation and subsequent priming of the adaptive immunity. This is 
coupled to increased antigen processing and presentation by upregulation of both 
the MHC I and MHC II components, upregulation of costimulatory molecules such 
as CD40, CD80 and CD86 and increased cytokine production (eg. IL-12, IL-10, 
TNF-α and IL-6).  
 
DCs that have undergone functional maturation would migrate to the T cell region 
of secondary lymphoid organs (Randolph et al., 2005), and are highly efficient at 
stimulating T cells via 3 distinct signals, i.e. antigen specific TCR stimulation, 
costimulatory surface signals such as CD80/CD86 stimulation of CD28 receptor on 
T cells, and also cytokines such as IL-12. Internalized antigens are degraded, loaded 
onto MHC II complexes and presented to CD4 T helper cells that express the 
antigen-specific TCR. Endogenous antigens are processed and loaded onto MHC I 
for the priming of cytotoxic CD8 T cells that bear the specific TCR.  
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DCs can polarize adaptive immunity by inducing specific CD4 T helper cell subsets 
(Guermonprez et al., 2002). The 3 main subsets of T helper responses currently 
studied are the Th1, Th2 and Th17 responses. Differentiation of naïve CD4 T cells 
into Th1 largely requires IL-12p70 production by DCs (Trinchieri, 2003). Th1 cells 
produce IFN-γ and TNF-β, and Th1 immunity is generally acknowledged to protect 
against intracellular pathogens and tumors. Th2 cells produce IL-4, IL-5 and IL-13 
and are responsible for promoting humoral immunity against parasites. IL-4 and 
OX40L are some known factors that direct Th2 polarization (Ito et al., 2005). Th17 
cells are more recently discovered and characterized. They produce IL-17A, IL-17F, 
and IL-22 and its differentiation is promoted by TGF-β, IL-6, IL-21 and IL-23 
(Korn et al., 2009). Functionally, Th17 cells are implicated in defense against 
extracellular pathogens such as fungi, and development of autoimmune and 
inflammatory diseases such as psoriasis and rheumatoid arthritis. 
 
Unabrogated inflammation caused by unabated T cell activation is detrimental to 
systemic homeostatis and can lead to autoimmunity. The normal immune system 
produces a population of T cells, called regulatory T cells (Tregs) that are 
specialized for immune suppression. Tregs are important in the maintenance of 
peripheral immunological self-tolerance. They suppress effector T-cell proliferation 
and thus can actively downregulate the activation and/or proliferation of self-
reactive T cells (Sakaguchi et al., 2008). Naturally occurring Treg arise in the 
thymus, and T cell activation usually induces a population of Tregs, and they are 
characterized as CD4+CD25+FoxP3+. In addition to Treg cells, there also exists DCs 
with tolerogenic properties that are crucial regulators of immunity (Morelli and 
Thomson, 2007). Immature DCs are long been known to be tolerogenic, and mature 
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tolerogenic DCs do not express the full armada of strong stimulatory signals. 
Tolerogenic DCs can present antigen to antigen-specific T cells, but provides 
inadequate co-stimulatory signals (or deliver net co-inhibitory signals) for effector 
T-cell activation and proliferation. This can result in T-cell death, T-cell anergy or 
regulatory T-cell expansion or generation. Thymic DCs can negatively select 
autoreactive CD4+CD8+ thymocytes and induce tolerance to self antigens (Brocker 
et al., 1997). Thus, tolerogenic DCs have been shown to suppress autoimmune 
conditions (Menges et al., 2002; Verginis et al., 2005). 
 
1.2.2 Heterogeneity of DCs 
There are loosely two categories of DCs. In the periphery, Langerhan cells and 
dermal DCs act as sentinels for pathogens or peripheral self-antigen, then undergo 
maturation and migrate via the lymphatics toward draining lymphoid organs and 
these are categorized as migratory DCs (Wilson et al., 2003). Lymphoid tissue 
resident DCs are found in all lymphoid organs of the mouse, including the spleen 
and draining lymph nodes. These cells are immature in the steady state, and are 
CD11chi CD45RAlo MHC IIint, which can be further broken into two broad subsets; 
the CD8+ conventional DC (cDC) and the CD8– cDC (Naik, 2008). On maturation, 
these DCs become migratory and are MHC IIhi.  
 
Plasmacytoid DCs (pDC) are CD11cint cells, and are considered as pre-DCs. At 
resting state, they resemble plasma B cells (Liu, 2005). In the steady state, pDCs 
express low levels of MHC I, MHC II and co-stimulatory molecules, and all are 
upregulated upon activation. Following activation, pDCs produce high levels of 
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type I interferon, and concomitantly acquire DC morphology and functions, such as 
antigen presentation and T cell activation.  
 
In the human blood, DCs are a heterogeneous cell population originating from bone 
marrow precursors and they make up approximately 1% of circulating peripheral 
blood mononuclear cells (PBMCs) (Kassianos et al., 2010). CD11c divides 
lin−HLA-DR+ blood DC into the CD11c− plasmacytoid (pDC) and CD11c+ myeloid 
(mDC) subsets. pDCs represent about 18% of the blood DC population and is 
distinguished from mDC by their expression of CD123, CD303 (BDCA-2) and 
CD304 (BDCA-4/neuropilin-1). mDC comprises over 70% of blood DCs and can 
be subdivided into 3 subsets. The CD1c+ (BDCA-1) subset makes up around 19% 
of blood DCs and is the most extensively studied mDC subset. The CD16+ subset 
constitutes about 50% of blood DCs and has not been studied extensively due to 
CD16 depletion in many isolation protocols and their poor viability in vitro. The 
CD141+ (BDCA-3) subset is the rarest, constituting around only 3% of blood DCs 
and is the least studied.  
 
Due to the rarity of DCs in peripheral blood, in vitro experiments have mostly 
relied on DCs generated from mouse bone marrow cells supplemented with GM-
CSF (Inaba et al., 1992) or from human blood monocytes cultured with GM-CSF 
and IL-4 (Sallusto and Lanzavecchia, 1994). A glaring disadvantage of this method 
is DCs generated this way are highly inflammatory and are only found in vivo 
following an inflammation (Shortman and Naik, 2007). Thus, they do not represent 
the steady state DCs that represent the normal population of DCs in healthy 
individuals. 
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1.3 Systemic Lupus Erythematosus (SLE) 
1.3.1 General overview 
Systemic lupus erythematosus (SLE) or lupus is a multi-factorial systemic 
autoimmune disease affecting multiple organs, including the heart, joints, skin, 
lungs, blood vessels, liver, kidneys, and nervous system. The clinical presentations 
of the disease range from rash and arthritis through anemia and thrombocytopenia 
to serositis, nephritis, seizures, and psychosis (Rahman and Isenberg, 2008). SLE 
patients have genetic susceptibility and it predominantly affects women, especially 
those of reproductive age. Females of African American or Hispanic American 
origins have a 3–4 times increased risk of developing disease compared to 
Caucasians (Reveille et al., 1998).  
 
The underlying pathogenic mechanisms of SLE remain poorly understood and as a 
result, treatment options are limited. However, major progresses have been made in 
the understanding of this disease (Croker and Kimberly, 2005). The development of 
antinuclear antibodies is a hallmark in SLE. These antibodies form immune 
complexes (IC) with nuclear antigens (e.g. chromatin and RNP) and cause unabated 
type I IFN production from plasmacytoid DCs which is highly pathogenic in SLE 
(Banchereau and Pascual, 2006; Pascual et al., 2006). These ICs can form or 
deposit in connective tissues to cause C1q-mediated complement activation leading 
to tissue inflammation and damages (Flierman and Daha, 2007). Therefore, both 
type I IFN and C1q are in theory predicted to have detrimental roles in SLE 
development. However, hereditary C1q deficiency is strongly associated with SLE 
development which, in contrary, suggests a strongly protective role for C1q (Petry 
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and Loos, 2005). A connection between C1q and type I IFN in SLE has not been 
established which is expected to provide novel insights into the pathogenesis of this 
disease. 
 
1.3.2 Antinuclear antibodies are characteristic of SLE and are pathogenic  
In SLE patients, many autoantibodies develop. The mechanisms by which self-
tolerance is broken down and hence allowing these autoantibodies to develop are 
unclear. Autoantibodies against nuclear antigens, such as chromatin/nucleosomes 
and ribonucleoproteins can form immune complexes (IC) with these autoantigens. 
IC are pathogenic in SLE (Banchereau and Pascual, 2006; Kyogoku and Tsuchiya, 
2007). For instance, ICs that are deposited in the kidneys can cause 
glomerular nephritis. 
 
Briefly, these IC can: 1) activate plasmacytoid dendritic cells (pDC) to produce 
IFN-α. As discussed later, unabated IFN-α production is highly pathogenic in SLE. 
2) These IC can be captured by conventional DC and chromatin and RNP antigens 
can be presented by DCs to stimulate autoreactive T and B cells. This will cause 
persistent production of pathogenic autoantibodies. 3) These IC can stimulate 
autoreactive B cells directly to produce anti-chromatin and anti-RNP autoantibodies. 
 
1.3.3 Recent identification of type I interferon (IFN) in SLE pathogenesis  
Beside complement, another major innate immune mechanism that is highly 
relevant to SLE pathogenesis is type I IFN, and in humans these include IFN-α and 
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IFN-β. Type 1 IFN was originally associated with conferring an antiviral response 
to cells before their roles in the autoimmune disease SLE were established by 
Pascual and Banchereau (Banchereau and Pascual, 2006; Pascual et al., 2006). 
They signal through the IFN-α/β receptor that consists of two subunits IFNAR1 and 
IFNAR2. The intracellular domains of both subunits are associated with the Jak 
kinases Tyk2 and Jak1 respectively. IFN-α/β binding to the receptors activates both 
the Jak kinases, which leads to the phosphorylation of IFNAR1, Stat1 and Stat2. 
Stat1 could homodimerize to form the IFN-α-activated factor (AAF) or IFN-
stimulated gene factor 3 (ISGF3) which is a heterotrimeric complex of Stat1, Stat2 
and IRF9 (Honda et al., 2005). Both complexes translocate into the nucleus, in 
which AAF binds to gamma-interferon activated sites (GAS) while ISGF3 binds to 
IFN-stimulated response element (ISRE). IFN-γ is the only member in the type II 
interferon family and it signals through the IFNGR1 and IFNGR2 receptor complex 
which is formed on ligand binding. It similarly leads to the transactivation of Jak1 
and Jak2, phosphyrylation of IFNGR1, homodimerization and phosphorylation of 
Stat1 and finally its translocation to the nucleus (Ikeda et al., 2002). Stat1 
homodimers in the nucleus bind to specific GAS elements and thereby effect the 
transcription of IFNγ-induced genes. 
 
Persistent production of IFN-α has been detected in SLE together with chronic 
expression of many IFN-regulated genes (Banchereau and Pascual, 2006; Kyogoku 
and Tsuchiya, 2007). Association of IFN-α with SLE was first indicated in 1979 
when elevated serum IFN-α was found in SLE patients (Hooks et al., 1979). Strong 
evidence that type I IFN is detrimental to SLE development came from therapeutic 
IFN-α treatment of cancer and viral infections because some patients treated with 
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IFN-α developed antinuclear antibodies, autoimmunity or even SLE (Ronnblom et 
al., 1991; Kalkner et al., 1998). More evidence is also supplied from recent 
genomics and proteomics studies in which the expression of IFN-regulated genes, 
known as the IFN signature genes, were found to be globally elevated in peripheral 
blood mononuclear cells and sera of SLE patients (Baechler et al., 2003; Bennett et 
al., 2003; Bauer et al., 2006). Additionally, single nucleotide polymorphism studies 
revealed that TYK2 and IRF5, two main transcription factors in type I IFN 
signaling and production, are associated with SLE (Sigurdsson et al., 2005).  
 
Based on these data, prevailing models of SLE pathogenesis have been developed 
(Pascual et al., 2006; Kyogoku and Tsuchiya, 2007; Pascual et al., 2008). Briefly, 
pDCs produce high IFN-α upon infection with virus and other pathogens (e.g. EBV) 
and this type of IFN-α production normally subsides after infection is resolved. 
However, when autoreactive B and T cells specific for chromatin or RNP are 
activated, e.g. due to molecular mimicry or breach of tolerance, antibodies are 
produced that react with the autoantigens to form pathogenic IC, which further 
activates pDCs to produce more IFN-α. Pathogenecity of IFN-α in SLE is mediated 
by differentiating monocytes into inflammatory DCs, activation of DCs, activation 
of cytotoxic CD8 T cells to lyse cells and produce more autoantigens, and 








1.4.1 Structure of C1q 
A C1q macromolecule consists of 18 polypeptide chains (6 A-, 6 B-, and 6 C-chains) 
(Fig 1.1). Each complete C1q polypeptide has a collagenous N-terminal half and a 
globular C-terminal half with the collagenous region from each of the three chain 
types forming a triple helix bringing the 3 C-terminal globules together (Reid and 
Porter, 1976). A C1q consists of 6 such heterotrimeric structures which are held 
together through inter-chain disulphide bonds at the N-terminal ends. It is viewed as 
a “bundle-of-tulips” under the electron microscope (Knobel et al., 1975). At the 
genomic context, the three human C1q genes are clustered together in a stretch of 
chromosome 1, in the sequence of C1qA - C1qC - C1qB, and all in the 5' to 3' 
orientation (Sellar et al., 1991). 
 
 
Figure 1.1.  Assembly of the 18 polypeptide 
chains to form the C1q molecule. C1q is 
assembled in macrophages and DCs from 
three types of chains, i.e., A-chain, B-chain 
and C-chain. Each chain has a collagenous N-
terminal half and a non-collagenous C-
terminal half which form globules. A and B 
chains dimerize through a disulphide bond at 
the N-terminal end and two C chains form 
homodimers through similar disulphide 
bonding. An A-B dimer and a single C-chain 
form a triple helix and the other C-chain in a 
C-C dimer trimerizes with another A-B dimer 
forming to triple helices linked by the 
disulphide between the two C-chains. Three 
such structures form a C1q molecule through 
N-terminal association. Reproduced from (Lu 
et al., 2008) 
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1.4.2 The classical roles of C1q and the complement system 
1.4.2.1   The complement pathways 
The complement system is an effector mechanism of the innate immune system, 
with 3 major roles in the defense against bacterial infection, bridging innate and 
adaptive immunity, and clearing inflammatory immune complexes and other 
inflammatory mediators following an inflammation (Walport, 2001). It is a complex 
interplay of 30-40 soluble plasma and cell surface proteins that proceeds through a 
series of proteolytic and complex-forming biochemical steps and culminate in the 
target destruction.  
 
Three routes of complement activation are recognized: the classical (antibody-
mediated) pathway, the mannose binding lectin (MBL) pathway, and the alternative 
pathway. Although each pathway has a unique combination of initiating proteins, 
all three converge in the activation of the complement component C3 and a 
common lytic pathway involving the formation of the membrane attack complex 
(MAC) on the target cell surface. The various complement pathways are 
schematically represented and described in Figure 1.2.  
 
1.4.2.2   C1q in complement-mediated inflammation and defense against 
pathogens 
C1q initiates the complement classical pathway by binding to the Fc portion of 
antibodies that bound to antigens on the surface of a bacterial cell (Duncan and 
Winter, 1988), and recruits C1r and C1s to form the C1 complex (one molecule of 
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C1q, two molecules of C1r, and two molecules of C1s) (Reid, 1986; Duncan and 
Winter, 1988). Complement activation can increase tissue inflammation through the 
generation of proteolytic complement fragments such as C3a and C5a which are 
anaphylatoxins to stimulate neutrophil chemotaxis to the affected tissue sites 
(Gasque, 2004). Another effector function of complement is the deposition of C3 
and C4 fragments on the reacted surfaces (microbial or endogenous) and these 
fragments have receptors on phagocytes such as macrophages and neutrophils. As a 
result, it causes enhanced phagocytosis of complement reacted targets for clearance 
(Underhill and Ozinsky, 2002). 
 
Complement can be activated by many microbial surfaces and the importance of 
this mechanism in host protection against microbial infections has been testified by 
the increased susceptibility of C1q-/- mice to microbial infections. With C1q 
deficiency, mice are more suscesptible to reinfection by Plasmodium chabaudi 
parasites (Taylor et al., 2001). These knockout mice also show increased infection 
upon multiple microbial challenges in the peritoneal cavity and increased 
susceptibility to Salmonella enterica serovar Typhimurium infection (Celik et al., 
2001; Warren et al., 2002).   
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Figure 1.2.  Schematic of the 3 pathways of complement activation - the 
Classical, Mannose-Binding Lectin (MBL), and Alternative Pathways. The 
three pathways converge at the point of cleavage of C3. The classical pathway is 
initiated by the binding of the C1 complex consisting of 1 C1q, 2 C1r and 2 C1s to 
antibodies bound to the bacterial cell surface. C1s first cleaves C4 and then cleaves 
C2, leading to the formation of a C4b2a enzyme complex (classical pathway C3 
convertase). The MBL pathway is initiated by binding of the complex of MBL and 
MASP1and MASP2 to arrays of mannose groups on the bacterial cell surface. 
MASP2 acts as a protease like C1s, and facilitate classical pathway C3 convertase 
formation. The alternative pathway is initiated by the covalent binding of a small 
amount of C3b to hydroxyl groups on cell-surface carbohydrates and proteins and is 
activated by low-grade cleavage of C3 in plasma. This C3b binds factor B, a protein 
homologous to C2, to form a C3bB complex. Factor D cleaves factor B bound to 
C3b to form the alternative pathway C3 convertase C3bBb. The C3 convertase 
enzymes cleave many molecules of C3 to C3b, which bind covalently around the 
site of complement activation. Some of this C3b binds to C4b2a and C3bBb to form 
C5 convertase enzymes which cleave C5 into C5a and C5b. C5b recruits C6, C7, 




1.4.3 Other roles of C1q  
In addition to the role of C1q in activating the complement classical pathway, 
numerous new studies have suggested additional physiological functions for this 
molecule. C1q was found to have chemotactic properties and stimulated migration 
for eosinophils (Kuna et al., 1996), mast cells (Ghebrehiwet et al., 1995), 
neutrophils (Leigh et al., 1998) and fibroblasts (Oiki and Okada, 1988).  
 
In addition to microbial killing via complement activation, C1q can directly bind to 
Listeria monocytogenes and this opsonizes the bacteria for enhanced macrophage 
uptake. C1q opsonized Staphylococcus aureus induces respiratory burst in 
neutrophils that is important for pathogen killing (Eggleton et al., 1994). C1q-/- 
mice was significantly poorer in the uptake and cross-presentation of ova antigen-
IC by DCs to CD8+ T cells, and exogenously added C1q restored this deficiency 
(van Montfoort et al., 2007). The C1q-/- mice also showed reduced ability to induce 
the proliferation and Th1 differentiation of antigen specific T cells (Baruah et al., 
2009) and its antigen specific T cells also produced less IFN-γ (Cutler et al., 1998). 
Of notable interest in SLE pathogenesis, C1q was also found to enhance the 
clearance of apoptotic and secondary necrotic cells (Quartier et al., 2005; 
Gullstrand et al., 2009). 
 
Several reports indicated that C1q can regulate cytokine production in different 
cells. C1q inhibited IL-4 and but enhanced IL-10 production by T cells (Lu et al., 
2007). In Lipid A-activated macrophages, autocrine C1q production stimulated 
TNF receptor synthesis, promoted TNF-α binding to the receptor and this induced 
nitric oxide synthase (NOS) synthesis (Jiang et al., 1996). C1q added to human 
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umbilical vein endothelial cells stimulated the production of IL-6, IL-8 and MCP-1 
(van den Berg et al., 1998). C1q modulated cytokine production by DCs and could 
suppress inflammation leading to autoimmune conditions such as SLE (Yamada et 
al., 2004; Csomor et al., 2007). 
 
In transmissible spongiform encephalopathies (TSEs), C1q had detrimental effects 
whereby mice deficient in C1q were highly resistant to scrapie isoform of prion 
protein (PrPSc) (Klein et al., 2001) and had a delayed onset of disease (Mabbott et 
al., 2001). It was further showed that PrPSc interacted directly with C1q to activate 
the classical complement pathway (Mitchell et al., 2007). C1q is also an important 
pathogenic factor in Alzheimer’s disease. In the brain, C1q binds to amyloid-β-
peptide (Aβ) which is a major component of senile plaque, and this activates the 
complement system and ultimately result in inflammation and neurodegeneration 
(Shen and Meri, 2003). This pathogenic role of C1q is also observed in another 
related disease known as familial dementia (Bonifati and Kishore, 2007). 
 
A recent paper indicated a novel role of C1q that is independent of complement 
activation, in phosphorylation and activation of the tumor suppressor WOX1 and 
causing its translocation into the nucleus (Hong et al., 2009). This led to the 
destabilization of tumor cell adhesion and leading to apoptotic cell death. Another 
novel role of C1q that has emerged is its involvement in neuronal development and 
remodeling (Stevens et al., 2007). In this model, C1q is hypothesized to be released 
from appropriately connected retinal ganglion cells, binding to neighbouring 
weaker synapses and targeting them for phagocytic removal.  
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1.4.4 C1q production and localization in vivo  
1.4.4.1   C1q production is distinct from other complement components 
Liver hepatocytes synthesize most of the complement proteins (Colten et al., 1986). 
C1q is different from most complement proteins in that it is not synthesized by liver 
hepatocytes, but is was long recognized to be produced by tissue macrophages 
(Muller et al., 1978; Loos et al., 1989). C1q expression in DCs was first detected in 
follicular DC and interdigitating DCs in the spleen (Schwaeble et al., 1995). In 
tonsil sections, DCs were also found to express C1q (Castellano et al., 2004). More 
recently, C1q expression was shown in human bone marrow stromal macrophages 
and DCs (Tripodo et al., 2007). Some reports have described C1q expression in 
other cell types such as endothelial cells (Cao et al., 2003; Bulla et al., 2008).  
 
However Petry et al. (2001) showed in vivo that physiological C1q are of 
hemapoietic origins. They showed that, when wild type mouse bone marrow was 
transferred to irradiated C1q-/- mice, serum C1q levels and C1 function were rapidly 
restored and reached the levels of normal mice within 6 weeks of transplantation 
(Petry et al., 2001). In reverse, when irradiated wild type mice received bone 
marrow from C1q-/- mice, serum C1q levels decreased over time and these mice 
became C1q deficient in 55 weeks.  
 
1.4.4.2   C1q is found to deposit around tissue macrophages and DCs 
C1q is abundantly present in the plasma, where healthy individuals have been 
reported to have C1q concentrations of 50 – 250 μg/ml (Dillon et al., 2009). 
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Besides circulating in plasma, we previously discovered by immunohistochemical 
staining of arterial walls that C1q also deposited in tissues around DCs and 
macrophages, and both cells were expressing C1q (Figs. 1.3 and 1.4) (Cao et al., 
2003). Staining of biopsy specimens from patients with Barrett’s esophagus (an 
inflammatory pre-malignant condition due to reflux of gastric contents), esophageal 
carcinoma or normal esophagus showed that DCs and macrophages expressed C1q, 
and C1q was again found surrounding DCs in the ECM (Bobryshev et al., 2010).  
 
How C1q deposits onto the tissue is unclear but it is structurally similar to the 
hexagonal type VIII and X collagens (Sellar et al., 1991). It has been reported C1q 
interacts with extracellular matrix (ECM) molecules such as collagen, fibronectin 
and laminin (Menzel et al., 1981; Bing et al., 1982; Pearlstein et al., 1982; 
Bohnsack et al., 1985) and interactions with these common ECM proteins may aid 
in C1q deposition in the tissues.  
 
Both macrophages and DCs are potent APCs and the deposited C1q around these 
cells may regulate their functions. For example, tissue deposition of C1q in the 
extracellular matrix may enable it to engage low affinity receptors on macrophages 

















Figure 1.3.  C1q is found inside and around DCs. Atherosclerotic lesions in 
arterial wall tissue sections were stained with DC-specific S-100 (green) and goat 
anti-C1q (red) antibodies. (A–C) A single DC in the intima (shown by a large arrow) 
expresses C1q (C) is a merged image of (A) and (B); (B) some other type cells 
(small arrows) also express C1q. (D) shows an area under the necrotic core of an 
atherosclerotic lesion containing several DCs and only some DCs express C1q. (E) 
C1q is present not only intracellularly in DC (large arrow, yellow cell), but also 
extracellularly (marked by small arrows). (F) Negative control. Reproduced from 






Figure 1.4.  C1q is found inside and around macrophages. Expression of C1q 
(red) by macrophages (identified with anti-CD68, red) around the necrotic core in 
atherosclerotic lesions. (C) is a merged image of (A) and (B). (D) and (E) are 
merged images of two other areas in the atherosclerotic lesion. In C, D and E, note 
that the proportions of C1q expressing cells markedly vary. Around some C1q-
expressing macrophages, C1q is also seen within the extracellular matrix. (F) 
negative control. Reproduced from Cao et al (2003). 
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1.4.5 The protein secretion pathway - how is C1q secreted? 
1.4.5.1   The classical protein secretion pathway 
Secreted proteins are mainly exported from mammalian cells by the classical 
endoplasmic reticulum/Golgi-dependent secretory pathway (Nickel, 2005). Sorting 
of the proteins into the correct compartments rely on specific signal tags on the 
protein itself. In the cytosol, newly synthesized nascent polypeptide chains 
emerging from ribosomal complexes are targeted into the endoplasmic reticulum 
(ER), where it undergoes chaperone-assisted folding, glycosylation and quality 
control steps to direct misfolded proteins for degradation (van Vliet et al., 2003). 
They then exit the ER at specialized membrane domains called ER exit sites or tER 
sites, are then packaged into transport vesicles containing coat protein complex II 
(COPII)-coat. The COPII vesicles fuse to become the ER-Golgi intermediate 
compartment (ERGIC). Many ERGICs merge to form the cis-Golgi network (CGN). 
Secretory proteins are then further modified, processed and transported across the 
Golgi cisternae to the trans-Golgi network (TGN), or Golgi exit site. Here, final 
modifications are performed on the proteins before they are sorted, packaged and 
dispatched towards their final destination. These could be directed towards the 
apical and basolateral membranes in polarised cells, regulated secretory granules, 
the endosome/lysosome system or retrograde transported back to earlier 






1.4.5.2   Unconventional protein secretory routes 
Recently, some proteins have been shown to be secreted independent of the ER and 
Golgi compartments of the classical secretory pathway (Nickel and Rabouille, 
2009). These unconventional protein secretions happens for proteins that have 
signal-peptides that are targeted to the ER, but are secreted independent of the 
Golgi network, or some proteins that lack signal peptides exit the cell independent 
of both the ER and Golgi pathways. 
 
1.4.5.3   How is C1q processed and secreted? 
A review of the C1q literature revealed that no study has been performed to 
investigate how C1q is secreted. It is difficult to imagine that C1q could be secreted 
independent of the ER/Golgi system of protein synthesis and secretion. The 
dimerization of the A-B and C-C chains requires correct disulplide bond formation, 
which usually occurs in the ER for eukaryotes. This involves protein disulphide 
isomerases (PDI) that works in concert with chaperones that can also perform 
checks to ensure correct disulphide bond formation (Fomenko and Gladyshev, 
2003). Further assembly of the 6 A-B and C-C chains to give the complete C1q 
macromolecule inconceivably requires chaperone assistance in the ER. The failure 
of proteins to fold and assemble properly results in their retention in the ER and 
eventually leads to their degradation. The collagen domain of C1q was found to be 
hydroxylated at certain proline and lysine resides (Reid, 1974). Inhibiting the 
hydroxylation of proline and lysine residues blocked C1q synthesis in macrophages 
(Muller et al., 1978; Mocharla et al., 1987). In general, hydroxylations of proline 
and lysine residues are required for stabilization of the collagen triple helix 
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structure and some of the enzymes involved have been found in the ER, such as 
prolyl 4-hydroxylase (Gorres and Raines, 2010) and lysyl hydroxylase 3 (Myllyla et 
al., 2007). This suggests that C1q synthesis, assembly and secretion require passage 
into the ER component of the classical secretory pathway.  
 
1.4.6 Association of C1q deficiency with SLE 
In addition to its classical role in complement activation and protection against 
microbial infection, C1q may also protect against autoimmunity. C1q deficiency in 
human is strongly associated with SLE-like autoimmune conditions, and C1q 
deficiency is the strongest genetic susceptibility to SLE, where more than 95% 
C1q-deficient human subjects develop SLE (Kolble and Reid, 1993). A protective 
role for C1q against SLE was strongly enhanced by the finding that C1q-/- mice also 
develop SLE-like conditions (Botto et al., 1998).  
 
1.4.6.1   Known mechanisms by which C1q may be connected to autoimmunity 
C1q may reduce SLE through enhanced clearance of apoptotic cells (ACs). 
Excessive apoptotic cell exposure can cause autoimmunity (Mevorach et al., 1998). 
Increased apoptotic body/chromatin levels have been detected in the blood of SLE 
patients (Decker, 2006). C1q-/- mice also showed increased tissue accumulation of 
apoptotic cells (Botto et al., 1998). However, elevated cell death or increased 
circulating nucleosomes does not necessarily cause autoimmunity unless tolerance 
is breached (Holdenrieder et al., 2001). The breach of self-tolerance is the key to 
SLE which originates ultimately from hyperactive APCs.  
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C1q was found to bind directly to surface blebs on ACs through calreticulin (Korb 
and Ahearn, 1997), and these opsonized cells are cleared by phagocytosis through 
CD91 (Ogden et al., 2001). Another indirect role of C1q in AC clearance requires 
IgM binding to late ACs (Zwart et al., 2004). C1q then binds IgM to activate the 
complement classical pathway, leading to C3 deposition and enhanced AC 
phagocytosis (Quartier et al., 2005). 
 
C1q-/- mice could develop autoantibodies by increased positive selection for 
autoreactive B1 cells by intracellular self antigens, and decreased negative selection 
of autoreactive conventional B cells by the same antigen (Ferry et al., 2007). 
Possibly, C1q plays a role in the negative selection of the autoreactive B cells in 
normal mice, and defective early B cell development checkpoints resulting in 
autoantibody production have been reported in SLE patients (Yurasov et al., 2005).   
 
C1q was also reported to inhibit the production of inflammatory cytokines. It was 
observed that C1q−/− mice produced more IL-12p40 than wild type mice when these 
mice were peritoneally injected with LPS (Yamada et al., 2004). A more recent 
study showed that immobilized C1q directly inhibited the production of some pro-
inflammatory cytokines while it enhanced the production of some anti-
inflammatory mediators such as IL-10 and IL-1 receptor antagonist (Fraser et al., 
2006). The dual roles played by C1q in enhancing AC clearance and inhibition of 
inflammatory cytokines suggest an anti-inflammatory role for C1q which may 
protect against SLE.  
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1.4.6.2   The selective C1q production by macrophages and DC, especially the 
latter, may hold important answers to its protective role against SLE 
Hereditary C1q deficiency is a very rare cause of SLE. More commonly, patients 
acquired partial deficiency of C1q due to complement activation and approximately 
one third of SLE patients develop anti-C1q antibodies and the detection of these 
antibodies strongly correlated to reduced serum C1q (Botto and Walport, 2002). 
Whether the production of C1q itself is reduced in SLE patients remains unclear 
and could be a novel mechanism in SLE development and pathogenesis. 
 
The complement system consists of more than 20 proteins which are mostly 
produced in the liver by hepatocytes, but C1q production is restricted to APC and 
its production by DCs implies a role in the regulation of adaptive immunity and 
tolerance (Muller et al., 1978; Cao et al., 2003). Blood monocytes only produce 
C1q after they differentiate into DCs and macrophages (Lu et al., 1996), although 
C1q is predominantly found in the blood circulation like monocytes. This mode of 
C1q production could subject DCs and macrophages to local autocrine or paracrine 
regulation by C1q under steady state. Immune complexes (IC) are a primary C1q 
ligand, which means that de novo C1q production by APC enables it to modify 
APC response to IC. For example, C1q binding to IC could modulate IC uptake by, 
and stimulation of, DCs to change the overall host immune response to these 
pathogenic identities. The extravascular tissue production of C1q also leaves a 
fraction of C1q deposited around these APC which may also regulate DC in T cell 
stimulation (Cao et al., 2003; Csomor et al., 2007). Overall, C1q production by 
APC, especially DCs, points to a potential role for C1q in the regulation of 
tolerance and IC processing. While recent studies have began to assess C1q in DC 
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regulation, how the DC origin of C1q is related to the known SLE pathogenic 
mechanisms has not been investigated. 
 
1.4.7 How is C1q production by macrophages and DC regulated by microbial 
and SLE-relevant stimuli    
1.4.7.1   Interferons 
IFN-γ has been found to increase or inhibit C1q expression in different studies. 
Murine peritoneal macrophages stimulated with various concentrations of IFN-γ 
produced a dose-dependent increase in C1q mRNA and increased the extracellular 
accumulation of C1q (Zhou et al., 1991a). A similar study using cultured mouse 
microglia found that IFN-γ also increased C1q mRNA (Haga et al., 1996). A 
corresponding increase in C1q production following IFN-γ stimulation was also 
observed in human THP-1 derived macrophages and primary human monocyte-
derived macrophages (Walker, 1998; Kaul and Loos, 2001). In another study, IFN-γ 
treatment of rat Kupffer cells which are liver tissue macrophages downregulated 
C1q production (Armbrust et al., 1997). Curiously, C1q-/- mice show a reduced 
capacity to produce IFN-γ, suggesting that C1q and IFN-γ are engaged in a mutual 
immunoregulatory mechanism (Cutler et al., 1998). How IFN-α affects C1q 
expression is yet to be determined and this may have implications in the 
pathogenesis of SLE. 
 
1.4.7.2   TLR ligands 
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Microbial toll-like receptor (TLR) ligands can upregulate C1q production by 
macrophages or DCs (Zhou et al., 1991b; Baruah et al., 2006). A study using 
human monocyte-derived DCs showed that the TLR4 ligand, LPS can potently 
upregulate C1q production while two TLR2 ligands, LTA and PGN also enhanced 
C1q levels but to a lower extent (Baruah et al., 2006). Peritoneal macrophages 
treated with C3b-opsonized zymosan also showed increased C1q production and 
secretion (Zhou et al., 1991b). However, there are also reports of LPS being able to 
suppress C1q production. In the same study where IFN-γ treatment downregulated 
C1q production, the authors also showed that LPS can also suppress C1q 
production in Kupffer cells (Armbrust et al., 1997). Another study showed that LPS 
maturation of human monocyte-derived DCs and DCs generated from CD34+ 
hematopoietic stem cells inhibited C1q production (Castellano et al., 2004). The 
study using mouse microglia found no difference in the expression of C1q mRNA 
after LPS treatment, but the levels from untreated cells were also non-detectable 
prior to IFN-γ stimulation (Haga et al., 1996). 
 
1.4.7.3   Drugs 
Phorbol 12-myristate 13-acetate (PMA) is an activator of protein kinase C and was 
shown to inhibit C1q production by THP-1 derived macrophages (Walker, 1998). 
The drug tacrine is a cholinesterase inhibitor used in the treatment of Alzheimer’s 
disease. Tacrine inhibited C1q upregulation by IFN-γ in THP-1 derived 
macrophages (Zhou et al., 1991b). Some non-steroidal anti-inflammatory drugs 
inhibited C1q production from thioglycollate-elicited macrophages but the same 
drugs upregulated C1q production from resting resident macrophages (Trinder et al., 
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1995). The organic gold compound auranofin greatly enhanced C1q production at 
both transcriptional and secretory levels in thioglycollate-elicited macrophages 
whilst, conversely, AFN reduced mRNA levels in resident macrophages. It is 
interesting to note that C1q expression is generally upregulated under 
immunosuppressive conditions. For example, a microarray study revealed that 
tumor-associated macrophages expressed elevated levels of C1q and two major 
immunosuppressive cytokines IL-10 and TGF-β (Biswas et al., 2006). 
Immunosuppresive drugs like dexamethasone, prednisone and hydrocortisone all 
enhanced C1q production in macrophages (Trinder et al., 1995; Armbrust et al., 
1997; Walker, 1998). 
 
1.4.7.4   Conclusion 
The regulation of C1q production is likely to have major impacts on SLE 
development but the mechanisms are poorly understood. The discrepancy in 
conclusions from studies on regulation of C1q production may have cell type, 
species and methodical contributions. It would be useful to have a systematic study 
with a single system used to examine the modulator effects of SLE-relevant stimuli 




1.5 Aims of this study 
C1q has diverse functions on a myriad of cell types. The aim of this study is to 
study C1q in the context of SLE pathogenesis where it has pathophysiological 
relevance. With different disease models linking its deficiency to SLE, 
understanding the processes that could suppress its production and understanding 
how the lack of C1q affects immune cells may lead to better understanding of the 
disease. 
 
The overall aims of this study are to: 
(1) Identify factors that may affect C1q production by DCs 
(2) Understand the mechanisms in which C1q production by DCs is regulated 
by certain factors 
(3) Investigate whether surface-deposited C1q, which was found around DCs 
in vivo, can regulate DC differentiation and activation 
 
(1) Identify factors that may affect C1q productionby DCs 
SLE is a complex autoimmune disease which involves chronic inflammation in 
multiple organs causing wide-spread tissue damages (Tsokos and Kammer, 2000; 
Croker and Kimberly, 2005). Also, SLE pathogenesis has complex pathogenic 
contributions from environmental and genetic factors. The etiology of SLE remains 
poorly understood, and what are the environmental factors that cause SLE are 
unclear. Here we search for stimuli that downregulated the production of C1q 
which is relevant to SLE pathogenesis.  
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To this end, a wide range of microbial structures, inflammatory factors, hormones 
and drugs will be screened for their ability to increase or decrease C1q production 
in DCs which may potentially trigger SLE under certain circumstances.  
 
(2) Understand the mechanisms by which C1q production by DCs is regulated by 
certain factors 
The protective roles of C1q in SLE have been strongly documented. We 
hypothesize that downregulation of normal C1q production in DCs could be 
detrimental to the patient and may be another underlying cause of SLE. This 
assumed that the known C1q effector functions, e.g. clearance of apoptotic cells or 
pathogenic IC which are ligands of C1q, is critical to SLE prevention.  
 
Factors that are identified after aim (1) and have known roles to play in SLE 
pathogenesis will be studied in further detail. 
 
(3) Investigate whether surface-deposited C1q, which was found around DCs in 
vivo, can regulate DC differentiation and activation 
We have previously detected C1q deposition in arterial wall tissues around DCs in 
vivo by immunohistochemistry (Cao et al., 2003). How deposited C1q may 
functionally regulate DC development from monocytes has not been investigated 






Chapter 2  Materials and Methods 
 
 
2.1 Cell Biology Techniques 
2.1.1 Isolation of monocytes from human buffy coats 
Enriched peripheral blood leukocytes were obtained from the National University 
Hospital (NUH) Blood Donation Centre, Singapore in the form of buffy coat 
preparations derived from healthy donors. The buffy coats were diluted two-fold in 
PBS. 30 ml of diluted buffy coat was layered on 12 ml of Ficoll-Paque (Amersham 
Bioscience Corp., Piscataway, NJ) in a 50 ml tube and centrifuged for 30 min at 
400X g without brake. Peripheral blood mononuclear cells (PBMCs) were collected 
from the gradient interface, resuspended in 50 ml of PBS and pelleted down by 
centrifugation at 200X g for 15 min to remove platelets. This washing step was 
repeated once, followed by two washes at 100X g each for 10 min. The washed 
cells were resuspended in 60 ml of RPMI medium containing 5% (v/v) BCS, 100 
units/ml penicillin and 100 μg/ml streptomycin and then divided into three T75 cell 
culture flasks and cultured for 2 hr at 37ºC.  
 
Non-adherent cells, which are mainly lymphocytes, were removed by four washes 
with 10 ml warm RPMI containing the above-mentioned supplements. The adherent 
fraction, mainly monocytes, was harvested by gentle scraping. Monocytes isolated 
by this method were >90% pure based on the expression of CD14 as judged by flow 
cytometry. 
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2.1.2 In vitro culture of monocyte-derived dendritic cells and macrophages 
The isolated monocytes were cultured in 6-well tissue culture plates at a density of 
1.5 x 106/ml in a DC culture cocktail, which is RPMI containing 10% (v/v) BCS, 
100 units/ml penicillin, 100 μg/ml streptomycin, 2 mM L-glutamine and 1 mM 
sodium pyruvate and 0.0012% (v/v) β-mercaptoethanol. The cells were cultured for 
6 days in the presence of 20 ng/ml of GM-CSF (R & D Systems Inc, Minneapolis, 
MN) and 40 ng/ml of IL-4 (R & D Systems Inc) to differentiate the cells into DCs. 
To culture DCs on immobilized C1q (C1qDCs), culture plates were coated 
overnight at 4°C with C1q (Sigma-Aldrich, St Louis, MO) or as a control, with 
BSA (both at 50 μg/ml in PBS) and the coated wells were washed 2X with PBS 
before cells were seeded. Differentiation of monocytes to macrophages was 
performed by adding 20 ng/ml of M-CSF (R & D Systems Inc.) instead. Every 
other day, half volume of the culture medium was removed and replenished with 
fresh media containing the respective cytokines at the stated concentrations. 
 
2.1.3 Culture of mouse bone marrow-derived DC (BMDC) 
Primary mouse bone marrow-derived DC were obtained from the laboratory of Dr 
Wong Siew Heng, Department of Microbiology, National University of Singapore. 
Briefly, cells were flushed from the long bones and cultured in DMEM containing 
10% FBS and 20 ng/ml GM-CSF (day 0). Cells were then fed with fresh complete 
DMEM containing 20, 15, and 10 ng/ml GM-CSF on day 2, 4, and 6, respectively. 
The cells were used on day 6 or 7 (Ho et al., 2008). 
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2.1.4 Isolation and sorting of mouse splenic DC 
Mouse CD8+, CD8- and plasmacytoid DC (pDC) were obtained from the laboratory 
of Professor Ken Shortman, The Walter and Eliza Hall Institute of Medical 
Research, Melbourne, Australia. A summary of the protocol used for the isolation 
process is given (Vremec et al., 2000) – Spleens were cut into small fragments and 
then digested for 25 min at room temperature in 10 ml RPMI 1640-FCS medium 
containing type II collagenase, DNase I and EDTA. Undigested fibrous material 
was removed by filtration. All subsequent steps were at 0–4°C in a balanced salt 
solution containing EDTA (EDTA-BSS). Cells were recovered from the digest by 
centrifugation, the pellet was resuspended in a 1.077 g/cm3 isoosmotic Nycodenz 
medium and centrifuged at 1700X g for 15 min, and then the low-density fraction 
was collected. The low-density cells were diluted in EDTA-BSS, recovered by 
centrifugation, and then incubated for 30 min with the following mAb: anti-CD3 
(KT3-1.1); anti-Thy 1 (T24/31.7, a pan-Thy 1); anti-Gr1 (RB68C5); and anti-
erythrocyte (TER-119). The cells coated with mAb were removed using anti-rat Ig 
coupled magnetic beads in a 5:1 ratio. The splenic DC (around 85% pure) were 
suspended in EDTA-BSS for presorting, staining, and analysis or sorting.  
 
2.1.5 Cell line culture 
Raw264.7 and Jurkat cells were obtained from the American Type Culture 
collection (ATCC) (Rockville, MD). These cells were maintained in Dulbecco's 
Modified Eagle's Medium (DMEM) for Raw264.7 or RPMI 1640 medium for 
Jurkat cells. Either medium was supplemented with 10% bovine calf serum (BCS) 
(HyClone, Logan, UT), 2 mM Lglutamine, 1mM sodium pyruvate, 100 units/ml 
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penicillin and 100 μg/ml streptomycin in a humidified incubator at 37°C in the 
presence of 5% CO2. The cells were sub-cultured every 3 days at a ratio 1:4. 
Raw264.7 cells are adherent cells and were removed by gentle scraping whereas 
Jurkat cells are suspension cells and removed by pipetting out the medium from the 
culture flask.  
 
2.1.6 Stimulation of cells with various agents 
Differentiated cells that were ready for use were harvested by gently scraping with 
a cell scraper and washed 2X. For all cell washings and culture, an activating 
medium consisting of RPMI 1640 supplemented with 10% heat inactivated BCS, 
100 units/ml penicillin and 100 μg/ml streptomycin was used unless stated 
otherwise. Cell stimulations were mostly performed in triplicates in 96-well plates 
with 100 μl of cell suspension at a density of 0.7 X 106 cells/ml. For extraction of 
RNA and protein where higher number of cells were required, 1 X 106 cells were 
seeded per stimulation in 2 ml of medium in a 6-well plate. 
  
PAMPs and stimuli 
The pathogen derived stimuli, cytokines/chemokines, drugs and hormones with the 
common dosage used to treat cells in this study are listed in Tables 2.1 to 2.3. 
 
Table 2.1.  PAMPs used in this study. 
Pathogen derived 
stimuli Source Receptors targeted 
Final 
concentration
Peptidoglycan (PGN) Invivogen TLR2, NOD1, NOD2 10 μg/ml 
Pam3CSK4 Invivogen TLR2, TLR1 5 μg/ml 
Lipoteichoic acid 
(LTA) Invivogen TLR2 10 μg/ml 
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Zymosan Invivogen TLR2, Dectin-1 50 μg/ml 
FSL-1 Invivogen TLR2, TLR6 1 μg/ml 
Pam2CSK4 Invivogen TLR2, TLR6 0.1 μg/ml 
Poly(I:C) Invivogen TLR3 50 μg/ml 
Lipopolysaccharide 
(LPS) Sigma TLR4 0.5 μg/ml 
Flagellin (Fla) Invivogen TLR5 1 μg/ml 
CL097 Invivogen TLR7/8 1 μg/ml 
CpG oligonucleotide 
type A (CpGA) Invivogen TLR9 2 μM 
CpG oligonucleotide 
type B  (CpGB) Invivogen TLR9 2 μM 
CpG oligonucleotide 
type C  (CpGC) Invivogen TLR9 2 μM 
TriDAP Invivogen NOD1 10 μg/ml 
Muramyl dipeptide 
(MDP) Invivogen NOD2 10 μg/ml 
Curdlan Sigma Dectin-1 50 μg/ml 
Depleted zymosan Invivogen Dectin-1 50 μg/ml 
 
 
Table 2.2.  Cytokines and chemokines used in this study. 
Cytokines / chemokines Source Final concentration 
BAFF Peprotech 0.1 μg/ml 
soluble CD40 ligand 
(sCD40L) R & D 1 μg/ml 
fMLP Invivogen 1 μM 
GM-CSF R & D 20 ng/ml 
IFN-α PBL 200 U/ml 
IFN-γ R & D 0.1 μg/ml 
IL-1β R & D 0.1 μg/ml 
IL-3 Peprotech 10 ng/ml 
IL-4 R & D 40 ng/ml 
IL-6 R & D 0.1 μg/ml 
IL-10 R & D 0.05 μg/ml 
M-CSF R & D 20 ng/ml 
MCP1 R & D 0.05 μg/ml 
Osteoprotegerin (OPG) R & D 0.5 μg/ml 
TGF- β R & D 2 ng/ml 
Thymic stromal 
lymphopoietin (TSLP) R & D 15 ng/ml 







Table 2.3.  Drugs and hormones used in this study. 
 
Cytokines / chemokines Source Final concentration 
Cortisone Sigma 1 μM 
Dexamethasone Sigma 1 μM 
Hydrocortisone Sigma 10 μM 
Prednisone Sigma 1 μM 
Estradiol Sigma 20 μg/ml 
Progesterone Sigma 20 μg/ml 
Human chorionic  
gonadotropin (HCG) Sigma 200 U/ml 
Insulin Sigma 100 nM 




In certain experiments, cells were treated with pharmacological inhibitors before 
further stimulation. In these cases, cells were pre-treated with the indicated inhibitor 
at specified dosages for 2 hr in a 37°C CO2 incubator. All inhibitors were 
purchased from Calbiochem. These inhibitors usually come in powdered form and 
are typically dissolved in DMSO for storage. A detailed list of the inhibitors used is 
given in Table 2.3 
 
Table 2.4.  Pharmacological inhibitors used in this study. 





100uM 5 nM 
LY 294002 phosphatidylinositol 
3-kinase 
100mM 25 μM 
Rapamycin mTOR 200 μM 20 nM 
Akt Inhibitor VIII Akt 50 mM 40 μM 
SC23766 Rac1 100 mM 50 μM 
JNK Inhibitor II c-Jun N-terminal 
kinase 
50 mM 20 μM 
PD98059 ERK 50 mM 40 μM 
U0126 MAP kinase & Mek 
inhibitor 




Protein kinase C 12.5 mM 0.5 μM 
SB 203580 p38 kinase 50 mM 40 μM 
GW 5074 Raf1 kinase 20 mM 1 μM 
Piceatannol Syk kinase 41mM 25 μM 





5 mg/ml 1 μM 
Pyrrolidine-2 cPLA2α 2 mg/ml 10 μM 
 
 
2.1.7 Total, naïve and memory CD4+ T cell isolation  
Non-adherent PBMCs following monocyte isolation, were either processed fresh 
for T cell isolation, or stored at 4ºC overnight in RPMI supplemented with 20% 
BCS for T cell isolation the next day. The following kits from Miltenyi Biotec 
(Germany) were used for isolation of the respective cells:– CD4+ T cell isolation kit 
II, naïve CD4+ T cell isolation kit and memory CD4+ T cell isolation kit. Cells were 
negatively selected using these kits, i.e. they were not labeled with antibody-
conjugated magnetic beads. The kits were used following manufacturer’s 
instructions. Briefly, total cell number was first determined and then resuspended at 
107 cells per ml in MACS buffer. Cells were centrifuged at 600X g for 5 mins. 
Supernatant was removed and the cell pellet was resuspended in MACS running 
buffer at 40 μl per 107 cells. 10 μl of biotinylated antibodies, which are specific for 
cells other than the cells of interest, was added per 107 cells, mixed well and 
incubated on ice for 10 mins. 30 μl of MACS buffer and 20 μl of anti-biotin 
antibody-conjugated microbeads were added to each 107 cells. These were 
incubated on ice for 15 mins. Cells were then washed by centrifugation and then 
resuspended in 500 μl MACS buffer. Cells were then separated by magnetic 
separation on the autoMACS Separator (Miltenyi Biotec, Germany) using the 
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‘depletes’ program. Isolated cells were then washed once in RPMI media and 
centrifuged at 600X g for 5 minutes. The purity of isolated cells was assessed based 
on surface CD3, CD4, CD45RO (memory cells) and CD45RA (naïve cells) 
expression. 
 
2.1.8 Isolation of plasmacytoid DC and myeloid DC from PBMC 
The Diamond plasmacytoid DC (pDC) Isolation Kit and human CD1c (BDCA-1)+ 
myeloid DC (mDC) Isolation Kit from Miltenyi Biotec were used for the isolation 
of these two types of human DC and according to the manufacturer’s instructions. 
Magnetic separation was performed using the autoMACS Separator. Only freshly 
obtained PBMCs, i.e. without prior monocyte adhesion, were used with these two 
kits. About 1-2 X 108 cells were used per isolation due to the rarity of these cells in 
the peripheral blood. pDC purity was assessed by CD123 and CD303 (BDCA-2) 
double expression on the surface while mDC purity was determined by the 
phenotype of CD19-,CD1C+. 
 
2.1.9 Cell adhesion assay 
Surface adhesion of monocytes which were differentiating into DCs was examined 
in 96-well plates pre-coated with eithere PBS, or C1q (50 μg/ml), BSA (50 μg/ml) 
or poly-L-Lysine (50 μg/ml). The plates were coated overnight at 4ºC and washed. 
200 μl of monocytes (0.5 X 106 cells) in the DC cocktail culture containing 20 
ng/ml of GM-CSF and 40 ng/ml of IL-4 were added to the wells in triplicates. 
Adherent cells were detected at days 1, 2, 4, 6 and 7 after washing the plates twice 
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with warm culture medium, and incubation for 10 min with 0.1% (w/v) crystal 
violet in 10% ethanol (v/v) in PBS. The plates were washed 4 times using warm 
PBS and crystal violet was released from the adherent cells using 2% SDS (50 μl 
per well). The absorbance was read at 570 nm. Alternatively, DCs cultured in 
normal and C1q-coated plates were resuspended at 5 X 105/ml and stimulated for 
24 hr in 96-well plates with LPS, IFN-γ, or both. Adherent cells were then stained 
using crystal violet and bound dye was eluted and measured. 
 
2.1.10 DC macropinocytosis 
DCs were washed and incubated for 30 min at 37oC with FITC-dextran (1 mg/ml) 
(Molecular Probes, OR) in normal culture medium supplemented with 25 mM 
HEPES buffer (pH7.4). As a control, DCs were also incubated with FITC-dextran 
for 30 min at 4oC. After 30 min, the cells were immediately chilled with an excess 
volume of ice cold culture medium and centrifuged at 600X g for 5 min. Two 
further washes were performed and the cells were fixed with 1% (w/v) 
paraformaldehyde in PBS. The uptake of FITC-dextran was analyzed via flow 
cytometry. 
 
2.1.11 Mixed Lymphocyte Reaction (MLR) 
For MLR, 0.1 ml T cells (2x106/ml) were co-cultured for 7 days with 0.1 ml DCs or 
macrophages (2x105/ml) in activation medium, in the presence or absence of 
LPS/IFN-γ. The culture supernatant was collected and IFN-γ and IL-17 were 
measured by ELISA.  
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For intracellular cytokine staining, at day 7, the cells were treated with phorbol 12-
myristate 13-acetate (PMA, 100 ng/ml) and ionomycin (1μg/ml) for 6 hr. Brefeldin 
A (10 μg/ml) was then added for the last 4 hr. Cells were processed using a 
Cytofix/Cytoperm Cell Fixation and Permeabilization kit (BD Biosciences). After 
staining with IL-17 and IFN-γ antibodies for 20 min on ice, the cells were analyzed 
by flow cytometry. DC stimulation of allogeneic naïve CD4 T cells was also 
assessed based on CD25 induction after MLR in which the cells were stained with 
CD4 (Pacific blue) and CD25 (PE) antibodies. 
 
For the re-stimulation experiments, cells were washed at day 7 of MLR and re-
stimulated for 2 days using beads coated with α-CD3/α-CD28 antibodies (bead:cell 
ratio = 2:1). IFN-γ and IL-17 production was determined by ELISA on culture 
supernatant. In similar experimental settings, the DC/naïve cell MLR was re-
stimulated at day 7 with the beads to examine CD25 expression on the CD4 T cells. 
 
2.1.12 Generation of anti-CD3 and anti-CD28 antibody latex beads  
Antibody-coated beads were used at a ratio of 2 beads to 1 T cell, i.e. 4 X 105 beads 
per well. An appropriate volume of latex beads (Polybeads microsphere 2μm, 
Polysciences Inc, USA) was resuspended in 1 ml PBS and centrifuged at 14 000X g 
for 5 minutes. Supernatant was removed and beads were resuspended in 1 ul PBS 
per 2 X 106 beads. 0.1 μg anti-human CD3 and 0.1 μg anti-human CD28 (Ancell, 
MN USA) were used to coat 4 X 105 beads by incubation in a 37°C CO2 incubator 
for 2 hr. Beads were then resuspended in 1 ml activation medium and centrifuged at 
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14,000X g for 5 minutes. Supernatant was removed and beads were resuspended 
with an appropriate volume of medium. 
 
2.1.13 Phagocytosis of apoptotic Jurkat cells 
Jurkat cells were fluorescently labeled with 2 μM CFSE (CellTrace CFSE Cell 
Proliferation Kit, Molecular Probes) according to the manufacturer’s protocol. 
Apoptosis was induced by UV irradiation (Spectrolink Select XLE-1000 UV 
crosslinker outfitted with 254nm lamp) of CFSE-labeled Jurkat cells (2 X 106 
cells/ml in serum-free RPMI) for 15 minutes and cells were further cultured for 4 hr. 
The percentage of apoptotic cells was quantified by using Annexin-V-FITC 
Apoptosis Detection Kit II (BD Biosciences) according to the manufacturer’s 
instructions. DCs (1 X 105 cells) were incubated with apoptotic cells at a 1:1 ratio in 
a total volume of 100 μl RPMI 1640 containing 10% human serum for 2 hr at both 
37ºC or, as a control, on ice. Phagocytosis was stopped by chilling the cells in an 
ice slurry. Fluorescence from non-ingested apoptotic cells was quenched with ice 
cold 0.2% Trypan blue (2 mg/ml in 20 mM sodium acetate and 150 mM NaCl, pH 
4.4). Cells were washed 2X in cold FACSwash, fixed with 4% (w/v) PFA, and 
stained with PE-labelled anti-CD11c prior to flow cytometry analysis. 
 
2.1.14 Determination of cell viability 
Annexin-V and propidium iodide staining 
The Annexin-V-FITC Apoptosis Detection Kit II (BD Biosciences) was used for 
this assay. 1 X 105 cells were used per staining reaction and resuspended with 100 
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μl of Annexin-V binding buffer. Then, 5 μl of Annexin-V-FITC and 5μl of 
propidium iodide (PI) or 7-AAD were added to each reaction and incubated for 15 
mins at room temperature in the dark. After incubation, 400 μl of Annexin-V 
binding buffer was added to each reaction. Cells were analyzed by flow cytometry 
immediately. Some assays were performed with PI or 7-AAD alone, whereby the 
cells were resuspended and stained in FACSwash instead of Annexin-V binding 
buffer. 
 
Lactate dehydrogenase release assay 
Lactate dehydrogenase (LDH) is a cytosolic enzyme that is released upon cell lysis. 
The CytoTox 96 Non-Radioactive Cytotoxicity Assay (Promega, WI, USA) was 
used to measure LDH levels in medium to assess cell death according to the 
manufacturer’s protocols. Briefly, cells were cultured at 100 μl/well. Additional 
wells of the cells were set aside for measuring total LDH released from all cells in 
the well after complete lysis. 10 μl of lysis solution were added to each of these 
additional cells and the supernatant was collected 45 min later. Another set of wells 
were included that contained only culture medium which were used to correct for 
absorbance contributions caused by phenol red. Cell culture supernatants were 
collected at the experimental endpoint. 50 μl of supernatant per well was transferred 
to a microtiter plate. 50 μl of reconstituted Substrate mix was added per well, 
incubated for 30 min at room temperature in the dark. Finally, 50 μl of stop solution 
was added per well and the absorbance was measured at 490 nm. The reading at 
OD450 was performed with the culture medium control and this was used to 
subtract the readings from the test culture supernatants.  
 
 44
2.2 Molecular Biology Techniques 
2.2.1 Total RNA isolation 
Total RNA from primary immune cells and cell lines was extracted using the 
TRIZOL reagent (Gibco BRL Life Technologies, Rockville, MD). Briefly, 1 ml of 
TRIZOL reagent was added to 0.3 to 1 x 106 cells and vortexed vigorously. This 
mixture is either stored at -80ºC or processed immediately. 0.2 ml of chloroform 
was added and vigorously mixed. After 2 min, the mixture was centrifuged at 4ºC 
for 15 min at 12,000X g. The aqueous phase was transferred to a fresh tube and 0.5 
ml of isopropyl alcohol was added to precipitate RNA by incubating for 10 min at 
room temperature. RNA was pelleted by centrifugation for 10 min at 12,000X g, 
washed with 1 ml 75% (v/v) ethanol and air-dried. The RNA pellet was dissolved in 
20 μl of RNAse-free water and stored at -80ºC, or further purified to remove 
genomic DNA.  
 
RNA obtained after TRIZOL extraction was further purified using Nucleospin RNA 
II (Clontech, CA, USA) following manufacturer’s protocol, and eluted using 40 μl 
of RNAse-free water. RNA concentration was quantitated using the Nanodrop 
spectrophotometer and typically the A260/280 ratio is above 1.9. Long-term storage 
of RNA was performed in -80ºC. 
 
2.2.2 Reverse transcription (RT) 
RNA reverse transcription (RT) was performed using the Advantage RT-for-PCR 
Kit (Clontech Laboratories, Palo Alto, CA). Briefly, RNA (0.2-1.0 μg) was mixed 
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with 1 μl oligo (dT) primers, heated for 2 min at 70ºC min and rapidly chilled on 
ice. RT was then performed in a 20 μl reaction volume containing MMLV reverse 
transcriptase, RNase inhibitor, dNTPs and reaction buffer for 1 hr at 42ºC. The 
reaction was terminated by heating at 94ºC for 5 min. cDNA was diluted to 100 μl 
final volume and used immediately or stored at -20ºC. 
 
2.2.3 Quantitative real-time PCR 
Real-time PCR reactions were performed in triplicates for each sample in a total 
reaction volume of 20 μl with the following components -  
SYBR Green PCR Master Mix (Applied Biosystems) 10 μl 
Forward and reverse primer mix (10 μM each) 1 μl 
cDNA 2 μl 
Nuclease-free water 7 μl 
 
The reaction mixtures were then run on the ABI Systems 7500 Real-Time PCR 
machine using the Comparative Ct quantitation method. The reaction conditions 
were 2 min at 50°C, 10 min at 95°C and 40 cycles of 15 sec denaturation at 95°C 
and 1 min annealing and extension at 60°C. Dissociation curve analysis was always 
performed at the end of all real-time PCR runs to ensure specificity of primers. The 
relative expressions of respective genes were normalized to that of GAPDH and 
calculated usingthe  ∆∆Ct method. Table 2.4 provides a complete list of the primers 
used for real-time PCR detection of gene expression in this study. Most of the 
primers were designed with the help of PerlPrimer open source software (Marshall, 
2004) and whenever possible, the primers would span two consecutive exons such 
that the amplification of the target gene on unspliced genomic DNA is eliminated.  
 
 46
Table 2.5.  Primers used for SYBR Green real-time PCR quantitation of 
various human genes in this study. 
 
Primers (5’….3’) : 
Forward (Sense) primer / 
Target human 
gene 
Reverse (Antisense) primer 
β-actin ACCACACCTTCTACAATGA 
  AAACATGATCTGGGTCATCTT 
    
BAFF ACATTTGTTCCATGGCTTCT 
  TTGCAATGCCAGCTGAATA 
    
C1qA CTTCCTCATCTTCCCATCT 
  GTTCAGCAGACACAGACA 
    
C1qB AGGCGTCTGACACAGTATG 
  CCTGGAAGCCCTTTCTCT 
    
C1qC ACCTGCAGTTCCTTCTCC 
  TTCTCCCTTCTGCCCTTT 
    
CCR7 TTCCAGGTATGCCTGTGT 
  AGGTTGAGCAGGTAGGTA 
    
CD1a ACGCTGTTTCTGTTAAGAC 
  CCAGGTCAGAACAACAAAT 
    
CD4 CTTCTTAACTAAAGGTCCATCCA 
  AGTCAATCCGAACACTAGCA 
    
CD40 CCAGCCAGGACAGAAAC 
  TACAGTGCCAGCCTTCT 
    
CD40L CGAAACATACAACCAAACTTCTC 
  TCATCTTCTATCTTGTCCAACCT 
    
CD68 CAGCACAGTGGACATTCTC    
  ATGATGAGAGGCAGCAAGA        
    
TGAGTCTGACACGCGATT cMaf – short 
isoform  CACCACCACCACAAACTC 
    
cMaf – long AGCCATCAGTGGGATACG 
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isoform  AAGGAGACTAAACAGAAGTCAGG 
    
EBI3 TCATAACAGAGCACATCATCAA 
  AGACTCCAGTCACTCAGTT 
    
FoxP3 CTTCATCTGTGGCATCATC 
  TCGCATGTTGTGGAACTT 
    
FZD5 GATCCGTGGAGAGTCCTTTCCCT 
  CAGAGGAATCCGGGCCGG 
    
GAPDH  CGGAGTCAACGGATTTGGTCG 
  TCTCGCTCCTGGAAGATGGTGAT 
    
GATA3 TGCGGGCTCTATCACAAA 
  TCTGTTAATATTGTGAAGCTTGTAGT 
    
GM-CSF CTGCTGAGATGAATGAAACA 
  AAGTCCTTCAGGTTCTCTTT 
    
IFN-α CCAGTTCCAGAAGGCTC 
  ATCTCATGATTTCTGCTCTGA 
    
IFN-β TTGCTCTCCTGTTGTGCT 
  CAAAGTTCATCCTGTCCTTG 
    
IFN-γ TTGGGTTCTCTTGGCTGTTA 
  TCTGTCACTCTCCTCTTTCC 
    
IFN-γ R1  GCCGAGATGGAAAAATTGGACC 
  TCGCTAACTGGCACTGAATCTCGT 
    
IFN-γ R2 AAACAATGGCAGATGCCTCCACT 
  CGTCATCCTTTGGTGAGCTGTCC 
    
IL-4 CGGGCTTGAATTCCTGTC 
  GCTCGAACACTTTGAATATTTCT 
    
IL-10 AATGCCTTTAATAAGCTCCAAGA 
  TCTCAGTTTCGTATCTTCATTGT 
    
IL-12p35 TTTACCCTTGCACTTCTGA 
  CAACTCCCATTAGTTATGAAAGA 
    
IL-12p40 TGCAGTTAGGTTCTGATCCA 
  CAGCAAAGATATCATTGTGATCCT 
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IL-17A CATTGGTGTCACTGCTACTG 
  TGGATCGGTTGTAGTAATCTG 
    
IL-17F CCTGGAATTACACTGTCACTT 
  ATTCATGGAGATGTCTTCCT 
    
IL-23p19 AATCAGGCTCAAAGCAAGTG 
  TCTTCTCTTAGATCCATGTGTCC 
    
IL-27p28 CTTCCCTTGCTCCTGGTT 
  AGGTGAGATTCCGCAAAG 
    
IRF1 CTCACCAAGAACCAGAGAAA 
  CCCACATGACTTCCTCTT 
    
IRF8 CTGCGTGAATGAAGTTACA 
  TCTGGGAGAATGCTGAAT 
    
M-CSF CAGGAACAGTTGAAAGATCCA 
  TTGTCAAGGAGATTCTTTGTTTC 
    
NOD1 CACTGTTCTCAGACTCAGCGTAAACC 
  GTTCTTCACAGCCAGGGCGAG 
    
NOD2 GCTAGAAGAACTCTGCCTGGAGGAG 
  GTGTTCCCTCGGAGCCAGACTT 
    
PU.1 AGAGCCATAGCGACCATTA 
  TATCGAGGACGTGCATCT 
    
RORγC TCATGCCACCTTGAATACAG 
  CCAGGTGCTCTATCTCTGTC 
    
SP1 AAACAGCATATTTGCCACATC 
  CAAATTTCTTCTCACCTGTGT 
    
Stat1 AACAGAAATACACCTACGAACAT 
  CACCAACAGTCTCAACTT 
    
T-bet AATGTGACCCAGATGATTGT 
  TTGGAAAGTAAAGATATGCGTGTT 
    
TGF-β1 AACCCACAACGAAATCTATGA 
  AATTGTTGCTGTATTTCTGGTA 
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Wnt5a GGCCGCAGGACGGTGTACA 
  TGGGCGAGTTGAAGCGGC 
    
 
Table 2.6.  Primers used for SYBR Green real-time PCR quantitation of 
various mouse genes in this study. 
Primers (5’….3’) : 
Forward (Sense) primer / Target mouse gene 
Reverse (Antisense) primer 
C1qA ATGACCCTAGTATGGACAGT 
 ATATTGCCTGGATTGCCTTTC 
   
C1qB AGGTTCTTCCTGCCTCTA 
 GGCTTCCTGTGTATGGAAT 
    
C1qC AAGGGAGAGCCAGGAATC 
 CTGTGCTTGGGTTGTAATG 
    
CD8α AAACGAAGGCTACTATTTCTG 
 AGTAGTAGAGTTCACTTTCTGA 
    
CD8β AAAGATGTCCTGTGAGGTTAA 
 CCACACTTTCACCATACAAA 
    
CD11b ATCAGTACCAGTTCAACAAC 
 ATCCCATACGGTCACATT 
    
CD11c TGGAGCTGAATGTAGATGT 
 CTGCTGGTCCTCTTTCTT 
    
CD45 AGAAGAAACCAGCAAATACAT 
 TTTCCAGTAACTCATCACAAAG 
    
GAPDH CATCTTGGGCTACACTGAG 
 TATTCATTGTCATACCAGGAAAT 
    
Sirp-a AACCTTCCCTGATAATAATGCT 
 CTTGGCTTTCTTCTGTTTGA 




2.3 Protein Chemistry Techniques 
2.3.1 Enzyme-linked Immunosorbent Assay (ELISA)  
Detection of human cytokines 
ELISA was performed using commercially available human cytokine detection kits. 
The DuoSet® ELISA Development System (R&D Systems Inc, Minneapolis, MN) 
was used for IL-1β , IL-17 and TNF-α while the BD OptEIA™ ELISA set (BD 
Biosciences, San Diego, CA) was obtained to quantitate IL-4, IL-6, IL-8, IL-10, IL-
12p40, IL-12p70 and IFN-γ and the Ready-SET-Go! Kit (eBioscience) was used for 
IL-23 detection. Briefly, 100 μl of a capture antibody was diluted with PBS (in 
DuoSet® ELISA) or Coating buffer (0.1 M sodium carbonate, pH 9.5) (in BD 
OptEIA and Ready-SET-Go!) was added to each well of a 96-well Maxisorp plates 
(Nunc, Denmark) and incubated overnight at 4ºC. The plates were washed 3X with 
PBS-T, blocked with Reagent Diluent (PBS with 1% BSA) (in DuoSet® ELISA) or 
Assay Diluent (in BD OptEIA and Ready-SET-Go!) for 1 hr at room temperature 
and washed 3X with PBS-T. Test samples or purified cytokine standards diluted in 
Reagent Diluent/Assay Diluent were then added into each well (100 μl/well) and 
incubated overnight at 4ºC. The plates were washed 3X with PBS-T. For DuoSet 
and Ready-SET-Go! ELISA, the biotinylated detection antibodies diluted in their 
respective diluents was added to each well (100 μl/well). After incubation at room 
temperature for 2 hr, the plates were washed and incubated with streptavidin-HRP 
conjugate in (100 μl/well) for 0.5 hr at room temperature. For BD OptEIA and  
ELISA, the biotinylated detection antibodies and streptavidin-HRP conjugate were 
diluted in Assay Diluent, added to each well (100 μl/well) and incubated for 2 hr at 
room temperature. 100 μl of TMB substrate solution (BD Biosciences) was added 
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to each well and the plate incubated in dark for 15-30 min. The colorimetrical 
reaction was stopped by adding 50 μl 1 M sulphuric acid. The absorbance at 450 
nm was read immediately with the Model 680 Microplate Reader (Bio-Rad). The 
linearized standard curve was constructed by plotting the cytokine concentrations 
versus that of the OD reading value (log scale). The concentration of each sample 
was derived by comparing with the standard curve and then multiplied by the 
dilution factors. Results were presented as means of triplicate experiments + SD.   
 
Detection of secreted C1q by ELISA 
For the detection of C1q in cell culture supernatant, an in-house developed 
sandwich ELISA system was employed. The capture antibody used was polyclonal 
goat anti-C1q diluted to 0.5 μg/ml in PBS and coated onto Maxisorp plates (100 μl 
per well) overnight at 4ºC. All washes consist of 3 rounds of washing with PBS-T. 
The wells were washed and blocked with 3% BSA in PBS for 1 hr. The wells were 
washed again and samples or purified C1q standards were diluted in 1% BSA in 
PBS, and added to the wells at 100 μl per well. The plate was incubated overnight 
at 4ºC. The following day, the wells were washed and a monoclonal mouse anti-
C1q antibody (1:2500 dilution in 1% BSA in PBS) was added and incubated for 2 
hr in room temperature. The wells were washed and a goat anti-mouse IgG 
conjugated with HRP (Dako) diluted 1:1000 in 1% BSA in PBS was added. A final 
wash was performed and TMB substrate was added to quantitate the antibody 
binding. The reaction was stopped with 50 μl of 1 M sulphuric acid and absorbance 




Detection of secreted fibronectin by ELISA 
This competitive ELISA assay was adapted from a method described by Pataki et al 
(2006). Maxisorp plate (Nunc) wells were coated overnight at 4ºC with 100 μl of 1 
μg/ml purified human fibronectin (in 0.1 M sodium carbonate, pH 9.5). 
Concurrently, a V-bottom plate was blocked with 200 μl of 1% BSA in TBS for 30 
mins. 100 μl of rabbit anti-fibronectin diluted 1:30000 in 0.1% BSA in TBS was 
then added, followed by 100 μl of purified fibronectin standards or samples diluted 
in 0.1% BSA in TBS. This plate was also incubated at 4ºC overnight. The Maxisorp 
plate was then washed 3X with TBS + 0.05% Tween-20. 100 μl of the antigen-
antibody mixtures were added to the wells of the Maxisorp plate and incubated for 
2 hr at room temperature. The wells were then washed 3X with TBS + 0.05% 
Tween-20 and 100 μl of anti rabbit-HRP antibody (diluted 1:1000 in 0.1% BSA in 
TBS) was added and incubated for 2 hr. A final washed was performed with TBS + 
0.05% Tween-20 and the TMB substrate was added. The reaction was stopped with 
50 μl of 1 M sulphuric acid and absorbance was read at 450 nm. 
 
2.3.2 Antibodies used in this study 
The table below gives a detailed account of all the antibodies that were used 
throughout this study. 
 
Table 2.7.  Antibodies used in this study. 
Target (human 





n Usage Source 
p44/42 MAPK Rb   W Cell 
Signaling 













Rb   W Cell 
Signaling 
Akt Rb   W Cell 
Signaling 





Rb 81E11  W Cell 
Signaling 




Ms 1A5 / IgG2a    
αV  Ms MAB1953Z / 
IgG1 
 F Chemicon 
β1 Ms MAB1951Z / 
IgG1 
 F Chemicon 
β2 Ms MAB1962Z / 
IgG3 
 F Chemicon 
α2β1 Ms MAB1998Z / 
IgG1κ 
 F Chemicon 
αVβ1 Ms MAB1999Z / 
IgG2bκ 
 F Chemicon 
αVβ3 Ms MAB1976Z / 
IgG1 
 F Chemicon 
αVβ5 Ms MAB1961Z / 
IgG1 
 F Chemicon 
β-actin Ms AC15 / IgG1  W Sigma 










C1q Ms IgG1  ELISA, F Raybiotech 
C1q Go   ELISA, 
W 
Sigma 
c-Maf Rb   W Santa Cruz 
Calreticulin Rb   F, IF, W Affinity 
Bioreagents
CCR7 Ms 150503 / 
IgG2a 
FITC F R&D 
CD1a Ms CB-T6 / IgG1 PE F Ancell 
CD1c Ms AD5-8E7 / 
IgG2a 
APC F Miltenyi 
Biotech 
CD3 Ms UCHT1 / IgG1 None, PE, 
FITC 
A, F Ancell 
CD4 Ms RPA-T4 / 
IgG1 
Pacific blue F BD 
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CD8 Ms UCHT4 / 
IgG2a 
PE F Ancell 
CD11b Ms ICRF44 / IgG1 PE-Cy7 F eBioscience
CD11c Ms B-ly6 / IgG1 PE F BD 
CD14 Ms UCHM1 / 
IgG2a 
PE, FITC F Ancell 
CD19 Ms BU12 / IgG1 PE F Ancell 
CD21 Ms HB5 / IgG2a PE F eBioscience
CD25 Ms BC96 / IgG1 PE F eBioscience
CD28 Ms ANC28.1/5D1
0 / IgG1 
 A Ancell 
CD35 (CR1) Ms E11 / IgG1  F Santa Cruz 
CD35 Ms J3D3 / IgG1  F Santa Cruz 




CD38 Ms HB7 / IgG1 PerCP-
eFluor-710 
F eBioscience
CD40 Ms 5C3 / IgG1  A, F eBioscience
CD54 Ms 15.2 / IgG1 FITC F Ancell 
CD56 Ms ANC7C7 / 
IgG1 
PE F Ancell 
CD80 Ms L307.4 / IgG1 PE F BD 
CD83 Ms HB15 / IgG1 PE F BD 
CD86 Ms BU63 / IgG1 PE  Ancell 
CD91 Ms A2MR-α2 / 
IgG1 
 F BD 
CD93 (C1qRP) Ms MAB4314 / 
IgG2b 
 F Chemicon 
CD123 Ms 6H6 / IgG1 eFluor-450 F eBioscience
CD303 Ms AC144 / IgG1 APC F Miltenyi 
Biotech 
Dectin-1 Ms 259931 / 
IgG2b 
 B, F R&D 
EEA-1 Rb   IF Santa Cruz 
Fibronectin Rb   ELISA Chemicon 
FoxP3 Ms 236A/E7 / 
IgG1 
APC F eBioscience
gC1q-R/p33 Ms MAB1160 / 
IgG1 
 B, F Chemicon 
gC1q-R/p33 Ms MAB1161 / 
IgG1 
 B, F Chemicon 
IgM Go F(ab’)2  A Jackson 
Immuno 
mouse IgG Go F(ab’)2  A Jackson 
Immuno 
Interferon gamma Ms 4s.B3 / IgG1 PE F eBioscience
IL-10 Ms 23738 / IgG2b  B R&D 
IL-12 Ms 24910 / IgG1  B R&D 
IL-17A Ms eBio64DEC17 
/ IgG1 
Alexa647 F eBioscience
MHC Class I Ms 3F10 / IgG2a FITC F Ancell 
MHC Class II Ms TDR31.1 / 
IgG1 
FITC F Ancell 
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Syntaxin 16 Rb   IF Synaptic 
Systems 
Keys:  Go – goat, Ms – mouse, Rb – rabbit, A – activating, B – blocking, F – flow, 
IF –  immunofluorescence microscopy, W – Western blotting.  
 
2.3.3 Cell lysate preparation 
Cells were seeded and stimulated for the specified timepoints before harvesting. 
The cells were harvested on ice, washed 2X using cold TBS and lysed on ice for 30 
min using 100 μl of Biosource (Camarillo, CA) cell lysis buffer supplemented with 
Protease Inhibitor Cocktail (Sigma) and PhosStop phosphatase inhibitor cocktail 
(Roche, Basel, Switzerland) according to the manufacturers’ recommendations. The 
lysates are occasionally vortexed to ensure complete lysis. Protein concentration 
was determined and the lysates are stored at -80ºC until use.  
 
Nuclear extract preparation 
Nuclear extracts were prepared from 1 x 106 cells using the NE-PER nuclear and 
cytoplasmic extraction kit (Pierce Biotechnology, IL, USA) according to 
manufacturer’s specifications. Briefly, cells were harvested in cold by scraping and 
were washed once in PBS. Supernatant was discarded leaving the cell pellet as dry 
as possible. Ice-cold CER I (containing protease inhibitors) was then added 
according to the cell pellet volume as specified by the manufacturer. Cell pellet was 
resuspended by vigorous vortexing for 15 seconds and then incubated on ice for 10 
min. Ice cold CER II was then added and vortexed vigorously for 5 seconds and 
then incubated on ice for 1 min. Next, cells were vortexed again for 5 seconds 
before centrifugation maximum speed for 5 min at 4C. Supernatant containing 
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cytoplasmic proteins were transferred to a new 1.5 ml pre-chilled tube. The pellet 
was then resuspended in ice cold NER (containing protease inhibitors), vortexed for 
15 seconds and incubated on ice for 40 min. Resuspended pellet was vortexed for 
15 seconds after every 10 min during the 40 min incubation. The tube was then 
centrifuged for 10 minutes at maximum speed at 4C. Supernatant (containing 
nuclear proteins) was then transferred to a new 1.5 ml pre-chilled tube. Cytoplasmic 
and nuclear proteins were stored at -80C. 
 
2.3.4 Protein concentration determination 
Protein concentration was determined using the Bio-Rad protein assay kit. Briefly, 
eight serial dilutions of a standard BSA solution were prepared, starting with 1.0 
mg/ml. 10 μl of the BSA standards and protein samples were added into the wells 
of a 96-well microtiter plate. The dye reagent was diluted (1 part Dye Reagent 
Concentrate with 4 parts distilled water) and filtered through 0.45 μm filter. 200 μl 
of the dye was then added to each well and incubated at room temperature for 5 min. 
Absorbance was measured at 595 nm. The standard curve was constructed by 
plotting the known BSA concentrations versus absorbance at 595 nm and sample 
concentrations determined from the curve. 
 
2.3.5 SDS-PAGE separation of proteins 
Typically 5-20 μg of protein samples were run per well and were mixed with 5X 
Laemmli buffer. The samples were denatured by boiling for 10 min at 95ºC before 
loading into the wells of a 12.5% SDS-PAGE gel. The gel was run in 1x SDS-
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PAGE electrophoresis buffer at 100V until the dye front is approximately at the 
bottom of the gel. 
 
2.3.6 Western blotting 
Proteins resolved by SDS-PAGE were electroblotted to a polyvinylidene difluoride  
(PVDF) membrane (Immun-Blot  PVDF, Bio-Rad® ) and incubated overnight at 4°C 
with blocking buffer (TBS-T containing 5% skim milk). Primary and secondary 
antibody incubations were done in blocking buffer. The membrane was washed 3 X 
5 mins with TBS-T and then visualized using the Immun-Star AP 
Chemiluminescent substrate (Bio-Rad). 
 
To reprobe a Western blot membrane after chemiluminescent detection, it was first 
rinsed 3X with TBS-T. Then it was incubated with 10 ml of Western blot stripping 
buffer in sealed ziplock bags at 50ºC for 20 min with occasional agitation. The 
membrane was then rinsed 3X with TBS-T and reprobed with another antibody. 
The efficacy of the stripping process was occasionally tested by incubating the 
stripped membrane with the chemiluminescent substrate. Absence of signal after 2 
hr incubation confirms successful stripping of antibody complexes.  
 
2.3.7 Flow cytometry 
Surface staining 
Cells were harvested and resuspended at 2 X 106/ml in cold culture medium + 1% 
goat serum. 50 μl of this mix were incubated for 30 min on ice with the respective 
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antibodies. For cells incubated with fluorochrome-conjugated antibodies, they were 
washed 2X in FACSwash and fixed with cold 1% (w/v) paraformaldehyde (PFA) in 
PBS. For non-conjugated antibodies, a second incubation using a PE-conjugated 
goat-anti mouse antibody was performed. Cells were then washed 2X in FACSwash 
and fixed with cold 1% PFA. Data acquisition and analysis were performed on 
Dako Cyan flow cytometer using the Summit 4.3 software (Dako-Cytomation). 
 
Intracellular staining 
Cells were harvested and washed 1X with cold culture medium. Fixation and 
permeabilization was performed using the BD Cytofix/Cytoperm kit. Briefly, ~106 
cells were fixed with 250 μl of Fixation/Permeabilization solution for 20 min on ice. 
The cells were then washed 2X in Perm/Wash solution. Fixed and permeabilized 
cells were then resuspended into 50 μl Perm/Wash solution + 1% goat serum and 
the respective antibodies were added and incubated for 30 min on ice. Cells were 
washed 2X in the Perm/Wash solution and resuspended with PBS + 0.1% BSA for 
analysis. For cells probed with non-conjugated antibodies, they were incubated with 
a fluorochrome-conjugated secondary antibody against the first antibody on ice for 
30 min. The cells were then washed 2X in the Perm/Wash solution and resuspended 
with PBS + 0.1% BSA for analysis. 
 
2.3.8 Confocal microscopy 
DCs were cultured on glass cover slips laid into 24-well plates with the respective 
stimulation conditions and durations. The cells were washed 3X with PBS and fixed 
for 20 min in 4% (w/v) paraformaldehyde and washed 3X. The cells were then 
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incubated for 20 min in 0.1% saponin in PBS at room temperature to permeabilize 
them, after which primary antibody was then added and incubated for 1 hr. For this 
incubation, the buffer was supplemented with 1% serum from the species used to 
develop the secondary antibody. This was followed by three washing steps with 
0.1% saponin. Secondary fluorescent-conjugated antibody was then added and the 
coverslips were incubated in the dark for 1 hr, washed four times with 0.1% saponin, 
and mounted on slides using VectaShield mounting medium with DAPI (Vector 
Labs, CA, USA). Confocal images were taken using the Leica TCS SP5 Confocal 
Microscope System and images were analyzed using the Leica Application Suite.  
 
2.3.9 Live cell microscopy 
Cells were examined in live culture using an IX81 inverted microscope equipped 
with the MicroPublisher 5.0 RTV imaging system (Olympus). Phase contrast 
images were captured using the Image-pro MC software. 10x objectives were used. 
 
 
2.4 Experimental repeats and statistical analysis 
Most figures presented are results representative of at least 3 independent 
experiments unless otherwise noted. Data were expressed as mean values of 
experimental triplicates ± SE (standard error). Analysis for statistical significance 
was performed using the Student’s two-sided unpaired t-test. Where applicable in 




2.5 Media and buffers 
1 x PBS pH 7.4 (diluted from 10X stock from 1st Base, Singapore) 
KH2PO4 1.76 mM 
Na2HPO4 10.4 mM 
NaCl 137 mM 
KCl 2.7 mM 
 
FACSwash buffer 
1 x PBS 
Heat-inactivated bovine calf serum 2.5% (v/v) 
Sodium azide 0.05% (w/v) 
 
MACS buffer  
1 x PBS 
0.5% bovine serum albumin 
2 mM ETA 
 
Tris buffered saline 
Tris-HCL, pH 7.5 50 mM 
NaCl 150 mM 
 
10 x SDS-PAGE electrophoresis buffer 
Tris base 250 mM 
Glycine 2.5 M 
SDS 1% (w/v) 
 
5 x Reducing Laemmli buffer 
Tris-HCL, pH 6.8 250 mM 
Glycerol 50% (v/v) 
SDS 10% (w/v) 
Bromophenol Blue 0.05% (w/v) 
Dithiothreitol (DTT) 0.5 M (added fresh before use) 
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10 x Western blot transfer buffer 
Tris base 250 mM 
Glycine 1.92 M 
To get a 1X buffer for Western blot, the 10X mix was diluted 1 part to 2 parts 100% 
methanol and 7 parts deionized water.  
 
PBS-T or TBS-T buffer 
1X of PBS or 1X TBS with Tween-20 0.05% (v/v) 
 
Western blot blocking and antibody incubation buffer 
Non-fat milk 5% 
(prepared in TBS-T buffer) 
 
Western blot stripping buffer 
62.5 mM Tris-HCl (pH 6.8) 































Our previous study (Cao et al., 2003) and that of others (Schwaeble et al., 1995; 
Castellano et al., 2004) have shown that DCs could produce C1q. In addition, 
different studies have been performed to examine how the expression of C1q could 
be regulated by various stimuli, such as LPS (Castellano et al., 2004), steroid drugs 
like dexamethasone (Armbrust et al., 1997) and cytokines like IFN-γ (Zhou et al., 
1991a). However, these studies have utilized different cells type, including 
macrophages and DCs or cell lines of human, mouse and rat origins. Hence, the 
effects of these stimuli on these different cell types could be sometimes 
contradictory. It would thus be advantageous if a unified study on how various 
stimuli could affect C1q expression on a particular cell type be performed.  
 
In this chapter, we used a human monocyte-derived DC culture system to 
investigate the regulation of C1q expression by the various stimuli. In our system, 
the C1q expression could be studied at different levels- mRNA expression was 
quantitated by real-time PCR, intracellular C1q protein expression was detected by 
Western blotting and intracellular flow cytometry, and secreted C1q was detected 
using an in-house sandwich ELISA. We started this project with the ELISA system 
to screen various stimuli for their effect on C1q production. 
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3.2 In vitro culture of monocyte-derived dendritic cells (moDC) and 
its phenotyping 
Throughout this study, the majority of experiments were conducted using human 
DCs differentiated from monocytes isolated from buffy coats of healthy blood 
donors. The method of Ficoll-gradient centrifugation coupled with plastic adhesion 
typically yields 1 to 4 X 107 monocytes. The purity of these cells was regularly in 
the range of 90 – 95% as judged by staining with fluorochrome-conjugated anti-
















Figure 3.1.  Flow cytometry profile of isolated monocytes. PBMCs were isolated 
from buffy coats using Ficoll-gradient centrifugation and washed repeatedly to 
remove platelets. Cells were allowed to adhere onto plastic culture flasks for 2 hr. 
Non-adherent cells were washed away and adherent cells that are mainly CD14  
monocytes were collected by gentle scraping. Isolated cells were then tested by 
staining with fluorochrome-conjugated antibodies (A) CD14 (PE) or (B) CD1a (PE). 
Grey histogram = isotype control, black line = CD14 or CD1a. Flow cytometry 










Human DCs were then differentiated from these monocyte precursors by culturing 
in the presence of IL-4 and GM-CSF for 6 days, with ½ volume of media being 
changed and fresh cytokines added every other day. This process was performed in 
6-well culture plates where 3 X 106 monocytes were seeded per well. After 6 days, 
the quality of DCs obtained was determined by staining for CD1a positivity and 
downregulated CD14 expression. Undifferentiated monocytes express a high level 
of CD14 (Fig. 3.1B) and without surface CD1a (Fig. 3.1A), whereas immature DCs 
(imDC) obtained after 6 days of differentiation express a high level of CD1a and 
downregulate CD14 (Fig. 3.2A). We usually obtained about 1.5 X 106 DCs per well, 
about half the number of monocytes originally seeded. Usually about 95% of the 
cells are CD1a positive, indicating a high purity of the DC preparation. 
 
The functionality of these DCs was confirmed by their ability to up-regulate DC 
surface markers upon maturation by IFNγ and LPS. ImDC expressed very low 
levels of CD83 and showed no surface CCR7. These two markers are effectively 
induced in mature DC (maDC) (Fig. 3.2B). CD40, CD80, CD86, MHC I and MHC 
II were expressed by imDCs but on mDCs their expressions were further increased. 
A more homogeneous population of mDC now expressed high levels of these 























Figure 3.2.  Surface phenotype of immature and mature DC. DCs 
differentiated from monocytes after 6 days of culture were considered as 
immature DC (imDC). Cells were harvested by gentle scraping, washed 2X with 
fresh media and stimulated with IFNγ (100 ng/ml) and LPS (500 ng/ml) for 2 
days to allow for complete maturation and these are matured DC (maDC). ImDC 
were stained for CD1a and CD14 (A). CD40, CD80, CD83, CD86, MHC I, MHC 
II and CCR7 antibodies were used to stain both imDC and mDC (B). Filled 
histograms are signals obtained with isotype IgG; Open histograms are staining 
with specific antibodies. 
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3.3 Establishing a system to detect DC expression of C1q in the 
levels of transcription, translation and secretion 
Upon acquiring DC phenotypes after 6 days of differentiation, we studied C1q 
expression in the cells. We harvested DCs after 6 days of differentiation, extracted 
total RNA from the cells, and converted the mRNA to cDNA. As a comparison, we 
also studied the mRNA obtained from undifferentiated monocytes and macrophages. 
We used the cDNA to perform a quantitative real-time PCR assay to detect the 
expression of all 3 C1q chains, C1qA, C1qB and C1qC. In this assay, cDNA was 
amplified by PCR, and the SYBR Green dye binds the amplified double-stranded 
DNA. As more copies of dsDNA were amplified, more SYBR Green would be 
bound and it results in increased fluorescence which was detected by the machine. 
 
DCs expressed significantly higher levels of all 3 C1q chains compared to 
monocytes (Fig. 3.3). In looking at the relative expression levels of the mRNA, 
whereby the expression level of each of the 3 C1q chains in monocytes is set to 1, 
C1qA expression on DC for C1qA, B and C respectively was 20-fold, 40-fold and 
140 fold higher. By comparison, macrophages differentiated under the presence of 
M-CSF have the highest level of C1q expression, about 400-fold higher for both 
C1qA and C1qB mRNA, and about 1800-fold higher for C1qC. Thus at the 
transcription level, DCs expressed all 3 C1q chains. 
 
Some of the DCs obtained were washed with PBS and lysed with a cell lysis buffer 
and subjected to SDS-PAGE. The proteins on the gel were then transferred to a 
PVDF membrane, which was then probed with a polyclonal goat anti-C1q antibody. 
The inclusion of DTT in the sample loading buffer prior to SDS-PAGE 
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electrophoresis will dissociate the C1q macromolecule into its 3 constituent A, B 
and C chains. This is because the A-B and C-C chains are held together by 
disulphide bonds which are broken under the reducing conditions in the presence of 
DTT. From our experience, the goat anti-C1q antibody gives a much stronger signal 
with the C1qA chain than with the C1qB and C1qC chains.  
 
In Fig. 3.4A, monocyte lysates did not give any signal with the C1q antibody, while 
the lysates of macrophages had high levels of C1q. C1q was also detected in DC 
lysates but at a lower level than in macrophages. This was further confirmed by 
intracellular staining of C1q, where macrophages expressed more C1q than DCs 
(Fig. 3.4B). The advantage of intracellular C1q staining is that the mouse 
monoclonal antibody used detects the globular domain of C1q, which is a part of 
the overall C1q macromolecule structure. Thus, it is specific in detecting the 
completely assembled C1q whereas there is a chance that Western blotting could 
also detect unassembled C1q chains. 
 
The final assay performed to confirm C1q expression in DC was a sandwich ELISA 
to quantitate the levels of secreted C1q in culture supernatant. A goat polyclonal 
anti-human C1q antibody was coated onto an ELISA plate to be used as the capture 
antibody. The ELISA plate was then blocked with BSA and diluted samples 
together with separately prepared C1q standards were then loaded. C1q in the 
samples or standards were bound by the capture antibody, following which the 
mouse monoclonal antibody against the globular domain of human C1q was used as 
a detection antibody. Finally, a HRP-conjugated goat anti-mouse antibody was used 
to detect the binding of the detection antibody to C1q. The dual layer of specificity 
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conferred by the two antibodies against human C1q allows for detection of C1q in 
RPMI 1640 medium supplemented with bovine serum. We have confirmed that the 
ELISA does not detect bovine C1q from the bovine calf serum (Fig. 3.5). 
 
Differentiated DCs and macrophages were harvested, washed and reseeded into 96-
well plates. The cells were incubated for two days before the supernatant was 
harvested and tested for C1q. As shown in Fig. 3.5, DCs secreted C1q typically in 
the range of 0.5 to 5 X 101 ng/ml levels. In agreement with the C1q levels as 
detected on the mRNA and cell lysate, macrophage secreted more C1q than DC, in 
this case about 85 ng/ml compared to 40 ng/ml by DC.  
 
Figure 3.3.  Real-time PCR quantitation of mRNA from monocyte, 
macrophage and DC for C1q expression. Total mRNA from the 3 cells were 
extracted, then reverse transcription performed to obtain cDNA and the levels 
of C1qA, C1qB and C1qC mRNA expression was quantitated using real-time 
PCR and normalized to GAPDH expression. The expression levels for 





















































Figure 3.4.  Intracellular C1q detection in monocytes, macrophages and DCs 
via Western blot and flow cytometry. (A) About 20 μg of total cell lysates were 
resolved via SDS-PAGE and electroblotted onto a PVDF membrane. A goat 
polyclonal anti-C1q antibody was then used to probe the membrane. The membrane 
was stripped and re-probed with an anti-β-actin antibody. Mo – monocyte; MF – 
macrophage; DC – dendritic cell (B) DC and MF cultured for 2 days were harvested, 
fixed and permeabilized. A mouse anti-C1q antibody or isotype control was used to 
stain intracellular C1q and a PE-conjugated goat-anti mouse IgG was used to 
visualize the C1q staining. Grey histogram – isotype control; Red histogram – DC, 
Blue histogram – Macrophage. 
Figure 3.5.  Quantitation of secreted C1q in cell supernatant. Macrophage and 
DC were cultured at a density of 7 X 10  cells per well (in 200 μl per well of RPMI 
1640 medium supplemented with 10% heat-inactivated BCS in 96-well U-bottom 
plates) for 2 days. Supernatant was collected and the secreted C1q was quantitated 
using a sandwich capture ELISA assay with purified C1q as standards. RPMI 
medium without any cells was used as a blank control. 
4
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3.4 Regulation of C1q production in DC 
Having established suitable assays to quantitate C1q production in moDCs, we then 
proceeded to utilize the ELISA method to screen a large amount of different stimuli 
for their ability to modulate C1q production in these DCs. We seeded DCs in 96-
well round bottom plates and stimulated them for 2 days, collected the culture 
supernatant, washed the cells and cultured them for another 2 days in fresh culture 
medium without adding back the stimuli. Thus for each stimulus, there are two sets 
of results, one for the first 2 days and another for the subsequent 2 days (2 + 2 days).  
 
The large number of stimuli used required that many separate experiments be 
performed to complete the screening. The results from each experiment were then 
tabulated, the effect on C1q production by each stimulus was expressed as a fold-
change over the unstimulated DC, and then the fold-change from multiple 
experiments were averaged and presented in Fig. 3.6 and Fig. 3.7. As the results 
presented in these two figures were averaged from a few independent experiments, 
the standard deviations of the fold-changes appear large in mose cases. 
 
In Fig. 3.6, the effects of various microbial stimuli on C1q production are shown 
whereas in Fig. 3.7, the effects of steroid drugs, hormones and cytokine/chemokines 
are presented. Typically, we observed that unstimulated DCs produce 2 to 3 times 
more C1q in the 2 + 2 days supernatant compared to the 2 days samples (Fig. 3.12 
and Fig 3.13). Table 2.1 summarizes all the microbial stimuli used and the pattern 
recognition receptors that they engage. The TLR3 and TLR5 ligands Poly(I:C) and 
flagellin had minimal effect on C1q production and so was the TLR7/8 ligand 
CL097. LPS, which stimulates TLR4 signaling, upregulated C1q strongly in DCs, 
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although in 2 experiments we observed that LPS had no effect. LTA which 
stimulates TLR2, and PGN which is a particulate ligand which stimulates both 
TLR2 and NOD1/2 also did not affect C1q production after 2 days of DC 
stimulation. However, both LTA and PGN increased C1q production after DCs 
were washed and cultured for another 2 days. The more specific NOD1 ligand 
TriDAP and NOD2 ligand MDP had minimal effect on C1q production. The 
synthetic agonists Pam3CSK4, Pam2CSK4 and FSL-1 which stimulate TLR2 in 
dimers with TLR1 or TLR6 all increased C1q production in both 2 and 2 + 2 days 
culture. Three different forms of CpG DNA were used in this experiment and all 
downregulated C1q production in DCs for both time-points. Interestingly, zymosan 
which also stimulates TLR2 together with TLR4 and TLR6 reduced C1q production. 
 
We also studied the effects of steroid drugs on C1q production in DCs. Cortisone, 
dexamethasone, prednisone and hydrocortisone all slightly reduced C1q secretion 
with 2 days stimulation but had minimal effects for 2 + 2 days stimulations. The 
female hormone estradiol showed the same effects but 3 other hormones 
progesterone, insulin and HCG reduced C1q secretion by about one third for the 2 
time-points. The appetite-inhibiting hormone leptin had no effect on C1q secretion.  
 
Among the chemokines and cytokines tested, the chemotactic peptide fMLP, IL-1β, 
IL-6, M-CSF, soluble CD40 ligand, TGF-β and a combination of GM-CSF with IL-
4 had minimal effect on DC secretion of C1q. Osteoprotegerin, thymic stromal 
lymphopoietin and TNF-α inhibited C1q secretion roughly by half for both time-
points. We noticed that GM-CSF on its own reduced C1q levels by about one-third 
for 2 days but after 2 + 2 days, it had no effect. In contrast, IL-10 also reduced C1q 
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levels by the same margin for 2 days, but C1q levels were double that of 
unstimulated cells in the 2 + 2 days sample.  
 
Interestingly, the type 2 interferon IFN-γ strikingly increased C1q production for 
both 2 days and 2 + 2 days samples. In contrast, the type 1 interferon IFN-α had no 
effect on C1q level with 2 days of stimulation, but it decreased C1q secretion in the 
long term 2 + 2 days culture. 
 
 
3.5 Expression of C1q in primary human plasmacytoid DC and 
CD1c+ myeloid DC from peripheral blood leukocytes 
We then sought to examine the expression of C1q in DCs isolated from the blood of 
healthy donors. We chose two frequently studied DCs from this group, 
plasmacytoid DC (pDC) and the CD1c+ myeloid DC (mDC) for this study. Firstly, 
PBMCs were purified from buffy coat of healthy donors as in the monocyte 
isolation procedure. Then, pDC and mDC were isolated from the total PBMCs 
using the relevant antibody-coated magnetic bead MACS kits from Miltenyi Biotec. 
Due to the rarity of these two cells, at least 1 X 108 PBMCs were used mDC 
isolation and about 2 X 108 PBMCs were used for pDC isolation. This resulted in a 
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For the isolation of pDCs, a cocktail of biotin-conjugated antibodies targeting T 
cells, B cells, NK cells, mDC, monocytes, granulocytes and erythroid cells was 
added and then subsequently anti-biotin magnetic beads were added. The non-pDC 
cells were then magnetically depleted, and pDCs were directly labeled with anti 
CD304 (BDCA-4/Neuropilin-1) magnetic beads and positively selected. The purity 
of isolated pDC was confirmed by double staining with CD123 and BDCA-
3/CD303. The scatter profile of the total PBMCs prior to isolation showed 
heterogeneity in the cell population whereas the isolated pDC was a highly 
homogeneous population (Fig. 3.8A). Staining for CD123 and BDCA-3 in total 
PBMCs showed about 1% of the cells expressing both markers whereas more than 
97% of the purified pDCs were CD123 and BDCA-3 double positive, indicating 
that the enriched cells were highly pure (Fig. 3.8B).   
 
The MACS method was also used to isolate mDCs. In this purification, PBMCs 
were labeled with anti-CD1c-PE and anti CD20 magnetic beads targeting B cells. 
The first round of magnetic purification depletes B cells, followed by labeling of 
the CD1c+ cells with anti-PE magnetic beads. The mDCs were then directly 
separated via a magnetic column. Purified mDCs were tested for CD1c expression 
and the absence of B cells via CD19 staining, as some B cells express low levels of 
CD1c. In Fig. 3.9C, more than 91% of the purified mDC cells were CD1c+ and 
about 4% of cells in this fraction expressed CD19 (Fig. 3.9B). Thus B cell 
contamination was at a minimum. In comparison, less than 5% of total PBMCs 
stained positive for CD1c (Fig. 3.9C) and the B cell fraction represented 2.4% of 
the total cells (Fig. 3.9B). 
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Total RNA was isolated from freshly purified mDC and pDC together with moDC 
differentiated after 6 days of culture, and all RNA were converted to cDNA for 
real-time PCR analysis. Quantitation of C1q A, B and C chain mRNA across all 3 
cell types revealed that mDC and pDC expressed about a 100-fold less C1q than 
moDC for each of the 3 chains (Fig. 3.10). Thus mRNA quantitation alone suggests 
that mDC and pDC expressed much lower levels of C1q than moDC. 
 
Next, we seeded the isolated mDC, pDC and cultured moDC in U-bottom 96-well 
culture plates for 2 days and collected the supernatant. The cells were then washed 
once and cultured for another 2 days with fresh medium. Supernatant from these 2 
+ 2 days cultures were also collected and analyzed by ELISA for C1q levels. moDC 
produced 4.5 ng/ml of C1q after 2 days culture while mDC secreted 1.5 ng/ml (Fig. 
3.11). When cultured for 2 + 2 days, moDC expressed 21 ng/ml of C1q while mDC 
expressed 3 ng/ml. Addition of IFN-γ to the culture increased C1q secretion by 
moDC to 15 ng/ml and 45 ng/ml for the 2 days and 2 + 2 days culture respectively, 
while mDC treated with IFN-γ also increased C1q expression to 5.5 ng/ml for 2 
days culture and 14 ng/ml for 2 + 2 days culture. In all cases, the secretion of C1q 

































Figure 3.8.  Flow cytometry profile of total PBMC and isolated pDC. Total 
PBMC and magnetically isolated pDC were stained with anti-CD123 and anti-
BDCA-3 and analyzed via flow cytometry. The forward and side scatter profiles 
are shown in the upper panel. Live cells were then gated according to the large 
rectangle gate in the scatter profiles and the cells were analyzed for CD123 and 
BDCA-3 staining (lower panel). The values shown in the lower panel represent 







Figure 3.9.  Flow cytometry analysis of PBMC and purified mDC. Total PBMC 
and mDC isolated via MACS were stained with anti-CD1c and anti CD19 and 
analyzed via flow cytometry. (A) The forward and side scatter profiles of both 
PBMC and mDC are shown. (B) Live cells were then gated according to the large 
rectangle gate in the scatter profiles for subsequent analysis. The percentage of 
CD19  B cells is given in the boxed region. (C) The black hollow histogram 
represents CD1c expression by mDC and the grey shaded histogram shows CD1c 
expression in PBMCs. The values shown are the percentage of cells positively 




















































Figure 3.10.  Quantitation of the expression of C1q A, B and C chains mRNA 
in mDC, pDC and moDC. Total mRNA was extracted from about 0.3 X 10  cells 
of freshly isolated mDC and pDC and immature moDC obtained after 6 days of 
differentiation. 0.3 μg of total RNA was converted to cDNA and then analyzed 
using real-time PCR. The values on the Y-axis are the expression levels of the 








































































2 + 2 days
Figure 3.11.  ELISA detection of C1q secreted by moDC, mDC and pDC into 
culture supernatant. 5 X 10  moDC, mDC and pDC together with total PBMC 
were cultured in triplicates with or without IFN-γ (100 ng/ml) in U-bottom 96-
well plates. Supernatant was collected after 2 days, then the cells were washed 1X 
with fresh medium and cultured for another 2 days. The supernatant was 
collected again (2 + 2 days). Secreted C1q in both sets of supernatant was 
quantitated using a sandwich capture ELISA assay with purified C1q as standards. 
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3.6 Expression of C1q in mouse BMDC and splenic DCs 
We then expanded from studying C1q production in human DCs to mouse DCs. For 
this study, we performed real-time PCR assay using specific primers for mouse 
C1qA, B and C genes. Total RNA from bone marrow-derived DC (BMDC) that 
was obtained from Dr Wong Siew Heng (Department of Microbiology, National 
University of Singapore) was extracted and converted to cDNA. Three functionally 
distinct DC subsets can be defined in a steady state mouse spleen. These are the 
plasmacytoid DC (pDC), CD8+ conventional DC (cDC) and CD8- cDC. They were 
enriched and FACS sorted from pooled mouse spleen in the laboratory of Professor 
Ken Shortman, The Walter and Eliza Hall Institute, Melbourne. The cells were 
shipped to our lab as frozen samples and we extracted RNA using our standard 
protocol, and converted the RNA to cDNA. As a control, we also used cDNA from 
the mouse RAW264.7 cell line, which does not produce C1q in our tests.  
 
Mouse DC subtypes sorted at the laboratory of Professor Ken Shortman were 
routinely >98% pure (Vremec et al., 2000; Lahoud et al., 2006). We verified the 
DC purity by performing real-time PCR analysis on the cDNA for genes that are 
known to be markers for these different DC subtypes – CD8α, CD11b, CD11c and 
SIRPα. All DCs expressed high levels of CD11c, with pDC showing the lowest 
expression (Fig. 3.12). BMDC and CD8- cDC expressed high levels of CD11b, with 
pDC showing intermediate levels and CD8+ cDC the lowest. CD8α expression was 
highest in CD8+ cDC while pDC also showed relatively high expression of this 
gene. CD8+ cDC expressed the lowest levels of SIRPα compared to the other 3 DCs 
tested, and SIRPα expression was high in CD8- cDC that are known to express this 
marker. The relative expression of these markers in our sorted mouse DCs is 
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consistent with their reported phenotypes (Lahoud et al., 2006; Shortman and Heath, 
2010) and should thus be of high purity. 
 
For the analysis of C1q mRNA, C1q expression in RAW264.7 cells was set to 1 as 
the calibrator for relative quantitation. BMDCs produced the highest level of C1q 
mRNA, 7 X 105 fold higher than RAW264.7 for C1qA, 4 X 104 fold more for C1qB 
and for C1qC, 3 X 104 fold higher (Fig. 3.13). This was then followed by CD8- cDC 
which produced half the amount of C1qA as BMDC and about 10-fold less C1qB 
and C1qC. Next, pDC produced 15-fold less C1qA and 10-fold less C1qB and 
C1qC than CD8- cDC. The CD8+ cDC expressed the lowest levels of C1q of all the 
mouse cells tested, 8-fold less C1qA and C1qC and 10-fold less C1qB than the 





















































Figure 3.12.  mRNA expression of various markers for subtyping mouse DCs. 
BMDCs were differentiated from mouse bone marrow cells for 7 days with GM-
CSF and total RNA was extracted from these cells. Splenic CD8+, CD8- and pDC 
cells were obtained from the lab of Professor Ken Shortman in the Walter and 
Eliza Hall Institute, Melbourne, in frozen form. Total RNA was then extracted. As 
a control, RNA was also extracted from the mouse macrophage cell line 
Raw264.7. All RNA were converted to cDNA and subjected to quantitative real-
time PCR analysis using mouse CD11b, CD11c, CD8α, SIRPα and β-actin 































































Figure 3.13.  Mouse DCs express C1q mRNA. The same cDNA samples in Fig. 
3.14 were used in this test where quantitative real-time PCR analysis using mouse 
C1qA, B and C and GAPDH specific primers was performed. The bars show the 
relative expression of mouse C1q genes and the results are normalized to β-actin. 














Chapter 4   Suppression of C1q production in DC by 




In a large scale screening study in Chapter 3.4, we examined a number of factors 
that are potentially related to SLE pathogenesis or factors which have been studied 
in previous studies on C1q regulation for their ability to modulate C1q production 
in moDC. An ELISA system has been developed for C1q detection and it provides 
sensitive detection of C1q in cell culture medium. Our results showed that a yeast-
derived structure, i.e. zymosan, can significantly inhibit C1q production in DC. 
Zymosan is a ligand for TLR2, but curiously other TLR2 ligands did not 
downregulate C1q production. Recently it has been highlighted that zymosan also 
stimulates a C-type lectin receptor called Dectin-1/Clec7A (Reid et al., 2009).  
 
We then performed a series of experiments to dissect the underlying mechanisms by 
which zymosan inhibits C1q production. We found that Dectin-1 indeed appears to 
be engaged by zymosan and this leads to the observed inhibition of C1q production. 
We then sought to study the downstream signaling events transduced by Dectin-1 







4.2 Zymosan down-regulates C1q production in DC 
We utilized the assays for analyzing C1q production that were developed in Chapter 
3 to study how zymosan suppresses C1q production in DCs. First, we sought to 
determine the optimal concentration of zymosan to use. We stimulated DCs with 
zymosan at different concentrations for 2 days and 2 + 2 days and analyzed the 
culture supernatant for C1q via ELISA. As shown in Fig. 4.1, zymosan 
downregulates C1q production by DCs is a dose-dependent manner. The inhibitory 
effect of zymosan was more obvious after prolonged stimulation. In the first 2 days, 
zymosan only showed significant inhibition on C1q secretion by DCs when it was 
used at 50 μg/ml or higher. At 10 μg/ml, it had no detectable effects. However, cells 
stimulated at 10 μg/ml in the first 2 days showed markedly reduced C1q production 
in the next 2 days. From this set of titrations, further experiments were conducted 
using zymosan at 50 μg/ml in order to observe its effects in the first 2 days.  
 
Next, we proceeded to study if the inhibition of C1q production occurs at the 
transcription and translation levels. We lysed DCs after 2 days of culture without 
any stimuli or with zymosan. The lysates were subjected to Western blotting and 
probed for C1q. After 48 hrs of stimulation with zymosan, intracellular C1q levels 
in DCs were drastically reduced (Fig. 4.2) compared to unstimulated cells. 
 
We progressed to look at the transcription of C1q mRNA in DCs stimulated with 
zymosan. We stimulated the cells for 5 hr, 1 day and 2 days and extracted total 
RNA, converted it to cDNA and analyzed via real-time PCR. For 5 hr and 1 day, no 
obvious changes were observed in C1qA and C1qB mRNA expression but C1qC 
mRNA expression was lower after zymosan treatment (Fig. 4.3). After 2 days of 
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zymosan stimulation, mRNA expression of all C1q chains was consistently reduced. 
For C1qA, it was reduced by 1.5-fold, for C1qB, the reduction was 2-fold and it 
































Figure 4.1.  Dose dependent suppression of C1q secretion by DC following 
zymosan treatment. 7 X 10  DCs were seeded in 96-well U-bottom plates and 
treated with increasing concentrations of zymosan. Supernatant was collected after 
2 days, cells washed and cultured for 2 more days (2 + 2 days). C1q levels in 
culture supernatant were measured by ELISA. This experiment was performed 
twice. 
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Figure 4.2.  Western blot of total DC lysate for C1q and β-actin after zymosan 
stimulation. 106 cells were either unstimulated when harvested on day 6 of DC 
differentiation (0h -ve), or cultured for a further 48 hrs with zymosan (48h zymo) or 
without stimuli (48h -ve) and then lysed and analysed via Western blotting with an 







Figure 4.3.  Quantitation of C1q mRNA in DC following zymosan treatment. 
106 cells DCs were stimulated with zymosan or left unstimulated. Cells were 
harvested for RNA extraction over the 3 time-points. mRNA was converted to 
cDNA and analyzed via real-time PCR for the quantitation of the 3 C1q chains. The 































































The downregulation of C1q expression by zymosan appeared to be specific and not 
due to increased death of DCs. This was determined by measuring lactate 
dehydrogenase (LDH) enzyme released by dead cells into the culture media (Fig. 
















Figure 4.4  Determination of cell death in DCs after various treatments by 
measuring released lactate dehydrogenase (LDH). Cell culture supernatant was 
collected after cells were treated with different stimuli for 2 days. The level of LDH 
enzyme which is released upon cell death was measured as reflected in the graph as 
the OD495nm values. Maximum lysis indicates the maximum LDH released upon 
total cell lysis of unstimulated cells. Stimulations were performed in triplicates and 










4.3 Neither opsonization of zymosan by serum factors nor its 
phagocytosis were required for C1q downregulation 
Zymosan is a particulate extract of S. cerevisiae cell wall which is widely used to 
represent the signature stimulus from fungi. It can be opsonized by complement 
components and can therefore interact with immune cells either directly or after 
complement opsonization (Le Cabec et al., 2002). In the experiments described so 
far, heat-inactivated bovine calf serum was used which should exclude the 
involvement by complements. To fully exclude any possible role played by 
complements, we stimulated DCs with zymosan in a serum-free media devoid of 
complements and other opsonins (Fig. 4.5A). This did not affect the downregulation 
of C1q production by zymosan, although the absolute amount of C1q produced was 
lower. It suggests that the inhibitory effect of zymosan probably involves direct 
zymosan interaction with DCs. The question remains if zymosan downregulation of 
C1q production requires its phagocytosis by DCs. However, when cytochalasin D 
was added to DCs, it showed no significant impairment of zymosan downregulation 
of C1q production (Fig. 4.5B). Cytochalasin D is an inhibitor of actin 




















4.4 Dectin-1 but not TLR signaling is required for zymosan 
downregulation of C1q production 
Zymosan recognition by DCs is mediated through TLR2/6 and the C-type lectin 
Dectin-1. When zymosan is treated with hot alkali (termed depleted zymosan here), 
it removes moieties that stimulate the TLRs but remains potent in Dectin-1 
stimulation (Ikeda et al., 2008). To identify the contributions from TLRs and 
Figure 4.5.  Neither serum factors nor phagocytosis are required for C1q 
downregulation by zymosan.  (A) DCs were either untreated or pre-treated with 
cytochalasin D (1 μM), which inhibits phagocytosis, before stimulation with 
zymosan. Supernatant was collected after 2 days for analysis using ELISA. (B) 
The experiment was performed using serum-free CD-hybridoma medium (Gibco). 
Downregulation of C1q production by DCs after zymosan treatment is observed 
after 2 days (unshaded bars) and also after 2 additional days (grey bars). 
Generally, C1q production by DCs cultured in CD-hybridoma medium is greatly 
reduced. All stimulations were performed in triplicates and results are presented 

































Dectin-1 in downregulating C1q production, DCs were stimulated separately with 
zymosan and depleted zymosan. Both stimuli resulted in similar levels of 
suppression of C1q expression (Fig. 4.6A). This suggests that Dectin-1 is a novel 
receptor that can mediate the downregulation of C1q in DCs. We confirmed that 
Dectin-1 was expressed on the surface of DCs (Fig. 4.7). Curdlan is a pure β-glucan 
ligand for Dectin-1 and does not activate TLRs, thus it is a more specific activator 
for Dectin-1 (LeibundGut-Landmann et al., 2007). Curdlan stimulation of DCs 
caused a downregulation of C1q production, similar to that caused by zymosan and 
the inhibition was also dose-dependent (Fig. 4.6B). We also confirmed via 
intracellular C1q staining that less C1q was detected inside DCs upon curdlan 
stimulation, similar to that observed with zymosan treatment (Fig. 4.8).  
 
We then examined whether co-stimulation of DCs with other TLR ligands affects 
zymosan inhibition of C1q production, as zymosan itself could activate TLR2 and 
TLR6 in addition to Dectin-1 (Ozinsky et al., 2000). An assortment of TLR ligands 
were used to co-stimulate DCs with depleted zymosan. None of these ligands 
affected C1q downregulation by depleted zymosan (Fig. 4.6C). Thus, zymosan 
downregulates C1q production by DCs through Dectin-1 stimulation and is 





























Figure 4.6.  Zymosan signals through Dectin-1 and not TLRs to mediate 
downregulation of C1q production in DCs.  (A) DCs were either treated with 
either 50 or 200 μg/ml of zymosan (zymo) or depleted zymosan (d.zym), which is 
devoid of TLR stimulatory ability but is still able to engage Dectin-1, or (B) curdlan, 
which is a specific Dectin-1 agonist. The dosage used was either 10 or 50 μg/ml. 
Supernatant was collected after 2 days and 2 + 2 days for analysis using ELISA. (C) 
DCs were left unstimulated or stimulated with zymosan or depleted zymosan 
together with various TLR ligands. Supernatant was collected after 2 days of culture 
and analyzed by ELISA. All experiments were performed in triplicates and the 


























































Figure 4.7.  Dectin-1 is expressed on DC surface. DCs were harvested after 6 
days of differentiation, stained with a monoclonal antibody specific against 
human Dectin-1 or an isotype control and counterstained with a secondary 
antibody. Cells were then fixed and analyzed by flow cytometry. Grey histogram 




















Figure 4.8.  Reduction in intracellular C1q levels upon curdlan or zymosan 
treatment. DCs were treated for 4 days with zymosan or curdlan at 50 μg/ml, 
fixed, permeabilized and stained with an anti-C1q antibody or isotype control, and 
then a PE-conjugated goat-anti mouse IgG was used to visualize the C1q staining. 
Grey histogram – isotype control; Black histogram – curdlan; Red histogram – 
zymosan, Blue histogram – untreated. MFI values are the mean fluorescent 
intensities of the respective histograms. 
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4.5 Dectin-1 inhibition of C1q production can suppress the IFN-γ 
enhancement of C1q 
We have shown in Chapter 3.4 that IFN-γ showed the opposite effect on C1q 
expression as Dectin-1 signaling, whereby it enhanced C1q production. Thus we 
wanted to determine if the suppressive effects of Dectin-1 signaling could 
overcome the C1q enhancing signals of IFN-γ or the reverse. 
 
The results Fig. 4.9A show the expected results after 2 days of DC stimulation, 
where zymosan and curdlan treatment suppressed C1q production and in contrast, 
IFN-γ enhanced C1q production. When zymosan or curdlan was added together 
with IFN-γ to DCs and cultured for 2 days, C1q production was suppressed down to 
the levels of zymosan or curdlan stimulation alone. This suggests that Dectin-1 
inhibition of C1q production is a powerful signal and can overcome the C1q 
upregulating effects of IFN-γ. 
 
In the same experiment, some cells were primed with zymosan, curdlan or IFN-γ 
alone, or zymosan + IFN-γ, or curdlan + IFN-γ, or left unprimed. After 2 days, the 
cells were washed and then stimulated with zymosan, curdlan, IFN-γ or left 
unstimulated and are labeled as (af) in Fig. 4.9B. These cells were then cultured for 
2 more days and the C1q levels secreted into culture supernatant was quantitated. 
C1q secretion by cells that were unprimed or primed with zymosan, curdlan or IFN-
γ, washed and then received no further stimulation (-ve (af)) followed the same 
profile as cells in Fig. 4.9A.  
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When cells that were primed with IFN-γ for 2 days and then treated either with 
zymosan (zymo(af)) or curdlan (curd(af)), less C1q was produced than in cells 
primed with IFN-γ and left untreated. Cells primed with zymosan and then 
stimulated with IFN-γ (IFN-γ (af)) showed no enhancement in the C1q levels. But 
in contrast, cells primed with curdlan and then similarly received IFN-γ stimulation 
had higher C1q secretion than cells primed with curdlan alone and left unstimulated, 
although the levels are still well below that of the unstimulated control.  
 
Cells that were unprimed for 2 days, and then stimulated with zymosan or curdlan 
still exhibited suppression in their C1q production. When the same unprimed cells 
were stimulated with IFN-γ after 2 days, C1q production was still enhanced. 
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 Figure 4.9.  Dectin-1 stimulation overcomes the enhancement of C1q 
production by IFN-γ. DCs were stimulated with the Dectin-1 ligands zymosan and 
curdlan (50 μg/ml for both) or IFN-γ (100 ng/ml) alone or together for (A) 2 days, 
or (B) after 2 days, the cells were washed and cultured for 2 more days without the 
addition of further stimulation, -ve (af); or with zymosan, Zymo (af); or with 
curdlan, Curd (af); or with IFN-γ, IFN-γ (af). C1q levels were analyzed by ELISA 
in all DC culture supernatant. Experiments were performed in triplicates and the 






























































































2 days stimulation, afterwards another 2 days with zymo, 
curd, IFN-γ or -ve (af) 
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4.6 Dectin-1 induced downregulation of C1q production does not 
signal through Syk 
Ligand binding of of Dectin-1 causes the ITAM domains to be phosphorylated by 
Src kinases which recruits Syk and forming a complex comprising of caspase 
recruitment domain 9 (CARD9), BCL10 and MALT1 (Hara et al., 2007). This leads 
to activation of NF-κB and production of cytokines following Dectin-1 activation. 
We asked whether inhibiting Syk can abrogate the inhibitory effects of Dectin-1 
activation. A Syk inhibitor piceatannol was to treat DCs at various dosages before 
the addition of curdlan. This inhibitor was unable to abrogate the inhibitory effects 
of curdlan, although at higher dosages it slightly inhibited C1q production in 
general (Fig. 4.10).  
 
To confirm that piceatannol is functional, we measured the levels of the cytokines 
IL-6 and IL-10 produced in the culture supernatant following piceatannol treatment. 
Curdlan stimulation of cells resulted in the production of IL-6 and IL-10 (Fig. 
4.11A and B). Piceatannol treatment inhibited IL-6 levels by about one-quarter 
while IL-10 levels were reduced by more than half. This indicates that piceatannol 
did indeed have inhibitory effects, which worked in inhibiting cytokine production 
following Dectin-1 stimulation, but showed no effects in subjugating the inhibitory 
effects on C1q production. Thus far the results suggest that Syk signaling 






























Figure 4.10.  Inhibition of Syk does not restore C1q levels downregulated upon 
curdlan treatment back to unstimulated levels.  Various concentrations of 
piceatannol (in μM), the inhibitor of Syk were used to pre-treated DCs before 
stimulation with curdlan. DMSO was added as a vehicle control. Supernatant was 
collected after 2 days for C1q analysis using ELISA. Stimulations were performed 




Figure 4.11.  The Syk inhibitor piceatannol attenuates production of IL-6 and 
IL-10 after Dectin-1 activation. Culture supernatant from the experiment in Fig. 
4.10 was assayed for IL-6 (A) and IL-10 (B) production to determine if piceatannol 
could inhibit Syk activation following Dectin-1 ligation with curdlan. Stimulations 









































4.7 Arachidonic acid release and ROS generation is not coupled to 
the downregulation of C1q production on Dectin-1 stimulation 
Cytosolic phospholipase A2 (cPLA2) is also activated by zymosan in macrophages 
and this leads to the release of arachidonic acid and production of eicosanoids, 
which initiate acute inflammation (Suram et al., 2006). So far, no report has shown 
that arachidonic acid regulates C1q expression and thus we asked if this could be 
the mechanism behind the observed downregulation of C1q production after 
Dectin-1 activation.  
 
We used a specific inhibitor of cPLA2, pyrrolidine-2 (Suram et al., 2006), during 
curdlan stimulation of DCs. The inhibitor alone without curdlan stimulation caused 
a slight increase in C1q production at 2 μM and C1q production was further 
increased when it was used at 10 μM (Fig. 4.12). Nevertheless, it showed no 
suppression of curdlan inhibition of C1q production in DCs. It suggests that cPLA2 
mediated arachidonic acid release, which was induced by curdlan through Dectin-1, 
was not responsible for Dectin-1 induced inhibition in C1q production. 
 
Signaling by Dectin-1 in macrophages also triggers ROS production (Underhill et 
al., 2005). We then investigated if ROS is inhibiting C1q production. This was 
examined by adding diphenylene iodonium (DPI), an inhibitor of the NADPH 
oxidase and nitric oxide synthase (Riganti et al., 2004), to DCs during the 2 days of 
curdlan stimulation. At a low concentration (0.05 μM), DPI alone without curdlan 
slightly increased C1q production. However, it did not affect the curdlan inhibition 
of C1q production (Fig. 4.12). At higher concentrations (0.2 μM and 1 μM), it 
inhibited C1q production but again it had no effect on the inhibitory effects of 
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curdlan. Thus, ROS production, which is expected to be induced by curdlan, does 
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Figure 4.12.  Neither arachidonic acid nor ROS release following Dectin-1 
ligation cause the downregulation of C1q in DCs.  DCs were pre-treated with 
pyrrolidine-2, an inhibitor of cytosolic phospholipase A2 that generates arachidonic 
acid, or diphenyleneiodonium chloride (DPI), which inhibits the processes leading 
to reactive oxygen species production, at the indicated dosages (in μM) before 
curdlan was added. Cells were stimulated for 2 days and supernatant was analyzed 
for C1q production by ELISA. Stimulations were performed in triplicates and 
results are presented as means ± SD. 
 
4.8 Involvement of both Raf-1 and Ca2+ signaling are excluded 
from the suppression of C1q production following Dectin-1 activation 
Raf-1 signaling is triggered downstream of Dectin-1 activation (Gringhuis et al., 
2009), and whether it leads to suppression of C1q production was examined. We 
used the same system of treating DCs with a specific inhibitor; in this case we used 
the Raf-1 inhibitor GW5074, prior to stimulation with curdlan. C1q secretion by 
DCs into the culture supernatant was then assayed by ELISA. Treatment of DCs 
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with low dosages of GW5074 (2 μM and 10 μM) did not restore C1q levels after 
curdlan stimulation to the levels of unstimulated cells (Fig. 4.13). A higher dosage 
of 25 μM slightly reduced C1q secretion by unstimulated DCs, but nevertheless 
there was still no abrogation of the inhibitory effects of curdlan.  
 
Dectin-1 stimulation elicits Syk-mediated activation of intracellular Ca2+ flux (Xu 
et al., 2009b). This leads to the production of many cytokines including IL-2, IL-6, 
IL-10, IL-12, IL-23, and TNF-α. To investigate whether Ca2+ signaling was 
involved in Dectin-1-mediated inhibition of C1q production, DCs were pre-treated 
with a cell permeable Ca2+ chelator BAPTA-AM before stimulation with curdlan. A 
total of 3 different concentrations were tested but all treatments failed to affect the 
downregulation of C1q levels following curdlan stimulation (Fig. 4.13). 
 
We also analyzed IL-6 and IL-10 levels in the culture supernatant to determine if 
the inhibitors were functional. GW5074 treatment at 25 μM inhibited curdlan-
induced IL-6 and IL-10 levels to about ¾ that of non-treated levels (Fig.4.14A and 
B). BAPTA-AM treatment at 10 μM only managed to reduce IL-6 levels by about 
10% but IL-10 levels were reduced by about ¼.   
 
These results suggest the exclusion of another two mechanisms, the Raf-1 and Ca2+ 
signaling, from being involved as the effectors downstream of Dectin-1 signaling in 





































Figure 4.13.  The inhibition of Raf-1 or Ca2+ influx inhibition could not 
abrogate the inhibitory effects on C1q production after Dectin-1 ligation. DCs 
were pre-treated with the Raf-1 inhibitor GW5074 or intracellular Ca2+ chelator 
BAPTA-AM at the indicated dosages before curdlan was added. Cells were 
stimulated for 2 days and supernatant collected and analyzed by ELISA. 
Stimulations were performed in triplicates and results are presented as means ± SD. 
A B
Figure 4.14.  Raf-1 inhibitor GW5074 and Ca2+ chelator BAPTA-AM partially 
attenuates the production of IL-6 and IL-10 after Dectin-1 activation. Culture 
supernatant from the experiment in Fig. 4.13 was used to assay for IL-6 (A) and IL-
10 (B) to determine if GW5074 and BAPTA-AM could inhibit cytokine production 
following Dectin-1 stimulation with curdlan. Stimulations were performed in 




Chapter 5   Regulation of DC production of C1q by 




ICs cause unabated IFN-α production in SLE patients, especially during disease 
flares (Pascual et al., 2006). The main cellular source of IFN-α are the pDCs 
activated by ICs. pDC numbers are reduced in SLE blood (Blanco et al., 2001), but 
this is pathogenic as these cells massively infiltrate inflammed lupus skin (Farkas et 
al., 2001). IFN-α contributes to increased autoantibody secretion and immune 
complex formation in SLE by directly activating B cells and differentiating mature 
B cells into antibody-producing plasma cells (Jego et al., 2005). IFN-α can 
directly induce inflammatory DC differentiation and maturation, and possibly 
activating autoreactive T lymphocytes that have escaped deletion during central 
tolerance (Blanco et al., 2005). Mature DCs generated from IFN-α exposure 
can activate cytotoxic CD8+T cells to lyse cells and release nucleosomes that can be 
captured and presented by DCs as autoantigens. 
 
In order to understand how the protective role of C1q is connected to the pathogenic 
role of type I IFN, we examined how IFN-α and IFN-γ regulate C1q production in 
DCs. There is no data so far whether IFN-α can modulate C1q production. We 
included IFN-γ in this study because there are earlier studies reporting that it 
increases or decreases C1q production in macrophages in different studies.  
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5.2 C1q production by DC is attenuated by prolonged IFN-α 
treatment 
Elevated serum IFN-α level is commonly detected in SLE patients (Kim et al., 
1987). SLE patients have chronically elevated serum levels of IFN-α during disease 
flares. Since C1q deficiency is associated with SLE development, whether IFN-α 
regulates C1q production by DCs is relevant to SLE pathogenesis. Therefore, we 
investigated if these two factors are intimately regulated.  
 
We established a system that addresses both short-term and chronic exposure of 
cells to the IFN-α inflammatory signals. We initially stimulated DCs for 48 hr with 
two concentrations of IFN-α (200U/ml and 5000U/ml, respectively labelled as 
IFNa(1) and IFNa(2) in the figures), but this short-term stimulation caused no 
detectable change in C1q production as determined by ELISA (Fig. 5.1A).  
 
After 48 hr, the IFN-α treated DCs were washed and cultured for a further 48 hr 
without any further stimuli (Fig. 5.1B, neg (af)) or with IFN-α (Fig. 5.1B, IFNa (2) 
(af)). This time, we observed a decline in C1q production in both cases. In the 96 hr 
culture, C1q production was decreased by about half in the IFN-α-primed DCs 
compared to the untreated DCs even though IFN-α was absent during the second 48 
hr. When IFN-α was used to prime the DCs in the first 48 hr, washed and added 
again in the second 48 hr, a marked decreased in C1q production was observed, 
whereby the C1q levels decreased by about ¼ compared to DCs that were initially 
unprimed and then IFN-α-treated for the subsequent 48 hr. These results show that 
IFN-α only significantly inhibits C1q production in DCs upon prolonged treatment, 
mimicking chronic IFN-α production in SLE. 
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5.3 IFN-γ enhances C1q production and also abrogates IFN-α 
inhibition  
In Chapter 3.4, IFN-γ was found to have opposite effects compared to IFN-α in C1q 
regulation, in that it upregulated C1q production over the 2 days and 2 + 2 days 
culture. Thus, we decided to further study how IFN-γ increases C1q production in 
DCs.  
 
Firstly, IFN-γ stimulation alone primed DCs to produce more C1q in the first 48 hr 
(Fig. 5.1A), and also after the cells were washed and cultured for another 48 hr (Fig. 
5.1B, -ve (af)) when compared to unprimed cells. Secondly, with both IFN-α and 
IFN-γ co-stimulation, DCs still produced high levels of C1q, equal to that of IFN-γ 
alone (Fig. 5.1A). In this same co-stimulation of DCs, IFN-α was unable to prime 
DCs so that less C1q was produced in the second set of 48 hr culture (Fig. 5.1B, -ve 
(af)).  Thirdly, IFN-γ has the ability to restore C1q production in IFN-α-primed DCs 
(Fig. 5.1B, IFN-γ (af) for cells treated with IFNa (1) and IFNa (2)). This shows that 
IFN-γ is of an antagonistic nature to the inhibitory effects associated with IFN-α, 




























Figure 5.1.  Distinct and antagonistic regulation of C1q production by IFN-α 
and IFN-γ. (A) DCs were cultured from monocytes using GM-CSF and IL-4 and, 
at day 6, the cells were treated with IFN-α at 200 U/ml (1) or 5000 U/ml (2) or IFN-
γ (100 ng/ml) for 48 hr, or left unprimed. `bf’, before further treatment. C1q 
production was measured by ELISA (B) After washing, the cells were then treated 
with IFN-α (2) or IFN-γ or left untreated for 48 hr. `af’, after initial treatment for 48 
hr. C1q production was measured by ELISA. All experiments were performed in 
triplicates and results are presented as means ± SD. 
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5.4 Decreased C1q secretion following IFN-α treatment is not 
associated with increased DC death  
The IFN-α-mediated downregulation of C1q expression appeared specific and was 
not due to increased death of DCs. We measured LDH enzyme secretion into the 
culture media following the treatment of DCs with both IFN-α and IFN-γ for 2 days 
and 2 + 2 days. (Fig. 5.2A). The levels of LDH release in all experiments were 
comparable with untreated DCs (-ve) for both time-points.  
 
In addition to measuring the LDH secretion, we also checked the viability of cells 
by propidium iodide (PI) staining. DCs were left unstimulated or stimulated with 
IFN-α and IFN-γ for 2 days, washed and then cultured for another 2 days. Cells 
were harvested at both time-points, stained with PI and analyzed immediately using 
flow cytometry. Cells staining positive for PI are non-viable and have disrupted 
membranes. For 2 days stimulation (Fig. 5.2B), non-treatment and IFN-α treatment 
resulted in 28% of DCs staining for PI while IFN-γ treatment actually resulted in 
37% of cells being PI positive. This was also consistently observed for the 2 + 2 
days cultures, whereby IFN-γ treatment resulted in the highest cell death of 26%, 
and IFN-α gave the lowest cell death percentage of 18% (Fig. 5.2C). For untreated 
cells, 24% were stained PI positive.  
 
Thus, IFN-α treatment does not downregulate C1q by increasing DC death, in fact it 















0.0 0.5 1.0 1.5
IFNγ 2+2 days
IFNα 5000 U/ml 2+2 days
IFNα 200 U/ml 2+2 days
-ve 2+2 days
IFNγ 2 days
IFNα 5000 U/ml 2 days












Figure 5.2.  Reduction in C1q secreted after IFN-α treatment is not due to 
increased cell death. (A) Lactate dehydrogenase levels were measured from 
supernatant of DCs stimulated with IFN-α, IFN-γ or left unstimulated for 2 days 
and 2 + 2 days. Maximum lysis indicates the maximum levels of LDH released 
upon total cell lysis of unstimulated cells. DCs stimulated with IFN-α, IFN-γ or left 
unstimulated for (B) 2 days and (C) 2 + 2 days were harvested, washed, 
counterstained with the vitality dye propidium iodide (PI) and analyzed via flow 
cytometry immediately. Blue – Unstimulated cells; Black – IFN-α; Red – IFN-γ; 
Grey histogram – no PI staining. These are the percentage of PI positive cells in the 
region R1 for 2 days (B): -ve – 28%; IFN-α – 28%; IFN-γ – 37% and 2 + 2 days (C): 
-ve – 24%; IFN-α – 18%; IFN-γ – 26%. 
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5.5 Downregulation of secreted C1q protein by chronic IFN-α 
stimulation does not occur at the transcriptional level 
We next examined the expression of C1q in DCs at the transcriptional level 
following IFN-α as well as IFN-γ treatments. Initially, IFN-α does not appear to 
affect the levels of all three C1q subunit mRNA up to 24 hr after stimulation. At 48 
hr, DCs treated with IFN-α upregulated all three C1q subunit mRNA (about 3-fold 
for C1qA and C1qB, and about 5-fold for C1qC, Fig.5.3, A-C) compared to 
untreated cells. At the maximum time-point assayed of 96 hr, mRNA of C1q 
subunits A, B and C were all significantly increased after prolonged treatment with 
IFN-α compared to untreated cells. This differs significantly from the ELISA 
analysis which showed that 96 hr of priming with IFN-α significantly inhibited the 
levels of secreted C1q protein. This discrepancy warrants further investigation into 
whether IFN-α stimulation of DCs affects C1q production at the translational level 
or its secretion.  
 
We also examined how IFN-γ regulates C1q expression in DCs at the transcriptional 
level by stimulating these cells with IFN-γ for 5, 24, 48 and 96 hr. All three C1q 
subunit mRNA species were increased by IFN-γ noticeably after 24 hr, and 









































































Figure 5.3.  IFN-α surprising increased C1q mRNA production in DCs 
together with IFN-γ. DCs were stimulated with IFN-α (200 U/ml; black), IFN-γ 
(100 ng/ml; red) or left untreated (blue) for 5 hr, 24 hr and 48 hr. The cells were 
then washed and cultured for another 48 hr to make up to 96 hr of total culture time. 
This mimics the system used in Fig. 5.1 to analyze secreted C1q protein in culture 
supernatant after prolonged stimulation of DCs with IFN-α. Total RNA were 
isolated for each time-point, converted to cDNA and subjected to real-time PCR 
detection of all 3 chains of C1q. mRNA levels were normalized to GAPDH and the 



















5.6 The downregulation of C1q after chronic IFN-α stimulation is 
also not regulated at the protein translational level 
As C1q mRNA levels were enhanced with both IFN-α and IFN-γ stimulation, we 
investigated if this led to a corresponding increase in the amount of C1q protein 
produced. Indeed the amount of C1q detected from Western blots of DC lysates 
corresponded to that of the mRNA levels (Fig. 5.4A). At every time-point, DCs 
stimulated with IFN-γ had the highest levels of C1q, followed by DCs stimulated 
with IFN-α and unstimulated DCs expressed the lowest levels of C1q. Generally the 
C1q levels increased in a time-dependent manner for all treatments. 
 
As a further confirmation, we detected the expression of the full C1q protein using 
intracellular flow cytometry after the DCs were stimulated for 2 + 2 days. The 
results corroborates the results observed for the real-time PCR and Western blot 
data, in that unstimulated cells expressed the least C1q and IFN-γ treated cells 
showed the highest expression, with C1q expression level of IFN-α stimulated cells 
in between unstimulated and IFN-γ stimulated DCs (Fig. 5.4B).  
 
Insofar, chronic IFN-α stimulation of DCs does not seem to reduce its transcription 
and translation of C1q. Instead, DCs stimulated with IFN-α actually expressed more 































Figure 5.4.  Intracellular C1q detection in IFN-α and IFN-γ stimulated DCs 
via Western blot and flow cytometry. (A) 5 X 105 DCs were stimulated with 
IFN-α, IFN-γ or were left unstimulated, and the cells were harvested and lysed at 
the time-points indicated. About 20 μg of each cell lysate was resolved via SDS-
PAGE, Western blotted and probed for C1q with a goat polyclonal anti-C1q 
antibody. The membrane was stripped and re-probed with an anti-β-actin antibody. 
(B) Densitometric analysis of C1q levels in Fig.5.4A normalized to -actin levels. 
(C) 5 X 105 DCs were stimulated with IFN-α, IFN-γ or left unstimulated for 2 
days, washed and cultured for 2 more days. The cells were then harvested, fixed 
and permeabilized. Intracellular C1q was detected using a mouse anti-C1q 
antibody or isotype control and a PE-conjugated goat-anti mouse IgG was used to 
visualize the C1q staining. Grey histogram – isotype control; Blue histogram – no 


























5.7 C1q is mainly trapped in the endoplasmic reticulum and not 
transported to the Golgi apparatus for secretion after IFN-α 
stimulation 
C1q synthesis was increased in DCs following IFN-α stimulation, but its secretion 
seems to be defective when compared to cells stimulated with IFN-γ. Proteins are 
exported out from cells via the secretory pathway. Newly synthesized proteins in 
the cytosol that are destined for secretion are translocated into the endoplasmic 
reticulum (ER), then packaged into vesicles which fuse to become and merge to 
form the cis-Golgi network (CGN). The proteins then moves through the Golgi to 
the terminal trans-Golgi network (TGN). Here, proteins are membrane-bound and 
secreted as vesicles (van Vliet et al., 2003). Thus, if C1q secretion is defective, the 
C1q could possibly be trapped in the ER and unable to translocate to the Golgi 
network, or could be stuck within the Golgi apparatus and not be packaged into 
secretory vesicles. 
 
We thus sought to pinpoint the localization of C1q within the intracellular 
compartments after IFN-α/IFN-γ treatment of DCs. C1q was stained together with 
the markers calreticulin (CRT) that localizes to the ER (Ramos et al., 2007) and 
Syntaxin-16 (Syn16) that is found in the Golgi apparatus (Tang et al., 1998). 
Proteins that are endocytosed at the plasma membrane are transported to the early 
endosome, of which the early endosome antigen-1 (EEA-1) is a marker (Mukherjee 
et al., 2006). We stained for early endosome as a negative control, as C1q is 
produced internally by the cells and not taken in by endocytosis. Thus C1q should 
not co-localize with EEA-1. 
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High levels of C1q expression were detected in DCs stimulated with IFN-γ for 2 
days (Fig. 5.5) and 2 + 2 days (Fig. 5.6), and most of the C1q were not localized in 
the ER. In fact, C1q were mostly found in the Golgi apparatus (Fig. 5.7 and 5.8) and 
this suggests that the C1q are ready to be packed for secretion. More C1q was 
detected after both 2 days and 2 + 2 days of IFN-α stimulation than in unstimulated 
cells. Strikingly, we found that most of the C1q were localized in the ER (Figs. 5.5 
and 5.6). Only a small amount of C1q was detected in the Golgi apparatus after 2 
days of IFN-α stimulation, and after 2 + 2 days of stimulation with IFN-α, more 
C1q now localize to the Golgi apparatus for secretion, but it is still noticeably lesser 
than in DCs stimulated with IFN-γ. Although C1q expression in unstimulated DCs 
was generally low, we observed that in cells that expressed C1q, the C1q appeared 
as distinct punctate bodies separate from the ER for both stimulation time-points 
(arrows for –ve DCs in Figs. 5.5 and 5.6). Some C1q in the unstimulated cells were 
seen to localize to the Golgi apparatus although in general, their expression levels 
were low (arrows for –ve DCs in Figs. 5.7 and 5.8). Co-staining of C1q with the 
early endosome marker EEA-1 shows no co-localization of the 2 signals for all 
stimulations and at both time-points (Figs. 5.9 and 5.10). This shows that C1q was 
produced intracellularly by the DCs, and that confocal microscopy can exclude 
compartments that C1q is not located in. 
 
In summary, although IFN-α treatment increased C1q expression, its secretion 
mechanism was impaired and the trafficking of C1q down the secretory pathway 
was defective. We found that the mature C1q protein was mainly retained in the ER 
and not transported to the Golgi apparatus to be packaged for secretion. 
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Figure 5.5  C1q is trapped in the ER following IFN-α stimulation for 2 days. 
Immature DCs (2 X 105) differentiated from monocytes for 6 days were seeded onto 
coverslips laid in wells of a 24-well culture plate. The cells were stimulated IFN-α, 
IFN-γ or left unstimulated for 2 days. The cells were then washed, fixed and 
permeabilized with 0.1% saponin. Mouse anti-C1q and rabbit anti-calreticulin 
antibodies were added and incubated for 1 hr on ice, washed and stained with 
secondary goat anti-mouse (FITC, green) and goat anti-rabbit (Cy3, red). Nuclei 
stained with DAPI appear as blue signals in the merged image. C1q co-localized 
with CRT in DCs stimulated with IFN-α, and appear as yellow signals pointed by 
the arrows. For IFN-γ treated DCs, minimal co-localization of C1q and CRT was 
observed. C1q in unstimulated cells was not localized in the ER and appeared as 
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Figure 5.6  C1q is trapped in the ER following IFN-α stimulation for 2 + 2 days. 
Immature DCs (2 X 105) differentiated from monocytes for 6 days were seeded onto 
coverslips laid in wells of a 24-well culture plate. The cells were stimulated IFN-α, 
IFN-γ or left unstimulated for 2 days, washed and cultured for another 2 days. The 
cells were then washed, fixed and permeabilized with 0.1% saponin. Mouse anti-
C1q and rabbit anti-calreticulin antibodies were added and incubated for 1 hr on ice, 
washed and stained with secondary goat anti-mouse (FITC, green) and goat anti-
rabbit (Cy3, red). Nuclei stained with DAPI appear as blue in the merged image. 
Most of the C1q co-localized with CRT in DCs stimulated with IFN-α, and appear 
as yellow signals pointed by the arrows. For IFN-γ treated DCs, C1q and CRT 
rarely co-localized and appeared as separate signals. C1q in unstimulated cells was 
not localized in the ER and appeared as distinct green signals indicated by the arrow 











Figure 5.7  Less C1q is transported to the Golgi apparatus for secretion 
following 2 days of IFN-α stimulation than IFN-γ stimulation. Immature DCs (2 
X 105) differentiated from monocytes for 6 days were seeded onto coverslips laid in 
wells of a 24-well culture plate. The cells were stimulated with IFN-α, IFN-γ or left 
unstimulated for 2 days. The cells were then washed, fixed and permeabilized with 
0.1% saponin. Mouse anti-C1q and rabbit anti-Syntaxin-16 antibodies were added 
and incubated for 1 hr on ice, washed and stained with secondary goat anti-mouse 
(FITC, green) and goat anti-rabbit (Cy3, red). Nuclei stained with DAPI appear blue 
in the merged image. C1q co-localized with Syn16 in DCs stimulated with IFN-γ, 
and appears as yellow signals pointed by the arrows. C1q in IFN-α treated DCs 
appears distinct from Syn16 and the signals are mainly green, showing minimal co-
localization with the Golgi apparatus. Some C1q was localized in the Golgi 












Figure 5.8.  Less C1q is transported to the Golgi apparatus for secretion 
following 2 + 2 days of IFN-α than IFN-γ stimulation. Immature DCs were 
seeded onto coverslips and stimulated with IFN-α, IFN-γ or left unstimulated for 2 
days, washed and cultured for another 2 days. The cells were then washed, fixed 
and permeabilized. Mouse anti-C1q and rabbit anti-Syntaxin-16 antibodies were 
added and incubated for 1 hr on ice, washed and stained with secondary goat anti-
mouse (FITC, green) and goat anti-rabbit (Cy3, red). Nuclei stained with DAPI 
appear blue in the merged image. Most of the C1q co-localized with Syn16 in DCs 
stimulated with IFN-γ, and appears as yellow signals. More C1q in 2 + 2 days IFN-
α treated DCs localized with Syn16 than the 2 days treated DCs, but is still less 
compared to IFN-γ stimulated DCs, as most of the C1q still appear as distinct green 
signals in the merged image (white arrows). Some C1q was localized in the Golgi 












Figure 5.9  C1q is not localized in the early endosome after 2 days culture. 
Immature DCs (2 X 105) differentiated from monocytes for 6 days were seeded onto 
coverslips laid in wells of a 24-well culture plate. The cells were stimulated IFN-α, 
IFN-γ or left unstimulated for 2 days. The cells were then washed, fixed and 
permeabilized with 0.1% saponin. Mouse anti-C1q and rabbit anti-EEA-1 
antibodies were added and incubated for 1 hr on ice, washed and stained with 
secondary goat anti-mouse (FITC, green) and goat anti-rabbit (Cy3, red). Nuclei 
stained with DAPI appear blue in the merged image. C1q did not co-localize with 
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Figure 5.10  C1q is not localized in the early endosome after 2 + 2 days culture. 
Immature DCs (2 X 105) differentiated from monocytes for 6 days were seeded onto 
coverslips laid in wells of a 24-well culture plate. The cells were stimulated IFN-α, 
IFN-γ or left unstimulated for 2 days, washed and cultured for another 2 days. The 
cells were then washed, fixed and permeabilized with 0.1% saponin. Mouse anti-
C1q and rabbit anti-EEA-1 antibodies were added and incubated for 1 hr on ice, 
washed and stained with secondary goat anti-mouse (FITC, green) and goat anti-
rabbit (Cy3, red). Nuclei stained with DAPI appear blue in the merged image. C1q 
did not co-localize with EEA-1 in DCs for all 3 conditions and is thus not located in 







5.8 Fibronectin secretion is not reduced following IFN-α 
stimulation 
We have delineated that DCs subjected to chronic IFN-α stimulation seemed to 
reduce C1q secretion but not its expression. Whether this is specific to C1q or 
applies to other proteins remains a question. We chose to investigate the expression 
of fibronectin following IFN-α and IFN-γ stimulation. Fibronectin (Fn) is expressed 
by DCs and is found in high levels in the plasma and is an important component of 
the extracellular matrix (ECM) (Lehtonen et al., 2007). 
 
First, we analyzed Fn mRNA expression in DCs following IFN-α/IFN-γ stimulation 
as before. After 2 days of IFN-α stimulation, Fn mRNA was unaffected whereas it 
was halved for IFN-γ stimulation (Fig. 5.11A). When we studied the secretion of Fn 
after 2 days, IFN-α stimulated DCs secreted about 3 times more Fn than DCs 
stimulated with IFN-γ (Fig. 5.11B). This roughly corresponds to their respective 
mRNA expression levels.  
 
For the 2 + 2 days treatment, IFN-γ stimulated DCs secreted 3.5-fold less Fn than 
DCs receiving IFN-α stimulation (Fig. 5.11B). Considering that the Fn mRNA 
expression for 2 + 2 days IFN-α and IFN-γ stimulation are about equal (Fig. 5.11A), 
we can infer that protein secretion was generally not affected by IFN-α treatment. In 
fact, IFN-γ treatment seems to reduce protein secretion. The inhibition on C1q 
secretion following prolonged IFN-α may be limited to C1q or an unknown subset 

























































2 + 2 days
 
B 
Figure 5.11.  Analysis of fibronectin secretion following IFN-α/IFN-γ 
stimulation.   The expression and secretion of the ECM protein fibronectin in 
DCs after IFN-α and IFN-γ stimulation was studied. (A) mRNA from DCs 
stimulated with both IFNs for 2 days and 2 + 2 days was analyzed for the 
expression of the Fibronectin-1 gene. (B) Culture supernatants for the 
corresponding time-points and stimuli were also collected and the fibronectin 
levels were quantitated using an indirect ELISA assay with purified human 
fibronectin as standards. Stimulations were performed in triplicates and the results 







Chapter 6   Deposited C1q induces differentiation of 




After the discovery of tissue deposited C1q around DC in tissues, the function of 
this C1q fraction has not drawn significant investigations (Cao et al., 2003). In one 
recent study, it was shown that deposited C1q could directly activate monocyte-
derived DCs like LPS but the underlying mechanisms were not investigated 
(Csomor et al., 2007). In contrast, another study suggested a tolerogenic role for 
C1q, in that LPS induced less IL-12p40 when excess C1q was added to bone 
marrow-derived DCs suggesting C1q inhibition of IL-12 production (Yamada et al., 
2004).  
 
Another mechanism by which deposited C1q may regulate DCs is to modulate 
monocyte differentiation into DCs with altered properties. This will be the focus of 
this section in which we present results showing that DCs cultured on deposited 
C1q were significantly different from DCs cultured without C1q. Overall, these 
C1q-differentiated DCs (C1qDCs) were less inflammatory and less able to stimulate 
Th1 and Th17 activation.  
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6.2 C1qDCs express the characteristic surface MHC, co-
stimulatory, CD83 and CCR7 molecules like normal DCs 
To examine whether surface-deposited C1q regulates DC development, monocytes 
were differentiated to DCs on C1q-coated plates (C1qDCs) or normal plates 
(normal DCs). Cells were cultured using the same procedure as established in 
Chapter 3.2, with monocytes seeded at 1.5x106/ml in a total volume of 2 ml and 
supplemented with IL-4 and GM-CSF. At day 6, the yields of the two DC types 
were similar (about 0.8x106/ml). As shown in Fig. 6.1, C1qDCs were minimally 
different from normal DCs in the expression of surface CD1a, CD14, MHC, CD80, 
CD86 and CD40. Upon activation with the powerful maturation stimuli of LPS + 
IFN-γ for 48 hr, MHC and co-stimulatory molecules were similarly upregulated and 
CD83 and CCR7 were similarly induced on the two DC types. Therefore, these 
C1qDCs have the characteristic normal DC phenotype. 
 
 
6.3 C1qDCs are less adhesive to cell culture wells than normal DCs  
C1qDCs visually showed marked differences from normal DCs. In live cell culture 
following 6 days of monocyte differentiation, normal DCs form cell clusters and a 
major fraction of these cells were adherent and spreading (Fig. 6.2A). C1qDCs also 
formed clusters, but these cells were mostly non-adherent. DCs cultured on BSA-
coated plates (BSA-DCs) appeared just as adherant as normal DCs (Fig. 6.2A).  
 
Staining of DCs during the differentiation period with crystal violet also detected 
less adherent cells in the C1qDC culture (Fig. 6.2B). Since C1q is a highly 
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positively charged protein (pI = 9.0), we also coated plates with poly-L-lysine to 
culture DCs. Poly-L-lysine increased rather than decreased DC adhesion (Fig. 6.2B). 
It shows that the reduced adhesion by C1qDCs was not due to the positively 
charged nature of the coated C1q and is a characteristic specific to the C1qDCs. 
 
 
6.4 C1qDCs phagocytose more apoptotic cells than normal DCs 
Failed clearance of apoptotic cells (AC) is postulated to be a mechanism that may 
lead to SLE pathogenesis (Truedsson et al., 2007). To examine whether C1qDCs 
are different from normal DCs in AC phagocytosis, CFSE-labeled ACs were 
prepared from Jurkat cells by UV-irradiation and added to DCs at a 1:1 ratio. After 
AC incubation with DCs, extracellular CFSE fluorescence was quenched with 
trypan blue. The cells were then stained for CD11c to identify DCs. In this 
experiment, CFSE signals detected in CD11c+ cells portrays DCs that have 
phagocytosed AC (Fig. 6.3). When the incubation was performed at 4ºC, minimal 
AC phagocytosis was detected with either DC type (2.3% and 3.5% respectively for 
C1qDCs and normal DCs) as there was no cytoskeletal rearrangement and actin 
polymerization. Incubation at 37ºC resulted in 31% phagocytosis with normal DCs 
but a significantly higher 49% with C1qDCs (Fig. 6.3). Therefore, C1qDCs are 






Figure 6.1.  Phenotype of C1qDCs and normal DCs. C1qDCs and normal DCs 
were cultured from monocytes and, at day 6 (imDCs), the cells were stained with 
fluorochrome-conjugated specific antibodies. Some imDCs were stimulated with 
LPS/IFN-γ for 2 days (matured DC) before staining with the same antibodies. Solid 
histograms, isotype IgG; red histograms, C1qDCs; blue histograms, normal DCs. 
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 Figure 6.2. Adhesion of C1qDCs and normal DCs. (A) Cultures of normal DCs, 
C1qDCs and BSA-DCs were examined at day 6. Images were captured using 10x 
and 20x objectives. Note the presence of adherent and spreading cells for normal 
and BSA-DCs when viewed under the 20x objective. (B) Monocytes were cultured 
in 96-well plates (2x105/well) to generate DCs. At the indicated time-points, non-
adherent cells were removed by washing and adherent cells were stained with 
crystal violet. Cell-bound dye was eluted and measured at 570 nm. In this 
experiment, plates were coated with C1q, BSA or poly-L-lysine (all 50 μg/ml) or 
PBS as a control. These experiments were performed in triplicates and results are 

















Figure 6.3.  C1qDCs display enhanced phagocytosis of AC. Jurkat cells were 
labeled with CFSE, UV-irradiated and cultured for 4 hr in serum-free RPMI1640 to 
induce apoptosis. This was assessed by propidium iodide and Annexin V staining. 
In the phagocytosis experiments, apoptotic Jurkat cells were incubated with normal 
DCs or C1qDCs in RPMI 1640 + 10% human serum for 2 hr at 37oC. In each 
experiment, 1x105 DCs were incubated with 1x105 AC in 0.2 ml volume. As a 
control, the cells were incubated at 4oC. Excessive fluorescence from non-engulfed 
cells was quenched in cold Trypan blue, washed and the cells were fixed with 4% 








6.5 C1qDCs produce less inflammatory cytokines TNF-α, IL-6 and 
IL-12 and IL-23 but more anti-inflammatory cytokine IL-10 than 
normal DCs 
With respect to IL-8, IL-6 and TNF-α production, the two DC types produced 
similar levels of IL-8 after LPS or LPS/IFN-γ stimulation but C1qDCs produced 
significantly less IL-6 and TNF-α than normal DCs (Fig. 6.4). With LPS stimulation, 
BSA-DCs also produced less IL-6 and TNF-α but this was not observed with 
LPS/IFN-γ co-stimulation. Overall, C1qDCs produced less inflammatory cytokines. 
 
We then examined IL-10, IL-12 and IL-23 production, which are intimately 
associated with the ability of DCs to stimulate adaptive immunity or autoimmunity 
(Oppmann et al., 2000). With LPS stimulation, C1qDCs consistently produce more 
IL-10 but less IL-12 (Fig. 6.4). Bioactive IL-12 (IL-12p70), which is a p35/p40 
heterodimer, was not induced with LPS alone from both DC types. IFN-γ co-
stimulation is required for IL-12p70 induction (Liu et al., 2003). LPS only induced 
IL-12p40, but much less IL-12p40 was induced from C1qDCs as compared with 
normal DCs. With LPS/IFN-γ co-stimulation, IL-12p70 was induced but C1qDCs 
also produced less IL-12p70 than normal DCs. As a control, BSA-DCs were similar 
to normal DCs in IL-10 and IL-12 production.  
 
Besides IL-12p35, IL-12p40 also dimerizes with IL-23p19 which forms bioactive 
IL-23, a cytokine which stimulates Th17 cell survival and effector cytokine 
production (Oppmann et al., 2000). LPS induced half the levels of IL-23 from 
C1qDCs as compared with normal DCs. LPS/IFN-γ co-stimulation induced IL-23 
more strongly, but C1qDCs still produced half the amount of IL-23 as normal DCs. 
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Therefore, DCs cultured on surface-deposited C1q, mimicking tissue-deposited C1q, 
selectively increase IL-10 but decrease IL-12 and IL-23 production when activated. 
 
Significant donor variations were observed throughout this study. C1qDCs can 
sometimes produce as up to 5-fold less IL-12p70 than normal DCs and similarly 
about 5-fold more IL-10. C1qDCs from other donors may not show such a striking 
difference and sometimes less than 2-fold less IL-12p70 or less than 2-fold more IL-
10 could be observed. The absolute levels of cytokines fluctuate between donors, 
with IL-12p70 levels varying the most out of all cytokines, from less than 100 pg/ml 
detected up to more than 5 ng/ml. However, it was consistently observed that 
C1qDCs produced significantly more IL-10 and less IL-12p70 than normal DCs. 
 
 
6.6 C1qDCs induce less Th1 and Th17 cells than normal DCs  
The reduced IL-12 and IL-23 production by C1qDCs implies weaker Th1 and Th17 
cell stimulation and this was examined by MLR. Naïve and memory CD4+ T cells 
that were more than 90% pure (Fig. 6.5) were isolated from PBMC for MLR co-
culture with C1qDCs, normal DCs and macrophages cultured with M-CSF as a 
control. These macrophages produce high IL-10 but little IL-12 and IL-23 (data not 
shown). After co-culture of normal DCs with T cells for 7 day, a large population of 
IFN-γ-producing Th1 cells was induced from naïve (25%) and memory (28%) cells. 
The IL-17-producing Th17 cells were only induced from memory cells (1.1%) (Fig. 
6.6). A significant cell population (0.9%) was induced to produce both IFN-γ and 





Figure 6.4.  Distinctive anti-inflammatory cytokine production profile by 
C1qDCs. DCs (7 X 104 per well) were stimulated for 24 hr in 96-well plates with 
IFN-γ, LPS, LPS/IFN-γ or left unstimulated (control). Cytokine production was 
determined by ELISA. As a control, DCs were cultured on BSA-coated plates 
(BSA-DC). IL-23 was measured in separate experiments. All experiments were 
performed in triplicates and results are presented as means ± SD. 
 
 
Compared with normal DCs, C1qDCs induced intermediate levels of Th1 and Th17 
cells. C1qDCs induced 9% and 17% IFN-γ positive Th1 cells from naïve and 
memory cells respectively (Fig. 6.6). From memory cells, C1qDCs induced 0.6% 
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Th17 cells. The population of T cells that produce both IL-17 and IFN-γ was 0.2% 
with C1qDCs. Therefore, C1qDCs are clearly weaker than normal DCs in Th1 and 
Th17 cell induction. This is consistent with their lower IL-12 and IL-23 production 
than normal DCs (Fig. 6.4). 
 
 
6.7 C1qDCs induce less IFN-γ and IL-17 secretion from allogeneic 
CD4+ T cells  
IFN-γ and IL-17 secretion were also measured in these MLR experiments. In 
agreement with the results of the intracellular cytokine detection (Fig. 6.6), C1qDCs 
also induced less IFN-γ secretion from the CD4+ T cells (Fig. 6.7A). In these 
experiments, IFN-γ (0.1 μg/ml) was added as a stimulus which was expected to 
interfere with IFN-γ detection by ELISA. We then washed the cells at day 7 and re-
stimulated the T cells with anti-CD3 and anti-CD28 antibodies coated onto beads. 
In these re-stimulation experiments, T cells that were primed with C1qDCs or 
macrophages in MLR, produced low amounts IFN-γ after re-stimulation. In contrast, 
T cells primed with normal DCs showed potent IFN-γ production upon re-
stimulation, irrespective of whether naïve or memory cells were used in the initial 
MLR (Fig. 6.7B). It was also noticed that, with normal DCs in MLR, naïve cells 
produce twice as much IFN-γ as memory cells when these cells were re-stimulated 
with bead-coated CD3 and CD28 antibodies (Fig. 6.7B).   
 
The polarization of adaptive immunity towards a Th1 phenotype critically requires 
IL-12 (Murphy et al., 2000). As high levels of IL-12 secretion are observed when 
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normal DCs were stimulated with IFN-γ + LPS (Fig. 6.4), we sought to clarify if 
this is the mechanism behind the superior induction of IFN-γ production by normal 
DCs compared to C1qDCs. We co-cultured total CD4 T cells with both DCs, and 
IFN-γ + LPS was added. Normal DCs induced about 3-fold more IFN-γ than 
C1qDCs (Fig. 6.8). When a blocking antibody against IL-12 was added, the IFN-γ 
production induced by both DCs dropped to almost basal levels (the levels detected 
in DC alone + IFN-γ/LPS). The IFN-γ levels were not affected when an irrelevant 
isotype control antibody was used. 
 
In MLR, IL-17 secretion was not detectable with naïve T cells. With memory cells, 
C1qDCs and macrophages induced low IL-17 secretion (~50 pg/ml), but 5-fold 
more IL-17 was induced by normal DCs (~250 pg/ml) (Fig. 6.7C). In the 
subsequent re-stimulation experiments, more IL-17 was detected in T cells that were 
primed by normal DCs in MLR, produced twice the amount of IL-17 than T cells 
primed by C1qDCs or macrophages (Fig. 6.7D).  
 
Regulatory T cells (Treg) play an important role in the maintenance of peripheral 
immunological self-tolerance by suppressing excessive effector T-cell proliferation 
and activation that may lead to generation of self-reactive T cells (Bonelli et al., 
2010). We thus stained the T cells following MLR culture for the Treg markers 
CD4, CD25 and FoxP3. There appears to be no difference in the ability of both 
normal DCs and C1qDCs to induce Treg cells following co-culture with naïve CD4 
T cells (Fig. 6.9). 
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Collectively, these results show that C1qDCs are weaker than normal DCs in Th1 
and Th17 stimulation. We found that the ability of normal DCs to produce high 
levels of IL-12 is coupled to its superior ability in inducing IFN-γ producing CD4 T 
cells compared to C1qDCs. The induction of Treg cells does not seem to contribute 






















Figure 6.5.  Purity of naïve and memory CD4 cells. Both subsets of CD4 T cells 
were isolated using MACS from PBMCs of healthy donors. The purity was 
determined by flow cytometry analysis. Naïve cells are CD4+ and CD45RA+ while 





























Figure 6.6.  Less Th1 and Th17 T cells are induced by C1qDCs than normal 
DCs. Naïve and memory CD4 T cells were isolated by MACS. In 96-well plates, 
DCs or macrophages (Mac) (4x104) were co-cultured with the T cells (4x105) (0.2 
ml/well). LPS and IFN-γ were added to all cultures. At day 7, cells were treated 
with PMA and ionomycin for a further 6 hr and Brefeldin A was added for the last 4 
hr. The cells were fixed, permeabilized, and stained with anti-IL-17 (AlexaFluor-

























Figure 6.7.  Induction of IFN-γ and IL-17 secretion from CD4 T cells by 
C1qDCs and normal DCs. Naïve (white bar) and memory (black bar) CD4 T cells 
were isolated and co-cultured with both normal and C1q DCs or macrophages 
(Mac). (A&C) 4x104 DCs or macrophages were co-cultured with 2x105 naïve or 
memory CD4 T cells. After 7 days, IFN-γ and IL-17 were determined by ELISA. 
(B&D) At day 7, cells were washed and re-stimulated with bead-bound CD3 and 
CD28 antibodies in 96-well plates at bead:cell ratio of 2:1. After 2 days, IFN-γ and 
IL-17 secretion was measured. Experiments were performed in triplicates and 

























DC only DC + CD4 T cells  
Figure 6.8.  The superior induction of CD4 T cell IFN-γ production by normal 
DCs is coupled to its IL-12 production. Total CD4 T cells were isolated and co-
cultured with DCs or C1qDCs. IFN-γ/LPS were added to some cells to induce a 
strong Th1 signature on the T cells. A blocking anti-IL-12 antibody or the isotype 
IgG1 control was added (10 μg/ml) to some of the cells. At day 7, culture 
supernatant was collected and IFN-γ levels were measured. Experiments were 





Figure 6.9.  No significant difference in the induction of regulatory T cells 
(Treg) was observed between C1qDCs and normal DCs. Naïve CD4 T cells were 
isolated and co-cultured with DCs in 96-well plates (2x105 T cells to 4x104 DCs) At 
day 7, cells were washed and re-stimulated with beads coated with CD3 and CD28 
antibodies at a beads:T cell ratio of 2:1. After 3 days, the cells were harvested and 
stained for surface CD4 (Pacific blue-conjugated antibody) and CD25 (Alexa647-
conjugated antibody). The cells were then permeabilized and stained with a PE-
conjugated anti-FoxP3 antibody. Dead cells and debris were excluded by forward 
and side scatter, and the Treg cells were gated based on the CD4 population and 
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6.8 Maturation stimuli attenuate C1qDCs, but enhance normal 
DCs, in activating naïve T cell  
In view of the similar MHC and co-stimulatory molecule profiles on C1qDCs and 
normal DCs (Fig. 6.1), we asked whether they similarly activate naïve CD4+ T cells 
by measuring naïve T cell proliferation and surface CD25 induction. As shown in 
Fig. 6.10, immature C1qDCs and normal DCs were similarly potent in stimulating T 
cell proliferation. When LPS was added, it caused reduced T proliferation in both 
C1qDCs or normal DCs. The presence of both LPS and IFN-γ further reduced T cell 
proliferation caused by both DC types. Nonetheless, no significant difference was 
observed between C1qDCs and normal DCs in stimulating naïve T cell proliferation. 
 
With respect to CD25 induction on naïve T cells, immature C1qDCs were as potent 
as immature normal DCs (MFI = 58 and 60, respectively) (Fig. 6.11). The presence 
of LPS increased CD25 induction by normal DCs (MFI = 84) but it attenuated 
CD25 induction by C1qDCs (MFI = 36). When both LPS and IFN-γ were present, 
CD25 induction by normal DCs was further increased (MFI = 156), but its induction 
by C1qDCs remained low (MFI = 40).  
 
Similar conclusions can be reached from the re-stimulation experiments. Naïve 
CD4+ T cells primed by immature C1qDCs and normal DCs both expressed high 
surface CD25 in the re-stimulation experiments (MFI = 332 and 242, respectively) 
(Fig. 6.11, lower panel). In fact, C1qDCs appeared to be more potent than normal 
DCs in CD25 induction in their immature states. However, when naïve T cells were 
stimulated with C1qDCs or normal DCs in the presence of LPS or LPS/IFN-γ, those 
T cells primed with normal DCs continue to express high CD25 in the re-
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stimulation experiments. However, those T cells primed with C1qDCs showed 
markedly attenuated CD25 expression upon re-stimulation with MFI values dropped 
to 160 and 59 respectively from 332.  
 
Therefore, maturation stimuli disparately regulate naïve T cell activation depending 
on whether C1qDCs or normal DCs are used. Normal DCs became more potent 

















Figure 6.10.  Allogeneic naïve CD4 T cell proliferation in response to normal 
DCs and C1qDCs.  Naïve CD4 cells were isolated from PBMCs by negative 
MACS selection and labeled with CFSE. The cells were then co-cultured with 
normal DCs (blue) or C1qDCs (red) for 7 days with LPS or LPS/IFN-γ stimulation 
or without stimulation (none). The T cells were gated, based on forward and side 
scattering, in flow cytometric analysis for the level of CFSE. Three independent 
















Figure 6.11.  CD25 induction by C1qDCs and normal DCs on naïve CD4 T 
cells. Upper panels: In 96-well plates, 4x104 DCs were co-cultured with 2x105 
naïve CD4 T cells (0.2 ml/well), in the presence or absence of LPS or LPS/IFN-γ. 
At day 7, cells were stained for CD4 (Pacific blue) and CD25 (PE) and CD4 cells 
were gated for CD25 detection. Lower panels: At day 7, cells were washed and re-
stimulated for 2 days with CD3 and CD28 antibodies in 96-well plates (0.2 ml/well). 
Cells were similarly analyzed for CD25 expression on CD4 cells. Red histograms, 
CD4 cells primed by C1qDCs in primary MLR; blue histograms, CD4 cells primed 
by normal DCs. The results shown are representative of 3 independent experiments. 
 
 
6.9 C1qDCs exhibit greater ERK, p38 and p70 S6 kinase activation 
than normal DCs 
How C1q induced these C1qDC properties is unclear. Without knowledge of the 
C1q receptors involved, we examined the signaling properties of C1qDCs that 
might impact their IL-10, IL-12 and IL-23 expression. ERK and PI3K signaling can 
regulate these cytokines and generally enhance IL-10 but reduce IL-12 and Il-23 
production (Yi et al., 2002; Fukao and Koyasu, 2003; Agrawal et al., 2006; Yang et 
al., 2006). The p70 S6 kinase (p70S6K) has been implicated in the cytokine 
regulation by PI3K (Fukao and Koyasu, 2003; Yang et al., 2006). C1q may indeed 
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activate ERK and PI3K through the CD91 and gC1qR receptors (Waggoner et al., 
2005; Jehle et al., 2006).  
 
DCs were stimulated for 10, 30, 60 and 120 min with LPS. ERK phosphorylation 
was examined by Western blotting. Significantly greater ERK activation was 
detected in C1qDCs as compared with normal DCs (Fig. 6.12). We found that 
another MAP kinase p38 also showed stronger activation in C1qDCs which 
supports a recent report that, like ERK, p38 signaling also enhances IL-10 but 
inhibits IL-12 production (Jarnicki et al., 2008). JNK activation was not 
significantly different between the two DC types. PI3K signaling was examined by 
detecting p70S6K and Akt kinase activation and C1qDCs showed higher p70S6K 
phosphorylation than normal DCs. However, Akt activation appeared slightly lower 
in C1qDCs and how this might be related to IL-10, IL-12 and IL-23 production by 
C1qDCs is unclear. However, a stronger p70S6K activity in C1qDCs is consistent 
with the high IL-10 but low IL-12 and IL-23 production by these cells (Fukao and 





















Figure 6.12.  C1qDCs exhibited stronger ERK, p38 and p70S6K activation 
than normal DCs. Normal DCs and C1qDCs were resuspended at 1x106/ml and 
then seeded in 24-well plate (0.5x106/well). The cells were stimulated with LPS for 
10, 30, 60 and 120 min. At the indicated time-points, the cells were chilled, lysed 
and subjected to Western blotting to detect phosphorylated (p-) ERK (Thr202/Tyr204), 
p38 (Thr180/Tyr182), JNK (Thr183/Tyr185), p70S6K (Thr389) and AKT (Thr308). As 
controls, total ERK, p38 and β-actin were also detected on the blots.  
 
 
6.10 Inhibition of ERK renders C1qDCs similar to normal DCs in its 
IL-10 and IL-12 production 
The relevance of elevated ERK activation in C1qDCs to its IL-10 and IL-12 profile 
was assessed by ERK inhibition in these cells. C1qDCs and normal DCs were pre-
treated with the MEK1 inhibitor PD98059 before further stimulation. As shown in 
Fig. 6.13A, this reduced IL-10 production by C1qDCs but not normal DCs. As a 
result, the two DC types produced similar levels of IL-10. On the other hand, 
PD98059 treatment increased IL-12p70 production by both DC types but it caused a 
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greater increase in C1qDCs. As a result, C1qDCs were drawn nearer to normal DCs 
in IL-12p70 production; from a 7-fold difference to < 2 fold (Fig. 6.13B). PD98059 
similarly restored C1qDC production of IL-12p40 close to the level of normal DCs 







Figure 6.13.  ERK inhibition partially restored the inferior IL-12 production in 
C1qDCs and abrogated its superior IL-10 production. Normal DCs and 
C1qDCs were pre-treated for 2 hr with the MEK1 ERK kinase inhibitor PD98059 
(40 μM), the vehicle DMSO or PBS before stimulation with LPS or LPS/IFN-γ for 
24 hr. As a control, the cells were not stimulated (-). (A) IL-10, (B) IL-12p70 and 
(C) IL-12p40 production was determined by ELISA. The experiments were carried 
out in triplicates and data was presented as means ± SD. 
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Chapter 7   Discussions 
 
 
7.1 Assays for analyzing C1q production in human monocyte 
derived DCs 
We set out to investigate the regulation of C1q production and to find novel factors 
that may influence C1q production, especially in the context of SLE. We have 
established a system to screen a panel of ligands and drugs for their ability to 
upregulate or downregulate C1q production. In this system, we exposed human 
monocyte-derived DCs to these stimulants and analyzed their ability to influence 
C1q production. Our analysis of C1q production began at the mRNA level by using 
real-time PCR, then we studied the cellular protein levels by using Western blot and 
finally we quantitated secreted C1q by ELISA. 
 
Our culture system consistently yielded highly pure monocytes, which did not 
express C1q. The monocytes were differentiatiated into functional DCs, which then 
expressed C1q mRNA and secreted C1q into the culture supernatant. We analyzed 
the ability of the different stimuli to influence C1q production in DCs over 2 time-
points (2 and 2 + 2 days). C1q mRNA and protein levels were mainly not affected 
over a short stimulation period of less than 1 day. The effects of stimulations on 
C1q production became clearer only after 2 days of stimulation and were even more 
apparent after 4 days (Figs. 4.3, 5.3 and 5.4). The increase in C1q protein correlates 
well to the mRNA levels for unstimulated and IFN-γ stimulated DCs.  
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Washing of the cells after the first 2 days of stimulation and culturing for a further 2 
days mimics the in vivo milieu, where DCs are exposed to inflammatory stimuli at 
the site of stimulation, mature and migrate away from their niches to lymphoid 
tissues (Randolph et al., 2005). DC maturation results in a profound change, where 
it upregulates co-stimulatory molecules like CD40, CD80 and CD86, increases its 
antigen presentation capability by upregulation of MHC I and MHC II and express 
surface CCR7 (Sanchez-Sanchez et al., 2006). The chemokine receptor CCR7 
guides the migratory DCs to the lymph nodes via the lymphatic system.  
 
Many of the previous studies on C1q production based their conclusions solely on 
mRNA expression or total cellular protein levels that may not represent the secreted 
bioactive fraction of C1q. This fraction can be quantitated by the ELISA assay and 
this assay was crucial in detecting the suppressed C1q secretion following 
prolonged IFN-α stimulation (Chapter 5). Another possible disadvantage in the 
mRNA and Western blot studies is that these analyze only the individual chains of 
C1q. Western blotting is usually performed on proteins resolved under reducing 
SDS-PAGE and thus the C1q macromolecule is resolved into its 3 constituent A-, 
B- and C-chains. Therefore, these two methods would still give results even if 
individual C1q chains were expressed but not assembled into the complete C1q 
molecule. 
 
Our analysis of C1q production using ELISA, intracellular flow cytometry and 
confocal microscopy were carried out using a monoclonal anti-C1q globular domain 
antibody. We observed that this antibody did not detect C1q in Western blots of 
proteins separated under reducing conditions (data not shown). We strongly suspect 
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that this antibody detects only the full C1q protein, and thus the assays using this 
antibody should detect only the fully assembled C1q molecule and not the 
individual A-, B- and C-chains. The intracellular flow cytometry detection of C1q is 
a novel method and has not been used before to our knowledge, although there are 
reports of antibodies able to detect membrane-bound C1q (Kaul and Loos, 2001). 
However we could not detect C1q on cells without permeabilization (data not 
shown). Our novel intracellular flow cytometry detection of C1q may possibly be 
applied to future studies in studying C1q synthesis and assembly.  
 
As we used primary monocytes obtained from healthy donors of a diverse 
background in the generation of DCs, the C1q levels in cell culture supernatant as 
detected by ELISA can fluctuate widely between ~10 ng/ml to ~250 ng/ml after 2 
days of culture without any stimulation. Nevertheless, the properties of various 
stimulants in upregulating or downregulating C1q production remain identical 
across DCs from various donors.  
 
 
7.2 Regulation of DC production of C1q by microbial and 
autoimmune disease factors 
With the ELISA system, we tested the influence that many microbial stimuli, steroid 
drugs, hormones and cytokine/chemokines may have on affecting C1q production in 
DCs. By focusing on a single cell type for analysis, in this case DC, we should 
eliminate conflicting results, such as when the same stimulant used on different cell 
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types giving different results. The list of stimulants used was curated loosely based 
on a previous review of how C1q production is regulated (Lu et al., 2008).  
 
Stimulation of TLR3, TLR5, TLR7/TLR8 and NOD1/NOD2 had minimal effects on 
C1q levels. Stimulation of TLR2 with its various ligands suggests that this receptor 
could potentially upregulate C1q production, the degree of which depends on the 
ligands used. FSL-1, Pam2CSK4 and Pam3CSK4 all stimulate TLR2 in synergy 
with either TLR6 or TLR1 and these 3 ligands upregulated C1q production more 
strongly than ligands stimulating TLR2 alone (LTA and PGN). Zymosan and CpG 
DNA are TLR ligands that suppressed C1q production.  
 
There are notable differences in the regulation of C1q expression based on our 
results and what other groups have reported. For example, one recent study using 
mouse BMDC has found that LPS maturation abrogates C1q production at both the 
mRNA and secretion levels (Castellano et al., 2010). An earlier study by the same 
group had similar results when moDC was used. TNF-α, LPS and CD40L were used 
to stimulate the DCs, and it was found that secreted C1q levels were reduced by 
about one-third for both TNF-α and LPS and by two-thirds for CD40L (Castellano, 
2004). Strikingly, they observed that mature DCs similar to our 2 + 2 days culture 
completely stopped producing C1q. TNF-α also reduced C1q production in our 
study. But in contrast, our study showed that CD40L had no significant effect while 
LPS either had no effect or it could increase C1q secretion by about two-fold (Fig. 
3.6). Nevertheless we never observed any downregulation of C1q with LPS 
stimulation for both 2 days and 2 + 2 days culture across many independent 
experiments. Another study using moDCs found that LPS increased C1q secretion 
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(Baruah et al., 2006). Upon closer inspection of the system employed by Castellano 
et al, it was noted that their stimulations were performed together with the DC 
differentiation cytokines IL-4 and GM-CSF, whereas in our experiment and that of 
Baruah et al, the DCs were stimulated with just LPS and no additional cytokines. 
This discrepancy suggests that the macro-environment of the DCs could influence 
the expression of C1q regulated by a same agent. The same study by Baruah et al 
found that PGN and LTA increased C1q secretion by about 2 times after 2 days, but 
we observed minimal difference in C1q levels after 2 days, although over 2 + 2 days 
the C1q levels were increased. Possibly, the effects of these two ligands are only 
apparent after the DCs are fully matured.  
 
Both osteoprotegerin (OPG) and thymic stromal lymphopoietin (TSLP) 
downregulated C1q production in DCs. OPG is a TNF receptor family member. It is 
a decoy receptor for the osteoclastogenic RANK ligand and thus it inhibits 
osteoclast formation. No studies have linked OPG to SLE pathogenesis, although it 
was observed that serum OPG levels of SLE patients were higher than healthy 
controls (Kwok et al., 2009). TSLP is a cytokine mainly expressed by barrier 
surface epithelial cells and is a potent activator of DCs, with a resulting Th2 
polarizing phenotype that can promote allergy (Ziegler and Liu, 2006). So far, there 
are no studies linking TSLP to SLE. IFN-γ clearly upregulated C1q secretion, 
whereas IFN-α suppressed C1q production only after 2 + 2 days. Most of the other 
cytokines had minimal effect on C1q production, except notably IL-10 increased 
C1q production after 2 + 2 days. As to whether this could be attributed to the anti-
inflammatory nature of IL-10 remains to be studied. 
 
 151
Of the steroid drugs tested, none of them dramatically affected C1q secretion, which 
differed from observations that they promoted C1q production in macrophages 
(Trinder et al., 1995; Armbrust et al., 1997; Walker, 1998). This could be a cell-
type or species specific issue, as the 3 studies respectively used rat liver 
macrophages, mouse peritoneal macrophages and THP-1 differentiated 
macrophages as compared to our study using human moDCs. We included female 
hormones into this study as about 90% of SLE patients are females and pregnancy 
and menstrual cycle can influence the disease activity in SLE patients (Kawasaki et 
al., 2009). Estradiol slightly reduced C1q secretion in 2 days but progesterone 
showed the same effect for both 2 days and 2 + 2 days cultures. Nevertheless our 
results here are too preliminary to conclude if female hormones in general could 
reduce C1q levels in females.  
 
Overall, most stimuli had minimal effect on C1q production. For stimulants that 
clearly affected C1q production, we chose 3 for further investigation – zymosan, 
IFN-α and IFN-γ and the results would be discussed in Chapters 7.4 and 7.5.  
 
 
7.3 Production of C1q by primary DCs 
In vivo, human DCs have been reported to produce C1q and C1q was also deposited 
around the DCs in various tissue sections as reviewed in Chapter 1.4.4. The 
localized C1q may have regulatory effects on the DCs and this was explored in 
Chapter 6. The monocyte-derived DCs used throughout this study are recognized to 
be generated only under inflammatory conditions and not in the steady state 
(Shortman and Naik, 2007). However they are functionally relevant in the immune 
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system. For example, inflammatory DCs generated from monocytes during Listeria 
monocytogenes are crucial for the clearance of the bacteria via TNF and iNOS-
induced ROS production (Serbina and Pamer, 2006), In colitic mice, monocyte-
derived inflammatory DCs that express E-cadherin, the receptor for CD103, 
promote intestinal inflammation and are detrimental to the host (Siddiqui et al., 
2010). The GM-CSF generated mouse BMDC are also inflammatory DCs similar to 
human moDC (Shortman and Naik, 2007). These two DCs respectively produced 
the highest levels of C1q among DCs from both mouse and human (Figs. 3.11 and 
3.13).  
 
The division of steady state DCs into pDCs and conventional DCs is accepted for 
both human and mouse. For the mouse, two functionally distinct populations of 
cDC have been recognized, one with high surface expression of CD8α and the other 
lacking this marker. CD8+ DCs are CD11c+, CD11blow, Sirpαlow and functionally 
these DCs are the major producers of IL-12, are able to capture dead cells and to 
cross-present different forms of exogenous antigens on their MHC class I molecules 
and can prime cytotoxic T cells (Villadangos and Schnorrer, 2007). mRNA analysis 
showed that CD8+ DCs expressed the lowest levels of C1q. Recently, the rare and 
hard to isolate CD141+ (BDCA-3) human cDC subset was found to closely 
resemble mouse CD8+ DCs (Villadangos and Shortman, 2010). It expresses the 
CD8+ DC markers XCR1 and Clec9A, is capable of phagocytosing dead cells and 
cross-presenting cell-associated and soluble antigens and produce IL-12. Whether 
the human CD141+ DCs express low levels of C1q in parallel to mouse CD8+ DCs 
was not studied.  
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The mouse CD8- DCs show high expression of MHC class II antigen processing 
and presentation genes, and are generally known to induce CD4+ T helper cell 
response and promote humoral immunity in response to bacteria or extracellular 
parasite infection. Besides being CD8α- and CD11c+, they are also CD11b+ and 
Sirpα+ and expressed the highest levels of C1q mRNA of all splenic DCs, but lower 
than C1q levels in BMDCs. Comparative genomics studies coupled with functional 
similarities have suggested that human myeloid CD1c+ (BDCA-1) DC is equivalent 
to mouse the CD8- DC (Crozat et al., 2010). CD1c+ DC produced C1q but at lower 
levels than moDCs. Both human CD1c+ DC and mouse CD8- DC produced higher 
levels of C1q than pDCs. Although we detected low levels of C1q mRNA in human 
pDCs, we failed to detect secreted C1q in pDC culture supernatants. Secreted mouse 
C1q was not measured in this study.  
 
Our results that showed the expression of C1q in different DC subtypes in both 
mouse and human is novel. The relative C1q production level seems to be unique to 
each DC subtype and could serve as a novel marker for differentiating DC subtypes 
in both mouse and human. Further analysis of C1q expression in other types of DCs 
such as the migratory Langerhans cell and dermal DCs and the CD11b+CD103+ 








7.4 Dectin-1 engagement is a novel mechanism that holistically 
downregulates C1q production – implications in SLE pathogenesis 
resulting from fungal infections 
Dectin-1 (Clec7a) is a member of the C-type lectin receptor (CLR) family, and is 
expressed mainly on innate cells such as macrophages, neutrophils, and DCs. 
Dectin-1 is involved in the recognition of a broad range of fungal pathogens, 
including Candida albicans, Aspergillus fumigatus and Pneumocystis carinii, and it 
promotes protective antifungal immunity against C. albicans that requires Th1 and 
Th17 responses (Taylor et al., 2007; Gringhuis et al., 2009). Structurally, Dectin-1 
is a glycosylated type II transmembrane receptor with a single extracellular C-type 
lectin domain connected by a stalk to a transmembrane region and a cytoplasmic tail 
(Kerrigan and Brown, 2010). Dectin-1 binds β-1,3-linked glucose oligomers, and 
this stimulation can induce many cellular responses including the respiratory burst, 
DC maturation, ligand uptake through phagocytosis and endocytosis, the production 
of arachidonic metabolites and various cytokines and chemokines such as TNF, 
CXCL2, IL-23, IL-6, IL-2, and IL-10 (Reid et al., 2009).  
 
Zymosan is a yeast cell wall derivative commonly used as a ligand to represent 
fungal pathogens and can activate both TLR2 and Dectin-1 through its β(1,3)-
glucans. With respect to C1q production, zymosan appears to act through Dectin-1 
to reduce C1q expression by DCs whereas most of the TLR ligands showed no such 
inhibitory effects. For example, with LPS, C1q production was enhanced and DCs 
stimulated with all other TLR2 ligands eventually showed enhanced C1q production 
(Chapter 3.4). Curdlan, which contains Dectin-1–stimulatory β(1,3)-glucans but 
lacks TLR-stimulatory motifs (Gringhuis et al., 2009) was also found to mediate 
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suppression of C1q production. Either mode of Dectin-1 stimulation downregulated 
C1q mRNA and intracellular protein production and secretion, and this was not due 
to increased cell death. 
 
Beyond the TLR family, Dectin-1 was the first PRR found to induce its own 
intracellular signaling (Reid et al., 2009). β-glucans engagement of Dectin-1 leads 
to Src family kinases phosphorylating the cytoplasmic immunoreceptor tyrosine-
based activation motif (ITAM)-like motif and thus providing a docking site for  Syk. 
The components of the signaling pathway have yet to be fully elucidated. 
Downstream of Syk, caspase recruitment domain 9 (CARD9) is known to assemble 
with BCL10 and MALT1 to form a complex linking to the canonical NF-κB 
pathway. There are reports of a Syk-dependent, but CARD9-independent pathways 
of Dectin-1 activation, and this leads to the induction of ERK and the production of 
cytokines such as IL-10 and IL-2 (Dillon et al., 2006; Slack et al., 2007). Our 
efforts to identify the specific Dectin-1 signaling pathway or effect that mediates its 
inhibition on C1q production were unsuccessful. This includes blocking Syk 
signaling, inhibition of arachidonic acid release and ROS production. 
 
Dectin-1 mediated phagocytosis in macrophages acts in a Syk-independent pathway 
and although this response still requires the ITAM-like motif of the receptor, it is 
still largely uncharacterised (Brown, 2006). Recently, Dectin-1 was recognized as 
the first PRR known to engage the non-canonical NF-κB pathway. This requires a 
Syk-independent pathway involving the serine–threonine kinase Raf-1, which 
integrates with the Syk pathway at the level of NF-κB (Gringhuis et al., 2009). 
Another recent study found that NFAT transcription factors were activated by 
Dectin-1 and this requires intracellular Ca2+ flux coupled to the phospholipase Cγ 
pathway (Xu et al., 2009b). Both pathways mediate Dectin-1 induced cytokine 
production. Blocking of both pathways through the use of a Raf-1 inhibitor and 
through intracellular Ca2+ chelation did not abrogate the inhibitory effects of Dectin-
1 on C1q production. Calcineurin activation downstream of Ca2+ influx was recently 
shown to mediate the NFAT activation (Greenblatt et al., 2010), but this pathway 
could be excluded from our system as it involves Ca2+ influx. 
 
In a C. albicans mortality study of various knockout mice including C1q−/−, 
complement factor B and C2 (Bf/C2−/−) and MBL-A and MBL-C (MBL-A/C−/−), 
C1q-/- mice had the lowest mortality rate of 15% compared to >90% and 40% for 
the other two knockout mice respectively, with wild-type mice showing just 4% 
mortality (Held et al., 2008). This suggests for a stronger contribution from both 
MBL and alternative pathways (via factor B) than C1q-mediated classical pathway 
for controlling Candida infection. In addition, it was shown that MBL and C3, but 
not C1q, act as recognition molecules for C. albicans in the vagina and there is an 
association between reduced levels of vaginal MBL and recurrent vulvovaginal 
candidiasis (Pellis et al., 2005). With less importance of C1q compared to other 
innate immune components in clearing fungal infection, suppression of C1q 
production by fungal stimulation of Dectin-1 does not appear to be an immune 
evasion mechanism employed by fungal pathogens. 
 
C. albicans is a common constituent of the normal flora of the oropharyx and the 
gastrointestinal tract of healthy individuals and of the female lower genital tract. 
However, under predisposing conditions this colonization may lead to 
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mucocutaneous and also invasive infection. A clue to a possible function of Dectin-
1 in SLE is that its patients are highly susceptible to infections from common 
microorganisms and also to opportunistic infections. Infection accounts for 20–55% 
of all deaths in SLE (Khalifa et al., 2007). C. albicans was the most frequent 
opportunistic organism identified in fatal infection in adult SLE (Hellmann et al., 
1987). This is due to immunological aberrations in SLE patients, both from the 
disease itself and from the regiment of immunosuppressive treatment of the disease. 
Some possible aberrations include dysfunctional phagocytic cells, defects in cellular 
immunity, reduced IgG production, low complement levels and ineffective 
elimination of microorganisms by reticuloendothelial systems and spleen (Kim et 
al., 2009).  
 
With high infectious fungal infection rates in SLE patients, could the inverse be true? 
Fungal infection activates Dectin-1 and this could result in suppression of C1q 
production by DCs and macrophages, potentially leading to SLE pathogenesis. It is 
well-known that in active lupus, serum C1q level is reduced. Clinically, individuals 
who are genetically susceptible to SLE or have developed SLE could encounter 
accelerated disease or suffer from SLE flares due to infections by fungi and other 
pathogens that can activate Dectin-1 such as mycobacteria. Another remote 
possibility is females, who constitute about 90% of SLE patients, could have the 
higher exposure to Candida via their lower genital tract acting as an environmental 
factor leading to their higher disease predisposition. The implicated connection 
between reduced C1q expression and fungal infections can help in the 




7.5 IFN-α, an important SLE pathogenic factor, downregulates 
C1q secretion  
IFN-α  is primarily produced by pDCs in response to infection or IC stimulation 
whereas IFN-γ is produced predominantly by T cells, natural killer (NK) cells and 
NKT cells following inflammatory activation. Generally IFN-α is a poorer inducer 
of DC maturation as compared to TLR stimuli. IFN-α activated DCs shows a high 
expression of the maturation marker CCR7 (Dauer et al., 2006), and can 
upregulated the expression of HLA-DR, CD80, CD86, but not CD83, (Luft et al., 
2002). Functionally, IFN-α can lead to the induction of CTL responses, CD8+ 
survival and enhanced autoantibody production via DC induction of class-switching 
(Honda et al., 2005). 
 
The roles of C1q as a suppressor- and IFN-α as an enhancer- of SLE pathogenesis 
were previously discussed in Chapters 1.3 and 1.4. A link between C1q and IFN-α 
has not been firmly established yet, and the two could interplay in two ways. Firstly, 
C1q can possibly suppress IFN-α production and thus limiting its pathogenesis in 
SLE. Secondly and in reverse, IFN-α could negate the suppressive effects of C1q by 
inhibiting its production and thus tilting the balance towards SLE progression. In 
agreement with the first hypothesis, it was recently reported that C1q reduced CpG 
and IC induced IFN-α production by pDC (Lood et al., 2009). In our study, we test 
the second hypothesis that type I IFN may have strong regulatory effects on C1q 




Using DCs, we showed that while IFN-γ enhances C1q levels in culture supernatant, 
IFN-α attenuates C1q secretion. The treatment of DCs with IFN-γ increased C1q 
production at the transcriptional, protein synthesis and secretion levels as assessed 
by mRNA, Western blotting and ELISA assays in both 2 days and 2 + 2 days 
stimulations. With respect to IFN-α, we observed a strong suppression in secreted 
protein levels in culture supernatant after 2 + 2 days of stimulation, although not 
much effect was observed within the first 2 days of stimulation. The downregulation 
of C1q production does not appear at the transcriptional and translational levels as 
C1q mRNA and cellular C1q were both increased upon IFN-α stimulation for both 2 
days and 2 + 2 days. This is in contrast to the decrease in secreted C1q as measured 
by ELISA upon IFN-α stimulation and thus the suppression of C1q production 
occurs at the secretion level. We showed that increased cell death with IFN-α 
stimulation was not the reason behind this. 
 
We then used confocal microscopy to localize the intracellular compartments of 
C1q. IFN-α stimulation upregulated C1q expression, but the C1q was found to be 
mainly trapped in the ER instead of being trafficked to the Golgi for secretion. 
Clearly, IFN-γ stimulated DCs have less C1q localized in the ER and more in the 
Golgi apparatus, indicating that they were ready to be packaged and secreted. The 
mechanisms behind this disparity between the two IFN treatments are unidentified 
in this study. By understanding the network of protein secretion from ER to Golgi, it 
is possible to identify the proteins that package C1q into vesicles for transport to the 
ER-Golgi intermediate compartment of the cis-Golgi network that could be affected 
after IFN-α exposure (van Vliet et al., 2003). There are also regulatory mechanisms 
in the ER that ensure proteins are properly post-translationally modified and folded 
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before transport form ER to the Golgi network. Although we believe that the 
monoclonal antibody against the C1q globular domain detects the fully assembled 
C1q protein in the ER, it is still possible that the collagenous domain may not be 
properly assembled and its transport to the Golgi could be halted. Hydroxylation of 
proline and lysine resides are important for stabilization of the collagen triple helix, 
and also for C1q production (Muller et al., 1978; Mocharla et al., 1987). Hence, 
another possibility is IFN-α effecting the expression or functionality of chaperones 
and hydroxylases in the ER that are required for C1q assembly.  
 
When the two IFNs operate alone, they have opposite effects on modulating C1q 
production from DCs. However, when the two stimuli were added concurrently to 
DCs, the C1q-enhancing signals from IFN-γ dominated over the C1q secretion-
suppressing signals from IFN-α. There are two potential mechanisms behind this. 
IFN-α and IFN-γ together could synergize to upregulate C1q expression and protein 
translation, such that even though its secretion is generally affected, there are still 
more C1q secreted than with IFN-α treatment alone. The other potential mechanism 
is that IFN-γ can abrogate the dysregulation of ER functions that trapped C1q in the 




7.6 C1q conditions the differentiation of DCs with 
immunosuppressive properties, possibly raising the threshold of 
immune activation required for autoimmunity 
The initiation of the complement classical pathway requires recognition of a 
microbial or self antigen by IgG or IgM antibodies. This is followed by C1q binding, 
and the binding is believed to cause a conformational change to C1q that triggers 
activation of the C1 catalytic subunit, the Ca2+-dependent tetramer and ultimately 
activating the entire complement cascade (Kishore et al., 2002). As reviewed in 
Section 1.4.4, C1q deposits in the ECM around DCs and it is possible that the C1q 
have direct effects on DC differentiation and functionality. The C1q deposited in 
normal ECM in the absence of autoantibodies is not expected to activate 
complement and inflammation, as the mechanisms that attach it onto ECM may not 
cause the conformational change similar to activation on IgG binding. Instead, 
excess soluble C1q during DC culturing rendered DCs refractory to maturation 
stimuli (Castellano et al., 2007). We thus sought to examine how surface-deposited 
C1q may regulate DC development from monocytes.  
 
The presence of immobilized C1q neither interfered with the monocyte 
differentiation to DCs nor did it influence the survival of DCs. We obtained roughly 
equal number of normal DCs and C1qDCs after 6 days of monocyte culture. Both 
types of DCs were similar in surface MHC and co-stimulatory molecules (CD40, 
CD80 and CD86) expression. On stimulation, the mature forms of both DCs 
upregulated the co-stimulatory molecules CD40, CD80 and CD86, MHC I and II 
and the maturation markers CD83 and CCR7 to similar levels. Thus, the 
differentiated C1qDC were phenotypically and functionally immature like normal 
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DCs. As deposited C1q did not significantly modulate the expression of the 
essential molecules for T cell stimulation, C1qDCs were also similar to normal DCs 
in stimulation naïve T cell proliferation.  
 
C1qDCs showed reduced adhesion to cell culture wells over the differentiation 
process. However, after the DCs were harvested to be reseeded for stimulation, we 
observed that C1qDCs could adhere and spread on the new cell culture surfaces and 
are now morphologically similar to normal DCs. We have stained normal DCs and 
C1qDCs for integrins and some surface receptors known to mediate cell adhesion, 
including integrin αV, β1, β2, α2β1, α5β1, αVβ3, αVβ5, E-cadherin and 
complement receptor 3, and did not find notable differences in the expression 
between both the DCs (data not shown). Thus the mechanism behind reduced 
adhesion of C1qDCs over the differentiation and its functional significance remains 
unknown.  
 
Nonetheless, when further analyzed, C1qDCs show major functional differences 
compared to normal DCs. C1qDCs are better at phagocytosis of ACs (Fig. 6.3), 
produce more IL-10 but less IL-12, IL-6 and IL-23 (Fig. 6.4) and consequently are 
weaker in polarizing CD4 T helper cells to a Th1 and Th17 phenotype (Figs 6.6 and 
6.7). The production of less TNF-α by C1qDCs also suggest it is less inflammatory 
in general when stimulated. C1qDCs and normal DCs also show disparate T cell 
activation properties in response to maturation stimuli. In the presence of maturation 
stimuli, normal DCs showed increased ability to activate naïve T cells (as adjudged 
by CD25 upregulation) while under the same conditions, C1qDCs showed reduced 
CD25 induction on these cells (Fig. 6.11). It suggests that both DCs are equal in T 
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cell stimulation in the steady state when self-antigens dominate in tissues, and 
during infection and inflammation, DCs conditioned without C1q are better at 
activating T cells. This would help in better clearance of infection, but unabated 
activation of the T cells could lead to breach of tolerance.  
 
We then attempted to understand the mechanisms leading to the characteristic 
higher IL-10 but lower IL-12 and IL-23 production by C1qDCs, as compared with 
normal DCs. How C1q induced these DC properties seems to involve the 
conditioning of these cells for elevated MAP kinase ERK, p38 and phosphoinositide 
3-kinase (PI3K) signaling in the regulation of IL-10, IL-12 and IL-23. It was shown 
that ERK activation enhances IL-10 but inhibits IL-12 production (Yi et al., 2002; 
Agrawal et al., 2006). Likewise, p38 activation also enhanced IL-10 while 
inhibiting IL-12 production (Jarnicki et al., 2008). PI3K activation inhibits both IL-
12 and IL-23 production while also enhancing IL-10 production, and the latter 
involves the activation of the p70 S6 kinase (p70S6K) (Fukao and Koyasu, 2003; 
Yang et al., 2006). From our results on MAPK phosphorylation, enhanced ERK 
signaling seems to be the most relevant in instilling C1qDCs with its unique 
cytokine profile compared to normal DCs, as was directly demonstrated by using 
the MEK inhibitor PD98059. To a large extent, it restored C1qDC production of the 
two cytokines to levels comparable to normal DCs. How increased p38 and p70S6K 
activation in C1qDCs may be interconnected with increased ERK activation is 
uncertain, but their reported relevance to IL-10, IL-12 and IL-23 production 
strongly suggests involvement of these signaling pathways in C1qDCs. How C1q 
tuned DCs for elevated ERK activation remains to be determined. 
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Kuchroo and colleagues described a 3-step process for Th17 induction: (1) TGF-β 
plus IL-6 induces the differentiation of Th17 cells, (2) IL-21 amplifies the 
frequency of Th17 cells, and (3) IL-23 terminally differentiates and stabilizes the 
phenotype of Th17 cells (Korn et al., 2009). RORγt, and RORα are transcription 
factors that define the Th17 transcriptional program. Thus, the high IL-6 and IL-23 
production by normal DCs is more permissive for Th17 development than C1qDCs, 
which can be amplified by positive feedback from IL-21 produced by Th17 cells.  
 
In SLE, the protagonist role of type I IFN was strongly established. However, the 
roles of Th1 and Th17 cytokines in SLE have not been consistently established. In 
mice, transgenic IFN-γ over-expression causes lupus-like autoimmunity (Seery et 
al., 1997). With lupus-prone NZB/NZW F1 mice, either breeding to IFNγ-/- 
background or the use of anti-IFN-γ antibodies reduced disease severity in both 
cases (Jacob et al., 1987; Balomenos et al., 1998). A study using a lupus-like 
disease mouse model generated by surface expression of an ER HSP gp96 showed 
no involvement of IL-23 nor expansion of Th17 population (Dai et al., 2007), 
although another study using the MRL/lpr mice lupus model detected an expansion 
of the Th17 cell population (Yang et al., 2009). Thus far, there are no studies 
investigating the mechanisms by which Th17 cells can be pathogenic in SLE mice 
models. 
 
The data in human studies are less clear, and only clinical studies on the prevalence 
of Th17 cells/cytokines in SLE patients were conducted until now. One older study 
detected that IL-17 levels were increased in serum from systemic sclerosis patients, 
but not in that from SLE patients or healthy donors (Kurasawa et al., 2000). 
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However, more recent studies have indicated otherwise. Serum IL-17A level and 
Th17 transcription factor RORγt mRNA in SLE patients were higher than that of 
controls (Chen et al., 2010). Another study revealed that the percentage of 
circulating Th17 cells and their ability to produce interleukin-17A (IL-17A) were 
increased in samples derived from patients with active SLE, and the number of 
Th17 cells increased during SLE flare but decreased following steroid treatments 
(Yang et al., 2009). Henriques et al observed a significant decrease in the frequency 
of Th1 and Tc1 (CD8+ T cells producing IFN-γ) cells, lower frequencies 
of Treg, and increased Th17 and Tc17 (CD8+ T cells producing IL17) cells in 
patients with active SLE, when compared with those with inactive disease and 
healthy controls (Henriques et al., 2010).  Another recent study concurred that SLE 
patients had an increased Th17 cells compared with healthy subjects but the 
frequency of Th1 cells was similar (Shah et al., 2010).   
 
Studies investigating the natural Treg frequencies in the peripheral blood of patients 
with SLE have generated controversial results (Bonelli et al., 2010). Although most 
studies have described decreased proportions of CD4+CD25high Treg in patients with 
SLE as compared with healthy controls and observed an inverse correlation of Treg 
numbers with clinical disease activity, other have reported no change or even higher 
proportions of Treg in patients with SLE and a positive correlation with disease 
activity. If Tregs do contribute to SLE pathogenesis, in patients with higher Treg 
detected, it is possible that their Tregs are functionally defective during active SLE 
(Henriques et al., 2010). Our data indicates that C1qDC does not induce more Treg 
than normal DCs, which could have been a possible mechanism in normal DCs 
inducing more Th1 and Th17 cells. However, the increased IL-10 production by 
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C1qDCs might play a potent inhibitory action on both Th1 and Th2 differentiation 
(Mills, 2004), in addition to its secretion of less IL-6, IL-12 and IL-23. 
 
Altogether, deposited C1q clearly induced a distinct property in DCs which renders 
these APCs potent phagocytes for AC or self-antigens. Compared against DCs 
without C1q conditioning, these DCs are just as potent at steady state T cell 
stimulation, which however recedes upon microbial or inflammatory activation. 
This is in agreement with the strong association between C1q deficiency and 
autoimmunity. We believe that these C1qDCs may better represent endogenous 




7.7 Final conclusions 
Genetic loss of C1q is known to be the strongest susceptibility factor in SLE. 
During disease progression in patients with no genetic C1q deficiency, suppressed 
C1q levels due to anti-C1q antibodies (Botto and Walport, 2002), consumption from 
complement activation and possibly reduced C1q production are all positively 
related with disease progression. 
 
With the immunoregulatory roles of C1q established, and reduced C1q expression 
by DCs being a possible mechanism in SLE pathogenesis, we have screened for 
factors that can suppress C1q production in DCs. We studied 2 novel pathways that 
suppressed C1q production. Dectin-1 stimulation downregulated C1q production in 
a conventional manner by reducing C1q mRNA expression and its protein synthesis, 
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thus less C1q was secreted. On the contrary, IFN-α suppressed DC production of 
C1q at the secretion level. 
 
Differentiation of DCs in the absence of C1q produced DCs with stronger 
immunostimulatory properties. In fact, DCs differentiated with C1q or “C1qDCs” 
may represent DCs in normal individuals with normal C1q levels, and the lack of 
C1q causes DCs to differentiate towards the “normal DC” phenotype as observed in 
our study. 
 
Overall, we postulate that with C1q insufficiency, DCs can cause excessive 
activation of Th1 cells which are pathogenic at the early development of SLE, with 
CD8 CTL causing excessive cell death that is not optimally cleared and releasing 
autoantigens. Non-C1q generated DCs are less effective in phagocytosis of ACs, 
and uncleared ACs can turn necrotic and more inflammatory. This ultimately leads 
to the breach of tolerance. In subsequent disease flares, tissue inflammation and 
damage would require Th17 cells, which are efficiently induced by DCs not 
differentiated with C1q, and also autoantibodies from B cells to generate ICs. Th17 
are the effector T cells involved in inflammation induction and autoimmune tissue 
injury (Korn et al., 2009). This is supported by the observation of Henriques et al 
(2010) that Th1 and Tc1 to Th17 and Tc17 ratios were decreased in active SLE. In 
fact, IFN-γ production during active SLE could be protective by subjugating the 
ability of IFN-α to inhibit C1q production (Chapter 7.5). Deficiency of C1q could 




7.8 Limitations of this study and future work 
As our initial screening study on modulation of C1q production was performed 
using moDCs, we have ignored contributions by macrophages, the other major APC 
producing C1q physiologically. Hence, performing the screening study using 
macrophages may help to answer the discrepancies between our results and that of 
others who have studied C1q expression in macrophages. The moDCs used in this 
study are only generated upon inflammation, but they remain the most convenient 
source of human DCs due to the large numbers that can be obtained (Shortman and 
Naik, 2007). Mouse bone marrow cells can be differentiated into DCs that resemble 
the population in steady state spleen by using the fms-like tyrosine kinase 3 (Flt3) 
ligand (Naik et al., 2005), and it is possible to explore the regulation of C1q 
production in these DCs to more closely simulate the in vivo steady state DCs.  
 
We found that CpG DNA also suppressed C1q production. It is generally 
acknowledged that moDCs do not express TLR9, the CpG DNA receptor and the 
major cells expressing TLR9 are pDCs and B cells (Bauer et al., 2001; Jarrossay et 
al., 2001; Wagner, 2004). However, there are also reports that TLR9 was expressed 
in moDCs (Hoene et al., 2006). Recently, new intracellular nucleic acid sensors 
were found, and more are speculated to exist (Takeuchi and Akira, 2010). For 
instance, plasmid DNA-activated a TBK1-dependent signaling that resulted in type 
I interferon signaling and this occured even in the absence of TLR9 or Z-DNA 
binding protein 1, a potential intracellular DNA sensor, suggesting that cytoplasmic 
DNA is redundantly recognized by as-yet unidentified receptors (Ishii et al., 2008). 
TLR9 deficient pDCs also mediated type-1 interferon production when stimulated 
with CpG DNA (Yanai et al., 2009). It would be interesting to study if the observed 
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downregulation of C1q production by CpG DNA is caused by direct TLR9 
engagement, or from some other novel receptors and signaling mechanisms, with 
implications in bacterial immune evasion and also possibly autoimmunity from C1q 
insufficiency following its downregulation after TLR9 stimulation. 
 
After discovering that Dectin-1 activation is a novel C1q inhibitory signal, our work 
remains largely incomplete. We could not delineate the signaling mechanisms and 
intermediates involved in the process. Although Syk, CARD9, Raf-1, PLC-γ, and 
NFATs are all implicated in signaling downstream of Dectin-1, the contribution of 
specific transcription factors to Dectin-1–induced transcriptional responses and the 
upstream signaling intermediates remains incompletely characterized (Greenblatt et 
al., 2010). As research on Dectin-1 is only starting to intensify, more signaling 
pathways could be discovered, and these may be the signaling involved in our 
observation. A possible option is to analyze the lipid raft components of Dectin-1 
activated DCs, as the Dectin-1 receptor together with its downstream signaling 
molecules were recently found to translocate to the lipid rafts upon stimulation of 
DCs with zymosan or β-glucan, and this was important for the functionality of 
Dectin-1 (Xu et al., 2009a). It is also possible that our inhibition on Syk was 
incomplete, as we could not fully inhibit curdlan-stimulated cytokine production. 
Using the new Syk inhibitor R406 (Braselmann et al., 2006)  with higher specificity 
and inhibitory constant than piceatannol inhibitor may help. However this is 
currently an experimental drug for the treatment of rheumatoid arthritis and is not 




The biochemical properties and structure of C1q has been extensively studied thus 
far, but the cellular processes that assemble, package and secrete the molecule have 
not been investigated. Delineating how IFN-α impaired C1q secretion is definitely 
worthwhile undertaking, as it may lead to better understanding of another 
mechanism that may contribute to SLE pathogenesis. Does this impairment affect 
the secretion of any other proteins? We showed that it did not affect secretion of 
fibronectin. But we need to test a wider panel of molecules to determine if only 
secretion of C1q is affected, or is the effect more general or restricted to a particular 
class of molecules. At the molecular level, it would also be interesting to identify 
possible chaperones and hydroxylases that are involved in C1q assembly, as under 
pathological conditions they may be impaired and thus affecting C1q production. 
 
Our data on C1q-differentiated DCs with a suppressive phenotype are all in vitro. 
Studying DCs and T cells from C1q-/- and normal mice as they progressively 
acquire SLE and looking for parallels with our normal DC (more immunogenic and 
perhaps parallel to DCs differentiated without C1q in C1q-/- mice) versus C1qDCs 
(have higher activation threshold and probably parallel to DCs developed in the 
presence of C1q in normal mice) could help to vindicate our data. Examining the 
Th17 cells in both mice could also indicate whether these cells are pathogenic in 
SLE or otherwise.  
 
Collectively, our data provides a foundation for further research into the connection 
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